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1 Introduction 
1.1 Cancer: general remarks 
Cancer is the leading cause of death worldwide with 14.1 million new cancer cases and 8.2 
million cancer deaths in 2012 (Ferlay et al., 2015). The complex and dynamic nature of 
cancer development makes difficult to unravel the fundamental key mechanisms that could 
prevent the patients from dying. One of the most enigmatic aspects of cancer pathogenesis is 
the complex multi-step process of metastasis starting from primary tumor. Metastasis is 
responsible for as much as 90% of cancer-associated mortality (Sleeman and Steeg, 2010). 
Despite the relative inefficiency of the metastatic process (Wong et al., 2001), the absolute 
magnitude of metastatic spread is enormous and represents the primary associated cause of 
cancer morbidity and mortality (Chaffer and Weinberg, 2011).  
1.2 Molecular biology of primary tumor  
The initiation of cancer needs the acquisition of some fundamental characteristics that 
constitute the major distinguishing features of cancer cells. The first trait a cancer cell has to 
gain is the ability to sustain chronic proliferation (Hanahan and Weinberg, 2011). In cancer 
cells this is possibly achieved by the continuous release of mitogenic signals, as growth factor 
ligands, binding the family of receptor tyrosine kinases (RTKs) localized at the plasma 
membrane, inducing the kinase activity of the receptor and activating signaling pathways that 
promote mitogenesis (Lemmon and Schlessinger, 2010). Also, activating mutations in 
mitogen-activated protein (MAP)-kinase pathway lead to cell survival and proliferation in 
cancer cells (Dhillon et al., 2007). Parallel to the acquisition of sustained proliferation, cancer 
cells have to avoid cellular programs that could suppress sustained growth. This growth-
control role is usually carried out by the prototypical tumor suppressor such as retinoblastoma 
(RB) and tumor protein p53 (TP53). In particular RB integrates inhibitory signals coming 
from the intracellular and extracellular environments and regulates whether or not the cell 
should enter the division cycle (Burkhart and Sage, 2008). TP53 acts mainly by collecting the 
input derived from the intracellular stress or DNA damage and arrests the cell cycle till the 
repair of DNA, or it can trigger apoptosis (Meek, 2009).  
Once cancer cells acquire unlimited proliferative capacity, they have to resist 
mechanisms of cell death such as apoptosis. In cancer cells, an imbalance between pro-
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apoptotic (BAX, BID, BAD, BAK) and anti-apoptotic (BCL-XL and BCL-2) molecules, in 
favor of the latter, leads to the evasion of apoptosis (Lessene et al., 2008).  
At this point the cancer cells are ready to form macroscopic tumors but, to succeed, 
they need to develop unlimited replicative potential. A pivotal role in this regard is performed 
by the telomeres providing the capability for unlimited proliferation (Blasco, 2005). During 
the course of multistep tumor progression, clones of cancer cells at early stages often go 
through telomere loss-induced crisis due to their inability to express significant levels of 
telomerase (Kawai et al., 2007). This transient situation actually fosters tumor progression 
because telomere crisis produces significant chromosomal instability, increasing the 
occurrence of genetic alterations, which favor neoplastic transformation (Artandi and 
DePinho, 2010).  
Furthermore, the continuous growth of the primary tumor increases the demand of 
nutrients and oxygen necessary for survival. In this regard, a mechanism called “angiogenic 
switch”, leading to the formation of neovasculature (Hanahan and Folkman, 1996), is 
fundamental and seems to be a very early step in the development of the invasive disease as it 
has been observed in histological analyses of pre-malignant, non-invasive lesions and 
dysplasia (Raica et al., 2009). Vascular Endothelial Growth Factor-A (VEGF-A) is a 
prototypic pro-angiogenic factor, responsible for the formation of new blood vessels. It is up 
regulated by hypoxia and oncogenic signaling, key feature of the tumor (Carmeliet, 2005). An 
important property that cancer cells need to acquire is the activation of invasion mechanisms 
enabling the penetration into the surrounding tissues. The switch from a polarized, epithelial 
phenotype to a highly motile fibroblastoid or mesenchymal phenotype, called “epithelial-
mesenchymal transition” (EMT), seems to be a fundamental requisite for the invasion and 
dissemination (Thiery et al., 2009).  
1.3 Models of metastatic progression and metastatic cascade 
For a long time the linear progression has been accepted as the only model of metastasis 
suggesting that the metastatic outgrowth is the final step of the primary tumor development 
(Fearon and Vogelstein, 1990). However, during the years the linear progression model has 
been placed side by side with the parallel progression model (Klein, 2009) (Figure 1).    
According to the linear progression model, primary tumor cells undergo successive 
rounds of mutation and selection giving rise to a biologically heterogeneous cellular 
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population in which a subset of malignant clones have accumulated genetic alterations, 
necessary for metastasis (Vogelstein et al., 1988; Cairns, 1975). The metastatic capabilities 
may be developed at the primary site as a by-product of the selective pressures, or may further 
evolve after the tumor cells reached the secondary organs. Nevertheless, studies with the final 
aim to quantify human cancer growth rates concluded that the metastatic process must start 
before the clinical symptoms appear or the primary tumor is diagnosed (Collins et al., 1956; 
Friberg and Mattson, 1997).  
In the parallel progression model tumor cells may disseminate very early, colonize 
multiple secondary sites at different times and ultimately accumulate genetic changes 
independently from those incurred by the primary tumor (Klein, 2009). This concept 
presupposes greater genetic disparity between the primary tumors and metastatic founders due 
to the fact that the early disseminated cancer cells (DCCs) are exposed to high selective 
pressure that is site-specific (Stoecklein and Klein, 2010). Moreover, the seeding of cancer 
cells can happen at different times to different sites and the outgrowth is determined by niche-
adaptation of the DCCs (Klein, 2009). Early dissemination can be deduced from disease 
course and patient-derived data (Engel et al., 2003; Klein, 2009; Klein and Holzel, 2006). 
Moreover, recent reports provide evidence that support early dissemination of metastatic 
tumor cells in transgenic mouse models of breast cancer (Eyles et al., 2010; Husemann et al., 
2008; Rhim et al., 2012). Corroboration for early tumor disseminations has also been found in 
pre-invasive lesions of patients with in situ carcinomas (Banys et al., 2012; Sanger et al., 
2011). These means that, even before clinical detection of a primary tumor, cancer cells can 
invade the adjacent structures, from where they travel through lymphatic (lymphogeneous) 
and blood vessels (hematogeneous) as circulating tumor cells (CTCs). CTCs colonize distant 
organ sites, becoming DCCs, and eventually form microscopic deposits (micrometastasis), 
which may remain dormant, but ultimately leading to an overt metastatic disease (Aguirre-
Ghiso, 2007).  
Whether or not dissemination occurs late or early, the process by which cancer cells 
escape from the primary tumor to begin the metastatic cascade can be summarized in the 
following sequence of steps: 1) local invasion of the host stroma. Thin-walled venules, such 
as lymphatic channels, offer very little resistance to penetration by tumor cells and provide 
the most common route for tumor cell entry into the circulation (intravasation) (Fidler, 2003). 
2) Detachment and embolization of single tumor cells or aggregates with most circulating 
tumor cells being rapidly destroyed. After the tumor cells have survived the circulation, they 
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become trapped in the capillary beds of distant organs by adhering either to capillary 
endothelial cells or to subendothelial basement membrane that might be exposed. 3) 
Extravasation from the bloodstream. 4) Survival and proliferation within the organ 
parenchyma which completes the metastatic process (Fidler, 2003; Valastyan and Weinberg, 
2011). 
 
Figure 1: Metastasis progression models. Left, in the early dissemination (parallel progression model) different tumor cell clones are seeded 
in parallel to different organs. Right, in the late dissemination (linear progression model) tumor cells undergo clonal selection, during which 
the advantageous clones expand and dominate over the others, with additional subclonal and mutational changes occurring within the clonal 
populations. When disseminated, the dominant clone seed and colonize different organs. Figure adapted from (Wan et al., 2013). 
1.3.1 Metastatic dormancy and reactivation at ectopic sites 
Once cancer cells have found new soil, they need to adapt to foreign tissue 
microenvironments in order to grow from DCCs to micrometastases, and ultimately into 
macroscopic tumors. The adaptation to the metastatic niche can take a long time. In some 
cancers such as breast cancer and melanoma, macroscopic metastases may erupt decades after 
the primary tumor has been surgically removed. This means that these metastatic cells can 
pass through a state of dormancy before acquiring full metastatic growth (Aguirre-Ghiso, 
2007). According to the current knowledge, the mechanism of dormancy can be summarized 
as a maladaptation of the DCCs to the new microenvironment because they are deprived of 
appropriate adhesive and signaling interactions (Liu et al., 2002; Shibue and Weinberg, 2009). 
So DCCs undergo dormancy as a consequence of intrinsic defects or in response to inhibitory 
signals originating in the stroma of target organs. Other systemic signals that appear to 
promote dormancy of micrometastic lesions are usually blocking neoangiogenesis (Hanahan 
and Folkman, 1996; Nyberg et al., 2005). During this lag time, DCCs need to overcome the 
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adaptation problem by activating other mechanisms like enhanced survival signaling (Chen et 
al., 2011; Gao et al., 2012; Zhang et al., 2009). After a variable time, a small minority of 
dormant DCCs undergoes reactivation in order to give rise to micrometastases. A large 
fraction of micrometastases regress because they fail to establish a tolerant microenvironment, 
further contributing to the inefficiency of colonization (Luzzi et al., 1998). However, small 
fractions of micrometastases that have adapted to the microenvironment grow into 
macroscopic lesions (Eyles et al., 2010).  
Systemic and local niche signaling can drive the reactivation of metastatic pathways. 
Carcinoma cells can establish an accommodating niche in the target organ even before the 
seeding. In fact primary tumors release systemic factors that shape the local 
microenvironment of the niche and other factors that promotes angiogenesis (Psaila and 
Lyden, 2009). Organ-specific reactivators originating in the parenchyma of target organ, such 
as Coco, induce solitary breast cancer cells to undergo reactivation at lung metastatic sites 
(Gao et al., 2012). Additional signals, such as the expression of Tenascin C (TNC) can 
participate in the reactivation of micrometastatic lesions facilitating the activation of WNT 
and NOTCH pathways (Malanchi et al., 2012; Oskarsson et al., 2011). The metastatic 
outgrowth relies also on the recruitment of other cells of the tumor microenvironment like 
endothelial progenitor cells (Png et al., 2012), myeloid cells (Kim et al., 2009) and stromal 
fibroblasts (Elkabets et al., 2011) suggesting that neoangiogenesis, inflammation, and fibrosis 
foster this process (Joyce and Pollard, 2009). 
1.4 Prognostic significance CTCs/DCCs as surrogate of minimal residual disease 
The intrinsic metastatic potential of CTCs/DCCs makes them suitable surrogates of minimal 
residual disease (MRD), which is clinically not detectable (Riethdorf and Pantel, 2010). The 
presence of MRD may influence patient’s prognosis despite successful tumor excision and 
completed adjuvant therapy. CTCs arrived quickly in clinical studies because of the easy 
accessibility of patient’s blood samples. Numerous studies, mainly based on the enumeration 
of CTCs, have shown the prognostic significance of CTCs correlating the number of detected 
cells with the poor overall survival (OS) and disease free survival (DFS) in different types of 
cancers (Lianidou et al., 2014). Also for DCCs, relevance for patient prognosis has been 
indicated in relevant studies correlating their presence in bone marrow or lymph node with 
relapse and poor OS (Braun et al., 2000; Hosch et al., 2000; Kubuschok et al., 1999; Passlick 
et al., 1994; Passlick et al., 1999; Pierga et al., 2004; Thorban et al., 1996; Vashist et al., 
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2012; Weckermann et al., 2001). Despite the numerous clinical data indicating that these cells 
are involved in the metastatic process, the genomic characterization of CTCs/DCCs is still 
incomplete and needs supporting data. 
1.4.1 Available genomic data of the CTCs/DCCs 
Genomic profiling studies have been performed on CTCs (Fabbri et al., 2013; Gasch et al., 
2013; Heitzer et al., 2013; Ulmer et al., 2004), although most of the data derive from patients 
with metastatic disease (M1-stage) or from pooled CTCs (Magbanua et al., 2013; Magbanua 
et al., 2012). In these studies detection of late-stage genomic alterations is evident. Only few 
studies have pinpointed the attention to a deeper genomic characterization of single early-
stage DCCs (Klein et al., 2002; Schardt et al., 2005; Schmidt-Kittler et al., 2003; 
Weckermann et al., 2009). DCCs isolated from patients without systemic tumor spread (M0-
stage) are genetically different from patients with tumor spread (M1-stage). DCCs from M0-
stage have a significantly low number of chromosomal changes than DCCs from M1 stage. 
For example, point mutations characteristic of the primary tumor are mainly absent (Klein et 
al., 2002) and typical chromosomal aberrations are often not present (Schmidt-Kittler et al., 
2003; Weckermann et al., 2009). Additionally, there are no evidences of telomere crisis or 
loss/gains of whole chromosomes (Schmidt-Kittler et al., 2003). Instead there are general 
genetic instability and subchromosomal DNA changes (gain/losses) (Schardt et al., 2005). 
DCCs isolated from the bone marrow or lymph nodes of patients without manifest metastasis 
(M0-stage), do not share much chromosomal aberration and present heterogeneous genomes 
(Klein et al., 2002; Schardt et al., 2005; Schmidt-Kittler et al., 2003; Stoecklein et al., 2008). 
This finding is true also for DCCs isolated from the same patient (Klein et al., 2002; Schmidt-
Kittler et al., 2003). On the contrary, when the metastatic disease spreads, the genome of the 
DCCs becomes stable and more similar between individual cells suggesting the expansion of 
an aggressive clone (Klein et al., 2002; Weckermann et al., 2009). Moreover, the genomes of 
DCCs in patients with metastatic disease are often similar, but not identical, to the 
predominant clone found in the primary tumors (Heitzer et al., 2013; Klein et al., 2002; 
Schmidt-Kittler et al., 2003). These data suggest that DCCs deriving from patients without 
overt metastasis disseminate in a genetically immature state without the typical genomic 
changes (Klein, 2013). Genomic instability accumulated outside the primary tumor, during 
years or decades, may play a role in the process of metastatic reactivation. 
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1.5 Genomic instability in cancer cells 
Genomic instability is a hallmark of cancer that leads to an increase of genetic alterations 
enabling the acquisition of additional capabilities for tumorigenesis and progression. Genomic 
instability generates a variety of genetic alterations ranging from single nucleotide differences 
to large-scale changes at the chromosomal levels (Lengauer et al., 1998). The establishment 
of genomic instability is probably the initiating event as it has been shown that it is present in 
all stages of cancer, from precancerous lesions, even before TP53 mutations are acquired 
(Bartkova et al., 2005; Gorgoulis et al., 2005), to advanced cancers. The most prevalent form 
of genomic instability, observed in over 90% of all malignancies, is chromosomal instability 
(CIN), and it is detected throughout the entire neoplastic transformation process, from 
premalignant lesions to metastatic lesions (Gagos and Irminger-Finger, 2005). In particular, 
chromosomal instability is occurring during the conversion from ductal hyperplasia to in situ 
carcinoma, that means before the cancer becomes morphologically invasive (Chin et al., 
2004). CIN refers to alterations of segments of chromosomes, or whole chromosomes, in 
terms of their structure or number, including also amplifications, deletions, translocations, 
insertions and inversions (Geigl et al., 2008). So far it has been proposed that chromosomal 
imbalances are among the earliest changes of pre-cancerous lesions and are associated with 
hyperproliferation in breast cancer (Allred et al., 2001; Buerger et al., 1999; Waldman et al., 
2000).  
1.6 Gene fusion in hematological and solid cancers 
Chromosomal aberrations, in particular translocations and their corresponding gene fusions, 
have an important role in the initial steps of tumorigenesis. At present 2276 gene fusions have 
been identified in both hematological disorders and solid tumors 
(http://cgap.nci.nih.gov/Chromosomes/Mitelman).  
Historically, fusion genes have been associated only with hematological malignancies 
because the first discoveries have been made in these groups of neoplastic disorders. For 
example, the first translocation with oncogenic properties BCR-ABL1 t(9;22)(q34;q11) was 
identified in chronic myelogenous leukemia (CML) (Rowley, 1973). This rearrangement 
forms a chimeric protein with increased tyrosine kinase activity and abnormal cellular 
localization. Around the same time, the IGH-MYC t(8;14)(q24;q32) translocation in Burkitt 
lymphoma was identified (Zech et al., 1976). This translocation links the immunoglobulin 
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heavy chain enhancer to the MYC oncogene leading to the enhanced activation (Mitelman et 
al., 2007; Rabbitts, 2009). Since then, dozens of fusions have been identified in hematologic 
cancers as the IGH-BCL2 t(14;18)(q32;q21) that drives the follicular lymphoma (Vaandrager 
et al., 2000) or the gene fusions PML-RARA t(15;17)(q22;q12) in acute promyelocytic 
leukemia (APL) and RUNX1-RUNX1T1 t(8;21)(q22;q22) in acute myeloid leukemia (AML) 
(Mitelman et al., 2007; Taki and Taniwaki, 2006).  
Until recently, fusion genes caused by recurrent chromosome aberration were thought 
to be a feature of hematological and sarcoma cancers, but not of carcinomas, where other 
mechanisms such as deletion and point mutation were thought to be more important, and 
recurrent chromosomal aberrations were rarely seen. Thyroid carcinoma was the first 
epithelial tumor in which a gene fusion, CCDC6-RET inv(10)(q11.2;q21), was detected 
(Pierotti et al., 1992). Rearranged-during-transfection gene (RET) encodes for a receptor 
tyrosine kinase. The juxtaposition of the C-terminal region of the RET protein with an N-
terminal portion of another protein leads to constitutive activation of the RET kinase 
(Mulligan, 2014). Together with this, other 14 gene fusions, 9 of which involve RET gene, 
have been identified in various subset of thyroid carcinoma with 40% of thyroid carcinomas 
harboring one of these chimeric genes (Pierotti, 2001).  
TMPRSS2-ERG gene fusion has been shown to be the most common gene 
rearrangement found in 40-80% of prostate cancer cases (Soller et al., 2006; Tomlins et al., 
2005). The fusion of these genes leads to the production of ERG under the control of the 
androgen sensitive promoter elements of TMPRSS2. This allows for a situation in which 
androgen-bound androgen receptor can bind these regions of TMPRSS2, resulting in the 
overexpression of ERG. This over-production of ERG can then exert its effects by binding 
target gene promoter regions, which results in their activation or inhibition, and the generation 
of a neoplastic phenotype (Tomlins et al., 2005).  
The fusion gene EML4-ALK identified in non-small-cell lung cancer (NSCLC) is an 
aberrant fusion gene that encodes a cytoplasmic chimeric protein with constitutive kinase 
activity (Soda et al., 2007). EML4-ALK is uncommon, occurring in 2 to 7% of all non–small-
cell lung cancers (Rikova et al., 2007). In general, while some fusions can be really specific 
by occurring between two invariant genes (i.e. BCR-ABL), it can also happen that one gene 
can be combined with many others, for example MLL, RET, ALK and the ETS family 
(Mitelman et al., 2004).  
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1.7 Mechanisms leading to the formation of chromosome translocations 
The formation of a translocation requires three basic steps: firstly, the occurrence of multiple 
DNA double strand breaks on distinct chromosomes, secondly, the physical association of the 
broken ends, and finally the rejoining of the broken partner chromosomes (Roukos et al., 
2013). Biologically, most, if not all, chromosome aberrations arise after DNA double-strand 
breaks (DSBs) that may arise spontaneously through replication errors, exogenous stress such 
as ionizing radiation and chemotherapeutic agents, or from scheduled breaks induced during 
development of the adaptive immune system, such as V(D)J recombination and 
immunoglobulin gene class-switch recombination (Aplan, 2006; Povirk, 2006). Additionally, 
complex damages that induce the collapse of the replication fork (Arnaudeau et al., 2001) are 
also responsible to generate DSBs. The main mechanisms joining the DSBs are homologous 
recombination (HR) and non-homologous end-joining (NHEJ). HR is mainly active during 
the S and G2 phases, in normal cells, at which a homologous sister chromatid is available. On 
the contrary, NHEJ is continually functional through the cell cycle (Branzei and Foiani, 2010; 
Shrivastav et al., 2008) without the need for template DNA. The characteristic of NHEJ is the 
absence of sequence homology at the end of DSBs that can result in either precise end-
joining, insertion between breakpoints, or deletions (Lieber, 2010). In a subclass of NHEJ, the 
micro-homology-mediated end-joining (MMEJ), the process of re-joining can be facilitated 
by regions of micro-homologies between ssDNA exposed at the ends of the DSBs (Lieber, 
2010) and it is responsible for structural mutations in primary cancers and cell lines (Chiarle 
et al., 2011; Hakim et al., 2012; Klein et al., 2011).  
An important factor that affects the translocation outcome and plays a role for the 
occurrence of gene fusions is the spatial proximity of the involved genes within the nucleus 
(Cremer et al., 2006). In fact, cytogenetic studies have pointed to a strong correlation between 
spatial proximity of chromosomes or genes and their translocation frequencies by showing 
that proximal genome sites are more likely to form translocations than distal ones (Meaburn et 
al., 2007). For example, the spatial proximity of the MYC gene, relative to its possible 
translocation partners IGH, IGK and IGL in Burkitt’s lymphoma, directly correlates with the 
observed frequency of these translocations in patients (Roix et al., 2003). Similar examples 
are BCR-ABL in chronic myeloid leukemia (CML) (Lukasova et al., 1997), TPR-NTRK1 and 
RET-ELE1 in papillary thyroid carcinoma (Nikiforov et al., 1999; Roccato et al., 2005). 
Factors that predispose genomic regions to breakage and translocations can be different. DNA 
sequence features as well as chromatin properties may facilitate breakage susceptibility of 
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genome regions (Figure 2). 
 
Figure 2: DNA and chromatin features involved in breakage susceptibility and examples of fusion genes formation.  
1.7.1 DNA sequence features as susceptibility sites of breakage 
DNA sequences, such as nuclease recognition sites, are recognized by endogenous nucleases 
and lead to the formation of DSBs and translocations. For example, in germinal center B cells, 
activation-induced cytidine deaminase (AID) recognizes a single-strand sequence motif 
during the transcription of regions involved in somatic hypermutation and class-switch 
recombination and promotes DSBs to generate antibody diversity (Stavnezer et al., 2008). 
However, misrecognition of non-Ig targets can generate translocations as observed in B cell 
lymphomas for IGH-MYC (Okazaki et al., 2007; Robbiani et al., 2008) (Figure 2A). It has 
been shown that in prostate cancer, AID is co-recruited with liganded androgen receptor (AR) 
to AR-binding DNA sequences, sensitizing them to DSB breaks and leading to the formation 
of translocations involving TMPRSS2, ERG and ETV1 (Lin et al., 2009).  
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CpG islands represent also candidates regions prone to breakage. In fact, CpG dinucleotides 
are present in 40–70% of bcl-2 and bcl-1 breakpoints in pro-B and pre-B lymphocytes 
suggesting that CpG islands facilitate the breakage (Tsai et al., 2008) (Figure 2A).  
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that repeats such as LINE-1 and Alu elements are major contributors to structural variation 
(Beck et al., 2010; Ewing and Kazazian, 2010; Huang et al., 2010) (Figure 2A). These can 
join either with other Alu elements or with non-Alu sequences. Alu–Alu intra-chromosomal 
recombination was seen in mixed lineage leukemia (MLL) gene, involved in acute myeloid 
leukemia (Hess, 2004; So et al., 1997). In the Philadelphia chromosome, BCR and ABL1 
genes contain Alu elements near their breakpoint regions, which may possibly lead to the 
occurrence of Alu-mediated DNA recombination (Jeffs et al., 2001). Furthermore, fine 
mapping of the deletion breakpoints located within the ERG and TMPRSS2 loci, followed by 
sequencing, revealed the presence of consensus sequences homologous to the human Alu-Sq 
and Alu-Sp subfamily (Liu et al., 2006). The presence of these consensus sequences within 
intronic regions correlated with the presence of the fusion gene and may be a factor 
contributing to the deletion at 21q22.2-3, resulting in the fusion gene. 
1.7.3 Common fragile sites and DNA structures 
Common fragile sites (CFS) have also been linked to translocations (Arlt et al., 2006) (Figure 
2B). CFSs are regions of chromosomes containing gaps and constrictions in metaphase under 
partial replication stress, and these regions have been shown to be prone to breakage (Ozeri-
Galai et al., 2012). A potential link between fragile sites and translocation formation comes 
from the observation that exposure of thyroid cells to chemicals that induce fragile sites 
promotes RET-PTC translocations (Gandhi et al., 2010). Some common sequence features 
have been identified responsible for the emergence of CFSs. CFSs are enriched in strings of 
AT-dinucleotide repeats that give these regions high DNA helix flexibility and the ability to 
form stable non-B DNA secondary structures, which may inhibit DNA replication (Inagaki et 
al., 2009). In fact, translocations have been postulated to form at AT palindromic sequences 
through a mechanism involving cruciform DNA structures that may be prone to breakage 
(Kurahashi et al., 2010). Indeed, computational analysis of five translocation genes (CBFB, 
HMGA1, LAMA4, MLL, and AFF4) revealed significantly high AT content (Burrow et al., 
2009).  
More direct evidence for DNA secondary structures in breakage and translocations 
was the discovery that the major breakpoint region of bcl-2 adopts a stable non-B DNA 
structure that is targeted by recombination-activating genes (RAGs) in a sequence-
independent manner (Raghavan et al., 2004). By containing stable regions of single-strands, 
this DNA structure promotes RAG-mediated cleavage of the bcl-2 locus and formation of the 
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translocation IGH-BCL2 t(14;18)(q32;q21) in follicular lymphoma (Raghavan et al., 2004). 
This secondary structure may be a ‘G-quadruplex,’ a four-stranded DNA structure that can 
spontaneously form in G-rich sequences (Katapadi et al., 2012) (Figure 2B).  
Topological features of DNA may also contribute to breakage susceptibility. 
Topoisomerase II (TOP2) generates a transient DSB to regulate under-winding and over-
winding of DNA, for example in mitotic chromosomes and in replication, and also during 
transcription (Felix et al., 2006; Ju et al., 2006). The TOP2 beta isoform has been shown to 
associate with androgen receptor upon transcriptional activation and to trigger DSBs at 
TMPRSS2 and ERG breakpoints in prostate cancer (Haffner et al., 2010) (Figure 2B).  
1.7.4 Chromatin structure and translocations 
Various aspects of chromatin may play a role in chromosome breakage susceptibility and 
translocations (Figure 2C). DSBs occur primarily in transcriptionally active regions. 
Breakpoints in, or near, transcriptionally active genome regions have been documented in 
anaplastic large cell lymphoma (Mathas et al., 2009). Similarly, liganded androgen receptor, a 
potent transcriptional activator, binds near the breakpoints of TMPRSS2, ERG, and ETV, 
which are involved in translocations in prostate cancer and under genotoxic stress, induces 
translocations (Lin et al., 2009). This means that chromatin remodeling and binding of 
transcription factors may predispose genomic regions to breakage and translocations. 
Histones, that modulate transcription, are also potential candidates in DSB susceptibility and 
translocation mechanisms. Genome-wide mapping of a set of histone modifications in seven 
primary human prostate cancers has indicated possible enrichment of active chromatin marks, 
H3K4me3, H3K36me3, and acetylated H3, over the TMPRSS2-ERG translocation region 
(Berger et al., 2011).  
1.8 Gene fusion as primary events of chromosomal instability in early tumorigenesis and 
potential relevance for CTCs/DCCs 
Translocations play an undisputed role in the initial steps of carcinogenesis and it is estimated 
that they are causal in 20% of cancers. There is striking evidence in support of their role the in 
the initiation of cancer. First, they are usually closely correlated with specific tumor 
phenotypes (Borden et al., 2003; Johansson et al., 2004). Moreover, it has been shown, 
predominantly in hematological malignancies, that successful treatment is associated to a 
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decrease or eradication of the disease-associated gene fusion (Deininger et al., 2005; Kern et 
al., 2005). Supporting studies in experimental animal models have shown that gene fusion 
constructs generally give rise to neoplastic disorders of the same type as those seen in 
sporadic human neoplasms that carry the same gene fusion (Rego et al., 2006). Finally, 
silencing fusion transcripts in vitro leads to the reversal of tumorigenicity, decreased 
proliferation and/or differentiation (Thomas et al., 2006). The identification of balanced 
structural chromosome changes is therefore very important, and the breakpoints involved 
could indicate the location of genes relevant for early metastatic progression.  
Based on these assumptions it will not be surprising that CTCs/DCCs, representing 
early metastatic cells, would contain gene fusions as some of the initial genomic aberration 
necessary for the migration and survival at ectopic site. For example, it has been shown that 
TMPRSS2-ERG is an early event necessary for the transition from prostatic intraepithelial 
neoplasia (PIN), a precursor lesion of prostate cancer, to invasive prostate cancer (Perner et 
al., 2007). In addition, transgenic studies have reported that mouse prostate with TMPRSS2–
ERG gene fusion alone develops PIN (Tomlins et al., 2008), but when cooperating with other 
oncogenic pathways, such as PTEN deletion or androgen receptor (AR) overexpression, it 
leads to the development of prostatic adenocarcinoma (King et al., 2009; Zong et al., 2009). 
So TMPRSS2-ERG, although alone is not responsible for cancer progression, can be 
considered a major driver of tumorigenesis by regulating and cooperating with other 
mechanisms (Sun et al., 2008; Wang et al., 2008; Yu et al., 2010). 
1.8.1 Technical challenges to detect gene fusions in early CTCs/DCCs 
Methods to identify chromosomal changes, which target different kind of aberrations, are 
available. In general, their applicability to single cells, such as for the deeper genomic 
characterization of CTCs/DCCs, is possible but still very challenging.  In order to identify 
recurrent and rare gene fusions with a role in early metastasis and to use them as a target to 
decrease, or even eradicate, MRD after the curative surgery, novel methods are needed. 
Figure 3 outlines some of the current methods used to identify genomic abnormalities. As can 
be seen, while some chromosomal changes can be easily assessed from the use of different 
technologies, genes fusions as balanced translocations are detected only with techniques such 
as spectral karyotyping (SKY) and multicolor FISH (M-FISH), but still with technical 
limitations. Even worse, karyotyping of solid tumors is more challenging due to poor 
chromosome morphology, and the karyotypes are often so complex that they cannot be 
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characterized completely (Mitelman et al., 2004). In fact, due to the complexity of 
combinatorial labeling used to color the chromosomes, unknown cryptic translocations may 
be very difficult to detect, and even the identification of known balanced rearrangements 
depends critically on the fluorochrome combination in the chromosomes involved in 
rearrangements (Kearney, 2006). Moreover the labor intensity required and the low resolution 
makes them not suitable for the screening of chromosomal rearrangements. It is now clear, 
with the advent of the next generation sequencing (NGS) that the lack of recurrent gene 
fusions in epithelial tumors stems from the difficulties of performing cytogenetic analysis and 
that the actual proportion of malignancies with recurrent rearrangements may be as high in 
epithelial tumors as in hematological malignancies (Mitelman et al., 2004). In fact, the 
discovery of TMPRSS2-ERG lead to the conclusion that, considering the high incidence of 
prostate cancer and the high frequency of the fusion, this is the most frequent gene 
rearrangement described (Tomlins et al., 2005). The advent of NGS technologies has started 
to unravel a complex universe of chromosomal translocations and to show that some are 
unique to individual tumors and even different from patient to patient. So only whole genome 
sequencing (WGS) approaches have the power to detect all the somatic mutations in a cell but 
the costs are still very high to make it affordable and applicable for routine screening. 
 
Figure 3: Comparison of techniques for identifying chromosomal abnormalities. A ‘+’ indicates that an approach is suited for identifying the 
chromosomal rearrangement, a ‘-’ indicates that the aberration would be missed. A (+) indicates that several experiments are needed.  
Adapted and modified from Speicher MR, Nat Rev Genet, 2005  
in the Ewing sarcoma family of tumours, is primarily
detected by FISH using a commercial probe with an approxi-
mate size of 190 kb. Owing to limitations in resolution, FISH
analysis may fail to detect microdeletions smaller than
190 kb.44 In their study, array CGH was performed which
revealed 9p21.3 deletions encompassing the CDKN2A
locus in eight-cell lines and in six tumours. In four cases
(two cell lines and two tissue samples), the deletion was
less than 190 kb in size, including a 58-kb microdeletion,
implicating CDKN2A FISH analysis can give false-negative
results in cases with small microdeletions.44
Conclusion
Despite the minor disadvantages discussed in the previous
section, the advent of FISH in cytogenetics in has proved
invaluable in both diagnostics and research. The power of
its ability to identify specific genetic aberrations has pro-
pelled FISH-based techniques to the forefront of screening
procedures for prenatal,45, 46 paediatric47 and adult cases48
in a wide variety of cell types, including paraffin-embedded
tissue, making FISH analysis data a useful tool in the
decision of therapy to combat cancer.49 This is supported
by a recently conducted survey by Wordsworth et al.50
who reported that the most common techniques used for
the testing of somatic mutations in laboratories were IHC
and FISH. Most of the laboratories surveyed predicted
testing would increase over the next 10 years, particularly
for DNA testing using microarrays.50 I agree with the
results of this survey and believe the near future of FISH
lies in array-based technology, either with disease-specific
CGH arrays that test for every known abnormality for a par-
ticular cancer; or disease-specific microarrays that display the
mRNA expression levels of any oncogene and tumour sup-
pressor gene; or a possible hybrid of the two displaying
both quantitative and qualitative data. Steps to achieving
these short-term goals have already been achieved: disease-
specific arrays have been constructed for cancer diagnostics
for some tumour types such as chronic lymphocytic leukae-
mia and certain types of lymphoma51, 52 and automated
FISH imaging systems such as the Ariol SL-50 are already
well-established in detecting patterns of genetic alterations
during cancer development.53
The ultimate goal of FISH utilization would be an array-
based screen using the complete oncogenic repertoire to diag-
nose any prenatal or postnatal aberration(s). Any mutations
could be rectified accordingly using gene therapy as a method
of cancer prevention. However, the prevalence of mutations
in human cancers are highly variable, each with a unique
assortment of abnormalities that contribute towards tumour-
genesis at different developmental stages and extents.
Improved aetiology through techniques such as FISH may
Figure 9. Comparison of cytogenetic techniques for identifying chromosomal abnormalities. A ‘þ’ indicates that an approach is suited for identifying the
chromosomal rearrangement, a ‘2’ indicates that the aberration would be missed. In the case of heterogeneity, both array CGH and conventional CGH
could detect the abnormality. Amplifications in which the amplified region is easily visible in banding analysis are noted as double minute (DM) chromo-
somes or homogeneously stained regions (HSR), and amplifications where the amplified region is scattered throughout the genome are noted as small
insertions (distributed insertions), making identification using banding analysis impossible. Asterisk indicates that several experiments are needed. Dagger;
indicates the detection rate of interphase cytogenetics depends on probe selection. Adapted from Speicher and Carter.35 Reprinted by permission from
Macmillan Publishers Ltd: Nat Rev Genet 6: 782–792, copyright 2005.
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1.9 Aim of the work  
The aim of this dissertation was to establish a method for the identification of novel genomic 
breakpoints in single-cell genomes. Available techniques used to identify chromosomal 
translocations, as karyotyping by G-banding showed to have a breakpoint resolution in the 
magnitudes of 5 to 15Mb. Interphase (and metaphase) FISH can only detect known genetic 
aberrations, providing that the specific probe is available. Therefore, FISH cannot serve as a 
screening test for chromosomal rearrangements since most FISH techniques can only detect 
known imbalances. SKY (and M-FISH) can detect multiple karyotype abnormalities 
simultaneously, but both techniques are dependent on combined fluorochrome probes. In 
addition, these techniques can be labor intensive. To overcome these limitations, a method to 
allow the isolation and enrichment of fusion breakpoints in single-cell genomes had to be 
developed. 
To identify genomic breakpoints at nucleotide resolution, the method should meet the 
following criteria: (1) applicability to single-cell Ampli1 whole genome amplification (WGA) 
products, (2) reduction in complexity by subdividing the WGA in distinct genomic 
populations according to determined nucleotide combinations, (3) enrichment of breakpoints 
contained in the subdivided genomic populations by subtractive hybridization technique, (4) 
monitoring the enrichment of genomic breakpoints by means of quantitative real time PCR, 
(5) high sensitivity enabling detection of low copies genomic breakpoints, (6) high specificity 
minimizing the rates of false-positive chimeric sequences. 
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2 Materials and Methods 
2.1 Materials 
 
Table 1: Chemicals 
Product Company 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 
(C8H18N2O4S) pH 8.0 
Applichem GmbH 
Agarose, for routine use Sigma-Aldrich 
Ammonium Acetate  3M pH 5.2 (CH3COONH4) Merck KgaA 
Bromphenolblu (C19H10Br4O5S) Fluka (Biochemika) 
Chloroform 99.8% pure (CHCl3) Sigma-Aldrich 
Deionized Formamide (CH3NO) Sigma-Aldrich 
Ethanol (C2H6O) 99,9 % J. T. Baker 
Ethidiumbromid (C21H20BrN3) Fluka BioChemika 
Ethylenediaminetetraacetic acid (EDTA-C10H16N2O8) Sigma-Aldrich 
Hank’s buffered salt solution, with NaHCO3 10X (HBSS) Biochrom AG 
Igepal CA-630 (Octylphenoxypolyethoxyethanol) 
(C2H4O)nC14H22O 
Sigma-Aldrich 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) (C9H18O5S) Biomol GmbH 
Linear Polyacrylamide Carrier (LPA) 5mg/ml Ambion, Inc. 
Magnesium Acetate BioUltra, 1M in H2O (Mg(CH3COO)2) Sigma-Aldrich 
Magnesiumchlorid (MgCl2) Carl Roth GmbH+Co 
Nonidet P40 (C18H30O3) (NP40) Sigma-Aldrich 
PCR-H2O (LiChrosolv for Chromatography, DNAse-RNAse free) Millipore-Merck 
PCR-Oil Sigma-Aldrich 
Percoll  GE Healthcare Life Sciences 
Potassium Acetate (CH3COOK) Sigma 
Potassium Chloride (KCl) Merck KgaA 
Potassium dihydrogenphosphat (KH2PO4) Merck KgaA 
Roti-Phenol/Chloroform/Isoamyl alcohol 25:24:1 pH 7.5 -8.0 Carl Roth GmbH&Co  
RPMI (Roswell Park Memorial Institute Medium) medium 1640  Gibco BRL 
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Sodium Chloride (NaCl) J. T. Baker 
Sodium dihydrogenphosphat (Na2H2PO4) Monohydrat Merck KgaA 
Sodium dodecyl sulfate (SDS) (C12H25O4SNa) Serva 
Tris EDTA-Buffer 1X - pH 8,0 AppliChem GmbH 
Tris-HCl pH 8,8 (C4H11NO3) Applichem GmbH 
Trizma Acetate BioUltra, >99.0% (NH2C(CH2OH)3·CH3COOH) Sigma-Aldrich 
TWEEN® 20 (C58H114O26) Sigma-Aldrich 
X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactoside) 
(C14H15BrClNO6) 
Roche 
Xylencyanol (C25H27N2NaO6S2) Merck KgaA 
 
Table 2: Consumables for cell culture and cloning  
Product Company 
Ampicillin Na-Salt (C16H18N3O4SNa) Biomol GmbH 
Bovine Serum Albumin, bioreagent 20 mg/ml, Protease Free (for 
picking) Sigma-Aldrich 
Fetal Bovine Serum (FBS) Sera Plus Pan-Biotech 
K562 leukemia cell line Sigma-Aldrich 
LAB-Tek Chamber slides, 8 well NUNC GmbH 
NEB 10-beta Competent E. Coli (High Efficiency) New England Biolabs 
Penicillin (100x) (C16H18N2O5S) PAA Laboratories 
pGEM®-T Easy Vector System I Promega 
Pepton (Select Pepton 140) Invitrogen 
Petri dish (90 mm) Greiner Bio-One 
Qiagen Plasmid Midi Kit Qiagen 
RPMI (Roswell Park Memorial Institute) Gibco 
Streptomycin (100X) (C21H39N7O12) PAA Laboratories 
Trypton/Pepton from Casein Carl Roth GmbH+Co  
Yeast extract (Select Yeast Extract) Invitrogen 
 
 
 
Materials and Methods  
 25 
Table 3: Consumables for Whole Genome Amplification (WGA), Fractioning, Subtractive Hybridization and 
Quality Control 
 
 
Table 4: Buffers and solutions 
Buffers and solutions Composition 
Binding Buffer (BP2X) for Dynal Streptavidin-
Beads 
2 M NaCl, 20 mM Tris-HCl (pH 8,0), 2 mM EDTA (pH 8,0) 
Binding Buffer (BP1X) for Dynal Streptavidin-
Beads 
1 M NaCl, 10 mM Tris-HCl (pH 8,0), 1 mM EDTA (pH 8,0) 
HEPES-Buffer 
140 mM NaCl, 1,5 mM Na2HPO4, 50 mM HEPES. Sterile filtered 
(0,22 µm).  
Hybridization Buffer  50 mM HEPES, 0.2 mM EDTA, pH 8.9 
Product Company 
Adenosine-5’-Triphosphate (ATP-10mM) Roche 
Agilent High Sensitivity DNA Kit Agilent 
Bovine Serum Albumin (BSA) 20 mg/ml Roche 
dATP, dTTP, dCTP, dGTP (Sequencing Grade) GE Healthcare Life Sciences 
DNA Molecular Weight Marker 2-Log New England Biolabs 
Dynabeads® M-280 Streptavidin  Invitrogen 
Expand Long Template PCR System Roche 
LightCycler FastStart DNA Master SYBR Green I Roche 
MAXYMum Recovery™ PCR Tubes Axygen Scientific 
Microcon YM-30 Millipore 
Nanolink Streptavidin Magnetic Beads Solulink, Inc. 
Phase Lock Gel  5’ Prime 
Pipets (P2, P20, P200, P1000) Gilson 
QIAprep Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
Qubit dsDNA Reagents and Kits Invitrogen 
Trimmer-2 cDNA normalization kit Evrogen 
UltraPure Herring Sperm DNA (10 mg/ml) Invitrogen 
Yeast tRNA (10mg/ml) Invitrogen 
Wizard® SV PCR Clean-Up System Promega 
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Nucleic Acid Binding and Wash Buffer (BW) 50 mM Tris-Hcl, 150 mM NaCl, 0,05% Tween 20, pH 8.0 
One-Phor-All Buffer plus (OPA+)  100mM NH2C(CH2OH)3·CH3COOH pH 7.5, 100mM 
Mg(CH3COO)2, 500mM CH3COOK 
Phosphate Buffered Saline (PBS1X) 8,5 mM Na2HPO4, 2 mM KH2PO4, 150 mM NaCl, pH 7,4 
PCR-Buffer with dNTPs 10x 
500 mM KCl, 100 mM Tris HCl (pH 8,5), 10 mM MgCl2, each 
1 mM dATP, dTTP, dCTP, dGTP 
Tris-Solution 50 mM Tris/HCL (pH 8,9) 
Washing Buffer 1 50 (WP150 ) 0,1% SDS in HEPES-Buffer, 50% Formamide (deionized) in WP1 
Washing Buffer 2 50 (WP250) 0,05% Igepal in HEPES-Buffer, 50% Formamide (deionized) in WP2 
 
Table 5: Enzymes 
Product Company 
BspTI  (AflII) (10 U/µl) plus Buffer O (10X) Thermo Fisher Scientific 
DNA Polymerase Mix (5 U/µl) Expand Long Template PCR System Roche 
DraI (10 U/µl) plus Buffer Tango (10X) Thermo Fisher Scientific 
Exonuclease I (20U/µl) plus ExoI Buffer (10X) Thermo Fisher Scientific 
KspAI (HpaI) (10 U/µl) plus Buffer B (10X) Thermo Fisher Scientific 
Mse I (50 U/µl) New England Biolabs 
Mung-Bean Nuclease I (10 U/µl) plus MBN Buffer (10X) New England Biolabs 
Proteinase K (14-22 mg/ml) Roche 
Quick Ligase (50U/µl) - Quick Ligation Kit  New England Biolabs 
T4 DNA Ligase (≥ 5U/µl) Roche 
Taq DNA Polymerase (5 U/µl) Roche 
TruI (50U/µl) plus Buffer R (10X) Thermo Fisher Scientific 
Vsp I (AseI) (10 U/µl) plus Buffer O Thermo Fisher Scientific 
XmnI (20U/µl) plus Buffer 4 New England Biolabs 
 
Table 6: Equipment 
Product Company 
Electrophoresis Chamber  Biorad 
MJ Research PCR Thermal Cycler MJ Research 
LightCycler 480 Instrument II 96 wells Roche 
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Magnetic Rack (MPC-9600) Invitrogen 
Nanodrop 2000 Thermo Fisher Scientific 
Qubit 2.0 Fluorometer Invitrogen 
Roller SRT6 Stuart Scientific 
Table Centrifuge 5417C Eppendorf 
Termomixer  Eppendorf 
 
Table 7: Oligonucleotides 
Oligonucleotide* Sequence 5´→3´ Modification* 
23R´C TCG CAC TCG ACT ATC CTC TGG TT  
23R´G GAG CAA ATG ACC ATG CTA GCA CC  
23R’Am AAT TCG TCA ATC AGC TGC GCT TG  
23R’Tm TAG TCT CGG CTC AAC GTC AGG AT  
26RAn AAT TCG TCA ATC AGC TGC GCT TGT TT 5´Bio* 
26RC CTA TCG CAC TCG ACT ATC CTC TGG TT 5´Bio* 
26RGn TCT GAG CAA ATG ACC ATG CAG CAC C 5´Bio* 
26RTn GTA TAG TCT CGG CTC AAC GTC AGG AT 5´Bio* 
ddMse11 TAA CTG ACA G 3´ddC 
J13A TAA TGT CTG AGA C 3´ddC 
J13C TAA GGT CTG AGA C 3´ddC 
J13G TAA CGT CTG AGA C 3´ddC 
J13T TAA AGT CTG AGA C 3´ddC 
J20n TAG GTT CCA GCG TCT CAG AC  
J21 AGT CTC CAG GCT CTC ACC GCT  
J24A TGT AGG TTC CAG CGT CTC AGA CAT T  
J24C TGT AGG TTC CAG CGT CTC AGA CCT T  
J24G TGT AGG TTC CAG CGT CTC AGA CGT T  
J24T TGT AGG TTC CAG CGT CTC AGA CTT T  
Lib1 AGT GGG ATT CCT GCT GTC AGT  
R12C AAC CAG AGG ATA 3´ddC 
R13An AAA CAA GCG CAG C 3´ddC 
R13Gn T TA AGG TGC TAG C 3´ddC 
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R14Tn TAA TCC TGA CGT TG  3´ddC 
R21 GAC CTC GAC TAT CCA GTG ACT  
*: All oligonucleotides were HPLC purified. 
**: Oligonucleotides are also used without modifications for the generation of the A/C, A/G, A/T, C/G, C/T, and G/T-
fractions. 
 
Table 8: Adaptors 
Adaptor* Long Oligonucleotide Short Oligonucleotide 
26RA 26RA R12A 
26RAn 26RAn R13An 
26RC 26RC R12C 
26RG 26RG R15G 
26RGn 26RG R13Gn 
26RT 26RT R13T 
26RTn 26RTn R14Tn 
J21 J21 J12 
J24An J24An J13An 
J24Cn J24Cn J13Cn 
J24Gn J24Gn J13Gn 
J24Tn J24Tn J13Tn 
Lib1 Lib1 ddMse11 
R21 R21 R12 
 
Table 9: Oligonucleotides for specific MseI-fragment control PCR 
Gene/Mark
er 
D* 
Frag-
ment** 
[bp] 
Position [GRCh38] Primer Sequence 5´->3´ 
T*** 
[°C] 
PCR-
Product 
[bp] 
D5S2117 AA 1376 133701437-133701583 5´ CCA GGT GAG AAC CTA GTC AG 58 147 
    3´ ACT GAG TCC TCC AAC CAT GG   
BCR  AA 751 23210945-23211187 5´ GAC CAT TCA GTG GTG GTT AG 61 243 
    3´ GCT CTA AGA ACT CTG TCA CC   
BRCA1 AA 594 43052727-43052877 5´ GGA TGG CCT TTT AGA AAG TGG 60 151 
    3´ ACA CAG ACT TGT CCT ACT GCC   
PDPR AA 568 70160956-70161099 5´ AAT CTT CTG TGG CCC ACA GT 55 144 
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    3´ GAC CCT TAT TGA CTA CAC TGG   
TP53  AA 558 7673515-7673888 5´ AGG ACC TGA TTT CCT TACTGC 58 374 
    3´ GAG GTC CCA AGA CTT AGT AC   
LPO AA 316 58242980-58267994 5´ CAG TTA GCC AAG ATA ATG CC 58 193 
    3´ CTC ATA AGG GGA TAA AGG AC   
TRAK1 AA 247 42212037-42212250 5´ GGG AGA ACA ATG AAT TGG CTC 55 214 
    3´ GAC CAG ACC ACC ATG GAT AC   
TRAK1 AA 128 42210614-42210726 5´ TAG AAC CAG GAA AGG CTC AG 55 113 
    3´ CAC TTT GAA CAC ATG TGT AAG C   
BCR TT 1936 23268437-23268849 5´ CGT GGA CAA CTA CGG AGT TG 61 413 
    3´ TCA GCC TCA GGA CTC TTG TG   
D16S3066 TT 536 73295993-73296182  5´ GCT GTT AAT ATG AAA CAA TTG CC 58 190 
    3´ GGG GTC TAA TGG TTC AGC C   
BCR TT 508 23218452-23218686 5´ CAC TAG TTG TCC CTG CTC AG 58 235 
    3´ GTC CAGTCA CTT GTG G   
CLASP2 TT 294 33510459-33510653 5´ CTG GCT GCA ATC AAA ATG CAA 58 195 
    3´ GAA GGC TTG ATC ATG CCA GT   
D6S314 TT 277 139693305- 139693514 5´ TAA TCC ACT TCC TGA CCT AG 60 210 
    3´ CTT CCC AGG TGA TTC TCA TG   
COG4 TT 261 70512286-70512502 5´ ACA CAA AGT GGC ATG GAC CT 55 217 
    3´ AAC CCA GCA GTG GGA AGA TC   
TFRC TT 242 196069661-196069791 5´ GCA TGA AAG ACA TAG GAG GC 58 131 
    3´ CAG GCA ACC CAA GTA AGA GAT   
TOP2B TT 209 25629781-25629957 5´ GAG ACT TGC CCG AAG ATG GT 58 177 
    3´ CTA CTT GTA GGT AGG CTG CTA   
ABL1  TT 173 130779351-130779475 5´ CAT CGT TCA TGATGG CAA GG 58 125 
    3´ GAA ATG TAC TGC GTT ATG CC   
D5S500 TT 159 138511343-138511474 5´ CTT TTT ACA TTT TTG GTA CCT TG 58 132 
    3´ GTA TCG GTG AAA TGC AAC TA   
ABL1 TT 157 130749086-130749227 5´ TTA TAC TAG ATC TTG AGC ACC 60 142 
    3´ CCC TCA TAA CTA CAA GAA CTC   
BCR CC 1233 23297396-23297719 5´ TTC GGT CCT TGC AGC AGA TC 61 324 
    3´ GTT GGG CAG AAT CTG AAC CTC   
ABL1 CC 291 130732130-130732401 5´ AGC TAC TTA GTG AAT AACG CAG 58 273 
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    3´ GAT CAG GTT GAG TAA ATG TCC   
ABL1 CC 203 130715659-130715806 5´ GTG ATG ATC ATG CAC CTT AC 59 148 
    3´ CAC AGG GAA CTA CAC TGC   
BCR  GG 1026 23309463- 23309759 5´ ACC GTC ATC GCC ATG AAT GG 60 297 
    3´ CCA GGT CCC TGA GTG GAG   
BCR GG 944 23295308-23295667 5´ CGG TGC CTG CAT GTA TCT TG 61 360 
    3´ ATT AGC CTG GGA GGA GAC C   
BCR GG 715 23272238-23272706 5´ TGT CAG GAA TTG TCA GTC AC 60 470 
    3´ AGC AGA CCT CTT AGC TGC TC   
D16S3019 GG 605 66095305-66095505 5´ CAA CTC ATT CCC TGT GTG AC 57 220 
    3´ AAC CAA GTG GGT TAG GTC AG   
BCR GG 367 23236242-23236571 5´ CTG GTC TCA GGT GAC TCT GA 58 329 
    3´ TAT CTT GGC TAG TAG GTG TGC   
D5S592 GG 348 119766170-119765980 5´ GTC AAC AAA GTA ATG TAA AGA CAG 58 191 
    3´ TGG AGT GGA GAG CGT CTC AG   
BCR GG 142 23238278-23238415 5´ AGA ATG GAA GAG TTC CTG GC 61 138 
    3´ ATG TTC CAG GTG TGG GCA G   
BCR AT 790 23173512- 23174076 5´ TGC AGG GGT ATG ATC ATA GC 64 583 
    3´ CTT CTC ATG CCT CAA AGC C   
BCR AT 701 23224613- 23224958 5´ AGC TCA CGC CTG TAA TCC C 66 346 
    3´ ATA AGA ACA CTT GCT CCA GCC   
BCR AT 600 23178127-23178700 5´ CCA TTG AGG GCT GGG TGC A 64 358 
    3´ GAG AAC ATT CCT GCC CTG GA   
D5S299 AT 550 102311503-102311661 5´ GCT ATT CTC TCA GGA TCT TG 58 159 
    3´ GTA AGC CAG GAC AAG ATG ACA G   
UBP1 TA 394 33393184- 33393363 5´ TCA GGT TTA CAG ACA GGG TC 55 180 
    3´ CCC AAC TCT CTG AAA ATG ATT C   
SRP19 AT 350 112877927-112878051 5´ ACT CAC TCT AGT GAT AAA TCG GG 60 110 
    3´ AGC AGA TAA GAC AGT ATT ACT AGT T   
D5S816 AT 307 135965886-135966063 5´ TTG CCA CTG AAA ATC ATA TCC 58 178 
    3´ CAG TGT CCC AGA CTC AGA C   
D16S3040 AT 302 79617710-79617849 5´ CTG CAA CAA GAA AGA TAC TCC 59 140 
    3´ AGT GCC TCA CAG GCT GCC   
APIG1 AT 220 71734412-71734630 5´ TAA AGT TCT GAA CCC TCA GAA G 56 219 
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    3´ TAA GAT GCC ACT AAG CCA CCT   
ZKSCAN7 CA 648 44555220-44555476 5´ CTA ACG GGC AGT AGA GTG TC 61 257 
    3´ CAC GTC TGC CCT GTT CAT CG   
CDH3 CA 637 68679828-68680048 5´ AGC TTC TGC TCT CAG AGT CA 57 221 
    3´ CAT GAG GAT GAT GCC ATC TAC   
RH27788 AC 576 23166313-23166701 5´ CAT AAG GGT GTG AAG AAC TG 60 389 
    3´ CTG TGA GAC TAG CCG TGC A   
D6S453 AC 479 141060084-14106022 5´ ACC TGG CTG AGG TAG GAC T 58 140 
    3´ ACT ATG GCT ACT AAT TGT GAC T   
AGTR1 AC 279 148742490-148742594 5´ CAG GAG ATG AGA GTT CCA GA 60 105 
    3´ GTA CCA GGT GCA AGT GTA GC   
D6S1633 AG 1317 156653724-156653993 5´ CTC ATG GAG CTT ATA GCC TG 59 270 
    3´ TGT TCC TTC TGG CTA GCA TG   
ULK4 AG 682 41455584-41455709 5´ AGA CTT CTG GGC CTG GAA C 59 126 
    3´ GAG GTA GAA TGC TTC CTC AG   
CDH1 AG 486 68823418-68823596 5´ GAA GCC AAA GAT GGC CTT AG 55 179 
    3´ CCA GAA TGG CAG GAA TTT GC   
ZFHX3 AG 480 72793791-72793934 5´ CAT GAC TTG AGG ACC TTC AG 56 144 
    3´ AAC CTC AAG CCT TGC AGA TC   
D5S399 AG 485 135991437 - 135991552 5´ ACG GAA CTT CAA TTG ACC TC 58 178 
    3´ GCA GGC TGT GGC CTC AAC   
RTP3 AG 394 46499543-46499844 5´ GTG TCC AGG GTT CTC CTA G 58 302 
    3´ GCA GCC ATG TGC TTC CTG C   
ANO10 AG 370 43549502-43549691 5´ CCT GTT TGC ATT GTG GTG AC 55 190 
    3´ CAG TAT CCA TAT TAC GTT TCT C   
D17S800 AG 333 40900195-40900347 5´ CTT ATG GTC TCA TCC ATC AGG 61 153 
    3´ GAC AGA AAG ATG GAT AAG ACA AG   
TP53 TC 1032 7674852-7675312 5´ TGC TGC CGT GTT CCA GTT GC 64 461 
    3´ ACC AGA CCT CAG GCG GCT CA   
ENTPD3 CT 651 40427301-40427590 5´ TGG CTA CAT GCT CAG CCT GA 61 290 
    3´ GGC AGC CAC TTC ACC TGC AT   
ZFHX3 TC 576 72798142-72798309 5´ CTG ACA TCC AAC AGC TTT ATG G 56 170 
    3´ GTA CTG ACC CAG AGT CAC TG   
CDH3 CT 552 68684785-68684903 5´ CAG AAC AAA CGT TGG CCA TG 59 119 
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    3´ ACA CTG CAG AAG ACC CTG AC   
D5S1360 TC 513 145518073-145518211 5´ ACA AAC AAA ACC AAG AGT GC 55 139 
    3´ TGG CTC ATG TAT CCC TAT GT   
D6S308 CT 262 140935578-140935791 5´ GCC TTG GAG AGA AAT TCA CGT A 61 214 
    3´ GGC CTC ATA GTC TAA TCA CTG   
OPN1SW TC 283 128773490-128773566 5´ GAC TCT ACC CAG GTT TCT AG 60 76 
    3´ CTG TGC TTA CCA AAG GCT TC   
BCR GT 1351 23240763-23241440 5´ CTG TCA CTA CTG TCC ATC TC 62 679 
    3´ GCA AAG GTG CTC AGC CAG   
BCR GT 1068 23270842-23271141 5´ ACA GCC TAG GCT ATT CAC TT 58 300 
    3´ ACA AAA TCA CGC CTG GCT G   
BCR GT 881 23253602-23253981 5´ GAG TGA GCT CAT GTT CAT CC 62 379 
    3´ CCG CTT TAG TGG ACT CCA G   
BCR GT 756 23211851-23212218 5´ GTG GAG CTG TTC TCA CTC AG 62 368 
    3´ CAT GTG GCT CGA TGG CTT CT   
BCR TG 670 23211862-23212054 5´ TGC CAG TTC AGA CCC TTA TG 58 192 
    3´ CTC ACT CAG TTT GTC CTC AG   
D5S615 TG 641 125827596-125827822 5´ GGT AAA CCC TCA AGC AGT C 57 227 
    3´ AAC CAG TTT CTT ATT ATA AGC C   
APC  TG 618 112840411-112840747 5´ CAA GGA AAC CAA GTC AGC TGC 57 330 
    3´ GCT TTA TTG TCA TCC AAT TCA G   
MYRIP TG 600 40162571-40162744 5´ GCA TTA TTG TGG GAC CTC ATG 57 174 
    3´ CAA AAA GGC TTC CTC CTG GCA   
FAM117A TG 260 49763020-49763196 5´ CAC GTT GGC TGC AAT GCC C 60 176 
    3´ CTG TCT CAT TCC AAC CAT CG   
CCK GT 231 42258050-42258159 5´ ACT ACA TGG GCT GGA TGG AT 60 109 
    3´ TCT GGG TTG GGA GGT TGC T   
ZNF19 GT 216 71474062-71474192 5´ GAA TTG GGT AGG GAG ATT CCA 56 131 
    3´ ACA CTG CAG AGA TCT CTC AG   
BCR GC 1071 23223449-23223707 5´ TTG TAG ATG CGG ATG CTG ACT CC 60 258 
    3´ TCA CCT GGA CCC TTG CCA ACT   
ZNF23 GC 417 71461493-71461783 5´ CCA AGT ACT GTA CTT TAG GTA G 55 290 
    3´ GCT CCT GAC ATA GGG TCA TG   
TRAK1 GC 355 42209657-42209884 5´ TCG TCC AGG TCA ACA TCC AG 56 228 
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    3´ AGG GGT TCA CGC TAA GCA CT   
ULK4 GC 298 41566092-41566235 5´ ACT TTG CAT GGT ATT ACC CAG 55 145 
    3´ ACC TTG TGC AAA GAA TGA   
HERBB2  GC 226 39698666-39698798 5´ GCT CAG CAC ATG GAA GCA AG 58 133 
    3´ GGA TCA AAG GCA CCT ATC AG   
D5S471 GC 188 119713478-119713583 5´ GTT TTC ACA CAT TTT CCC AGC 60 106 
    3´ GTT ACA ACA AAT AGC AAC AGC   
BCR/ABL  GG 201 t(9;22)  5´III AGG AAG GAC TCA TCG GGC AG 58 122 
    3´ TCT GTT TGG GTA TGG AAG CTG   
*: Differentiating base (genomic nucleotide immediately following the MseI restriction site); ** MseI-Fragment length based 
on human reference genome (hg19); ***: Annealing-Temperature.  
 
Table 10: Oligonucleotides for Ampli1 WGA quality control 
Gene/Mar
ker 
Fragment** 
[bp] 
Primer Sequence 5´->3´ T*** 
[°C] 
PCR-
Product 
[bp] 
D5S2117 1376 5´ CCA GGT GAG AAC CTA GTC AG 58 147 
  3´ ACT GAG TCC TCC AAC CAT GG   
TP53 1374 5´ GAA GCG TCT CAT GCT GGA TC  58 301 
  3´ CAG CCC AAC CCT TGT CCT TA    
CK19 1146 5’ GAA GAT CCG CGA CTG GTA C  58 614 
  3´ TTC ATG CTC AGC TGT GAC TG    
KRAS 192 5’ ATA AGG CCT GCT GAA AAT GAC  58 91 
  3’ CTG AAT TAG CTG TAT CGT CAA GG    
** MseI-Fragment length based on human reference genome (hg19); ***: Annealing-Temperature.  
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2.2 Methods 
2.2.1 Sample preparation 
2.2.1.1 Cell culture: K562 leukaemia cell line 
1-2x106 K562 cells were isolated from a suspension culture in RPMI 1640 medium (Gibco, 
Carlsbad, CA) supplemented with 10% Fetal Bovine Sera (FBS) (Pan-Biotech GmbH, 
Aidenbach, DE) and 200g/ml of penicillin and streptomycin (PAA Laboratories GmbH, 
Pasching, Austria).  The cells were collected and centrifuged at 4°C for 5 minutes and 500g; 
the pellet was washed once with 1X Phosphate Buffered Saline Solution (PBS), centrifuged 
again and resuspended in 1-2 ml of 1X PBS. 
2.2.1.2 Isolation of peripheral blood lymphocytes (PBL)   
Peripheral blood was collected from a group of healthy donors, directly transferred to a 50ml 
Falcon tube and filled up to a final volume of 50ml with Hanks Buffered Salt Solution 
(HBSS) (Biochrom AG, Berlin, DE). Blood samples were centrifuged at 4°C for 10 minutes 
at 170-200xg, the supernatant was removed and cells washed again with HBSS followed by 
an additional centrifugation step at 4°C for 10 minutes at 170-200xg. The supernatant is 
removed and the blood filled up to 9ml with HBSS. The solution is poured slowly on 6ml of 
Percoll 60% (GE Healthcare, Buckinghamshire, UK) in a 15 ml Falcon tube. The sample is 
centrifuged at 4°C for 20 minutes at 1000xg, the interphase collected, transferred to a new 
50ml falcon tube and filled up with 1X PBS to a final volume of 50 ml. The sample is 
centrifuged again at 4°C for 10 minutes at 500xg, the supernatant removed and cells 
resuspended in 1-2 ml of 1X PBS.  
2.2.1.3 Isolation of pools and single cells  
Ten single lymphocyte cells (Drivers), a pool of five K562 cells (positive controls), and nine 
K562 single cells (Testers) were isolated by micromanipulation at an inverse microscope. 
Cells were plated at a density of 250.000 cells/0.8 cm2 in a volume of 200µl on a 8 well 
chamber slide (NUNC-Thermo, Rochester, NY). Single cells were aspirated into a glass 
pipette of 30µm diameter containing FBS and transferred to a new slide. After confirming that 
only a single cell had been transferred, this cell was finally picked in 1µl of 1X PBS into the 
PCR reaction tube. 
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2.3 Whole Genome Amplification (WGA) of single cells and cell pools  
1. The single cells and cell pools, contained in 1µl of 1X PBS, were subjected to proteinase K 
digestion by adding 2µl of the following mix: 
 
 
 
 
 
 
 
2. Restriction digestion with endonuclease MseI (New England Biolabs-NEB, Ipswich, MA) 
was performed by direct addition of 0,5µl of the following MseI digestion mix to the 
Proteinase K mixture of Step 1.  
MseI digestion mix (1 reaction) [µl] 
MseI (50U/µl) 0,25 
H2O 0,25 
Incubation: 3 h at 37°C  
Inactivation: 20 min at 80°C 
 
3. The Lib1-adaptor is formed by pre-annealing of Lib1 primer and ddMse11: 
Pre-annealing Reaction mix (1 reaction) [µl] 
OPA+ Buffer (10X) 0,5 
Lib1 primer (100 µM) 0,5 
ddMse11 (100 µM) 0,5 
H2O 1,5  
Annealing is started at temperature of 65°C and the shifted down to 15°C with a ramp of 
1°C/minute.  
Proteinase K digestion mix (10 reactions) [µl] 
OPA+ Buffer (10X) 5 
Tween 10% 1,3  
Igepal 10% 1,3 
Proteinase K (10mg/ml) 2,6 
H2O 12,7 
Incubation: 10 h at 42°C 
Inactivation: 10 min at 80°C 
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4. At 15°C, 1µl of ATP 10mM (Roche) and 1µl T4 DNA Ligase (Roche) are added to the pre-
annealing reaction: 
 
 
 
 
5. Five µl of the ligation reaction mix is added to each MseI-digested sample and ligation 
carried out over night at 15°C.  
6. For PCR amplification of the ligated sample, the following WGA amplification mix was 
prepared:  
WGA amplification mix (1 reaction) [µl] 
PCR Buffer 1 (10X) 3  
dNTPs (10mM) 2 
DNA Polymerase Mix (5U/µl) 1  
H2O 35  
 
7. Forty µl of the WGA amplification mix is added to each sample and the reaction directly 
transferred to a thermocycler: 
Ligation Reaction mix (1 reaction) [µl] 
Pre-annealing reaction 3 
ATP (10mM) 1                                                                                   
T4 DNA Ligase (≥ 5U/µl) 1  
WGA Protocol       
Temperature 1 Cycle 14 Cycles 8 Cycles Temperature 22 Cycles 1 Cycle 
94°C  40 sec 40 sec 94°C 40 sec — 
57°C  30 sec 30 sec + 1°C/Cycle 65°C 30 sec — 
68°C 3 min 
 
1 min 30 sec 
+ 1 sec/Cycle 
 
1 min 45 sec 
+ 1 sec/Cycle 
68°C 
1 min 53 sec + 
1 sec/Cycle 
3 min 40 sec 
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2.3.1 Quality control of the WGA library  
2.3.1.1 Ampli1 WGA quality control PCR 
The quality of each WGA library is assessed by performing a multiplex control PCR assay 
detecting the presence of four marker genes (Table 10: Oligonucleotides for Ampli1 WGA 
quality control). Only WGA libraries positive for at least 3 markers are subjected to further 
processing.  
Ampli1 WGA Control PCR mix [µl] 
PCR Buffer (10X), Tube 2 (Green) 1 
Primer mix (4 primer pairs) (3 µM each)* 1 
dNTPs (10 mM) 0,2 
BSA (20mg/ml) 0,2 
FastStart Taq Polymerase (5U/µl) 0,1 
WGA Template 1 
H2O 6,5  
*primers mix: 6µl of each primer (100µM) in a final volume of 200µl 
Temperature 1 Cycle 17 Cycles 19 Cycles 1 Cycle 
95°C 4 min 30 sec 30 sec 30 sec 
58°C - 30 sec 20 sec 30 sec 
72°C - 20 sec 20 sec 2 min 
PCR products are separated on a 1,5% agarose gel for 45 minutes at 160V in 1X TBE. 
2.3.1.2 Assessment of the WGA MseI-fragment length profile 
One µl of 1:10 dilution of each amplified WGA library was assessed for the length 
distribution of the MseI-fragment on an Agilent DNA High Sensitivity Kit (Agilent 
Technologies, Santa Clara, CA) according to the instructions of the manufacturer.  
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2.3.1.3 Specific MseI-fragment control PCR  
A control PCR with different primer pairs amplifying markers specifically residing in discrete 
MseI-fragment (Table 9: Oligonucleotides for specific MseI-fragment control PCR) is 
performed to check the presence of ten MseI-fragment populations, each one representing the 
ten possible nucleotide combinations presents in the original WGA library. 
Temperature 1 Cycle 17 Cycles 19 Cycles 1 Cycle 
94°C 2 min 30 sec 30 sec 30 sec 
55 − 64°C* 30 sec 30 sec 20 sec 30 sec 
72°C 2 min 20 sec 20 sec 2 min 
*: Tanneal of the primers pair 
Specific MseI-fragment control PCR Mix [µl] 
PCR-Buffer (10X) with dNTPs (each1 mM)  1 
5´-Primer 8 µM 0,5 
3´-Primer 8 µM 0,5 
BSA (20mg/ml) 0,25 
Taq DNA Polymerase 5 U/µl 0,15 
H2O 7,25 
DNA sample 1:10 0,5 
 
The PCR products were separated for 45 minutes at 160V on a 1,5% agarose gel in 1X TBE. 
2.3.1.4 Double strand DNA quantification of the WGA library 
The double strand DNA (dsDNA) concentration of the WGA was measured with Qubit 
dsDNA Reagents and Kit – high sensitivity assay (Invitrogen, Carlsbad, CA) following the 
instructions of the provider. 
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2.3.1.5 Development of an absolute qPCR assay to determine the enrichment/loss of the 
BCR/ABL breakpoint-MseI-fragment 
A calibration curve was designed and assayed on the single cell K562 WGA libraries in order 
to follow the trend of the BCR-ABL breakpoint-MseI-fragment during all the critical steps of 
the WGA library modification, genome fractioning and subtraction. The BCR/ABL 
breakpoint-MseI-fragment was amplified from the cell line K562 with the following primers: 
BCR/ABL forward 5’ CTGGATTTAAGCAGAGTTCA 3’ and BCR/ABL reverse 5’ 
GAAAATCCTTAAGGGTATTTCTG 3’. The amplified BCR/ABL breakpoint-MseI-
fragment was cloned in pGEM-T Easy plasmids according to the manufacturer instructions 
(Promega, Fitchburg, WI). NEB10 beta competent cells (New England Biolabs) were 
transformed and grown according to the instructions of the manufacturer. The plasmid 
isolation was performed using Qiagen Midi Kit (QIAGEN, Hilden, Germany). The isolated 
plasmid DNA was quantified using Nanodrop (Thermo Scientific) and linearized with 100U 
of the restriction enzyme XmnI (New England Biolabs), purified using QIAquick PCR 
Purification Kit (Qiagen) and quantified with Qubit dsDNA Reagents and Kits (Invitrogen). A 
10-fold serial dilution of the plasmid standard DNA was prepared in molecular biology pure 
water, containing 100-1.000.000.000 copies per 5 µl. The following formulas were used to 
calculate the copy numbers for the standard curve: 
1. Calculate the mass of a single plasmid molecule: 
 
m = (n) * (1.096*e-21 g/bp) 
 
where n is the plamid sizes (bp), m is the mass, e-21=*10-21 
       
2. Calculate the mass of plasmid containing the copy numbers of interest: 
 
Mass of plasmid DNA needed = copy number of interest * mass of single plasmid 
 
A triplicate of each dilution was amplified with primers K562 5’ and 3’ using LightCycler 
480 SYBR Green I Master 2X (Roche Diagnostic GmbH) according to the manufacturer. 
Transformations were performed using a calibration curve, because Ct values are 
proportionally related to the log2 of the copy number of marker.  
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Absolute qPCR mix [µl] 
Syber Green I Master mix (2X) 10 
5’ Primer (10 µM) 1 
3’ Primer (10 µM) 1 
H2O 3  
DNA Template  5ng 
 
 
2.4 WGA library modification for genome fractioning  
2.4.1 Re-amplification of primary WGA  
One µl of primary WGA generated from pooled lymphocytes and single K562 cells, 
respectively, were used as starting material for a limited number of re-amplification cycles. 
Eight reactions per sample were prepared in order to minimize reaction bias and generate 
sufficient amounts of high-quality WGA samples for the fractioning process.  
Re-amplification mix [µl] 
PCR-Buffer 1 (10X) 5 
Lib1 Primer (10 µM) 5 
dNTPs (10 mM) 2 
BSA (20mg/ml) 1,25 
DNA Polymerase Mix (5U/µl) 1 
Template 1 
H2O 35,0  
 
qPCR Activation  Amplification 
 Melting 
Curve  
Cooling 
Temperature 1 Cycle Temperature 40 Cycle Temperature 1 Cycle Temperature 1 Cycle 
95°C 5 min 95°C 10 sec 95°C 5 sec —  
— 30 sec 60°C 20 sec 65°C 1 min  —  
— — 72°C 20 sec  95°C — 40°C 10 sec 
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 Re-amplification protocol 
Temperature 1 Cycle 9 Cycles 
94°C 1 min 30 sec 
60°C 30 sec 30 sec 
68°C 2 min 2 min + 20 sec/Cycle 
 
All reactions were combined and the PCR product purified using Agencourt AmpureXP 
(Beckman Coulter, Brea, CA) according to the manufacturer. DsDNA concentration was 
measured with Qubit dsDNA Reagents and Kits-Broad range assay (Invitrogen, Carlsbad, 
CA) following the instruction of the provider.  
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
2.4.2 Removal of the Lib1-adaptor 
The re-amplified PCR product was digested with the enzyme MseI (NEB) to release the Lib1-
adaptor: 
Lib1-adaptor digestion mix [µl] 
OPA+ Buffer (10X) 5  
MseI (50U/µl) 1  
 5µg of re-amplified product X 
Add H2O to final volume 50 
Incubation: 3h at 37°C  
Inactivation: 20min at 65°C 
 
The reaction was purified to remove the Lib1-adaptor and dsDNA concentration measured as 
described in paragraph 2.4.1 
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
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2.4.3 Preparation, Ligation of J24 (A,C,G,T) adaptors and J20 secondary PCR  
After removal of the primary Lib1-adaptor, different restriction recognition sites for six-cutter 
enzymes were implemented in the MseI-fragments by the ligation of secondary J24 (A,C,G,T) 
adaptors. These adaptors differ in the single nucleotide preceding the reformed MseI 
recognition site. J24-adaptors are created by combining the corresponding J24 (A,C,G,T) 
primers and  J13 (A,C,G,T) oligonucleotides in equimolar ratios: 
J24 (A,C,G,T) adaptor annealing mix [µl] 
OPA+ Buffer (10X) 10  
J24 (A,C,G,T) (100µM) 45  
J13 (A,C,G,T) (100µM) 45  
Adaptor annealing is carried out by incubation at 95°C for one minute followed by cooling to 
15°C at a rate of 1°C per minute. The adaptors J24A, J24T, J24C and J24G were mixed prior 
to ligation in a 1:1:1:1 ratio to ensure random ligation to MseI-fragments.  
J24 (A,C,G,T) ligation mix [µl] 
Quick ligation buffer 2X 20 
J24 (A,C,G,T) Mix (45 µM) 8 
Quick Ligase (50U/µl) 1 
MseI digested DNA 400ng X 
Add H2O to final volume 40 
 
The ligation reaction was carried out for 15 minutes at room temperature. Eight parallel 
reactions of the ligated DNA product were amplified to generate sufficient dsDNA amounts 
for the subsequent steps. The amplification performed with the J20 primer facilitates the 
uniform amplification of the J24 (A,C,G,T) adaptor-ligated MseI-fragments. 
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J20n-PCR mix [µl] 
PCR-Buffer 1 (10X) 5 
J20n Primer (10 µM) 5 
dNTPs (10 mM) 2 
BSA (20mg/ml) 1,25 
DNA Polymerase Mix (5U/µl) 1 
MseI-digested DNA  5  
H2O 30,75 
 
J20n-PCR protocol 
Temperature 1 Cycle 8 Cycles 5 Cycles 1 Cycle 
94°C — 40 sec 40 sec — 
57°C — 30 sec 30 sec (+ 1°C/Cycle) — 
68°C 3 min 1 min 30 sec+ 1 sec/Cycle 1 min 45 sec + 1 sec/Cycle 3 min 40 sec 
 
The amplified J24 (A,C,G,T) adaptor-ligated MseI-fragments were combined, purified and 
dsDNA concentration measured as described in paragraph 2.4.1. 
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5 
on the J20 PCR secondary amplification. 
2.4.4 Preparation of the specific fractioning-adaptors 
Depending on the six-cutter restriction site intended to reform at the end of the original MseI-
fragment, site-specific fractioning-adaptors (26R A,C,G,T and Bio26R A,C,G,T) are selected 
according to Table 11. Depending on their use in the protocol to select original MseI-
fragments harbouring different or identical reformed six cutter restriction sites at their 
opposite ends, 26R (A,C,G,T) adaptors are applied either in a biotinylated (26R A,C,G,T) or 
non-biotinylated form (Bio26R A,C,G,T). 
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Table 11: Adaptors selection according to the restriction site reformed at the end of the MseI-fragment  
 
 
 
 
 
 
 
 
 
 
These third type of adaptors are created by pre-annealing two long oligonucleotides, 26R 
(A,C,G,T) and Bio26R (A,C,G,T), respectively, in a 1:1 ratio to the short oligonucleotide R13 
(A,C,G,T). 
Bio26RN and 26RN primer-adaptor annealing mix [µl] 
OPA+ Buffer (10X) 10 
Bio-26R (A,C,G,T) or 26R (A,C,G,T) (100µM) 45 
R13 (A,C,G,T) (100µM) 45 
Both oligonucleotides are incubated at 95°C for one minute and cooled down to 15°C at a rate 
of 1°C per minute.  
2.4.5 Coupling of the Bio26R (A,C,G,T) fractioning-adaptors to magnetic streptavidin 
conjugated beads 
Five µl of Nanolink magnetic streptavidin-conjugated beads (Solulink, Inc., San Diego, CA) 
are washed two times with 200µl of Nucleic Acid Binding and Wash Buffer (BW), 
resuspended in 200µl of BW buffer in low binding PCR tubes (Axygen). Ten µl of Bio26R 
(A,C,G,T) adaptors are added to the beads and roll-incubated for 15 minutes at room 
temperature. After incubation the streptavidin-conjugated fractioning-adaptor complex was 
Enzyme 
Recognition 
sequence 
Fractioning-adaptor Sequence 5´→3´ 
DraI TTT´AAA Bio26RA AAT TCG  TCA ATC AGC TGC GCT TGT TT 
VspI AT´TAAT Bio26RT GTA TAG TCT CGG CTC AAC GTC AGG AT 
KspAI GTT´AAC Bio26RC CTA TCG CAC TCG ACT ATC CTC TGG TT 
BspTI C´TTAAG Bio26RG TCT GAG CAA ATG ACC ATG CAG CAC C 
DraI; VspI  26RA; Bio26RT  
DraI; KspAI  26RA; Bio26RC  
DraI; BspTI  26RA; Bio26RG  
VspI; KspAI  26RT; Bio26RC  
VspI; BspTI  26RT; Bio26RG  
BspTI; KspAI  26RG; Bio26RC  
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washed two times with 200µl of BW buffer and resuspended in 200µl of BW buffer. By this 
way a streptavidin conjugated-adaptor complex is pre-formed and ready for the use in the next 
step of the protocol. 
2.5 Genome Fractioning of the modified WGA-libraries 
2.5.1 Restriction digestion of the amplified J24 adaptor-ligated MseI fragments 
After secondary amplification with a J20n primer, amplified J24 adaptor-ligated MseI-
fragments were digested with six-cutter enzymes DraI (TTTAAA), VspI (ATTAAT), KspAI 
(GTTAAC) and BspTI (CTTAAG) alone or in combination of two different enzymes. (Thermo 
Fisher Scientific, Inc.). The digestion is enabled by the incorporation of J24 (A,C,G,T) 
adaptor (in bold character the single nucleotide preceding the re-formed MseI recognition 
site), which, in conjunction with the genomic nucleotide immediately following the MseI 
restriction site (in underlined character the differentiating base) specifies the restriction sites 
of the selected enzymes. Amplified J24 adaptor-ligated MseI-fragments are digested 
separately by each of the four selected restriction enzymes: 
1st Specific restriction digestion mix [µl] 
Fast Digestion Buffer (10X) 10  
Fast Digestion Enzyme 10 
J24 adaptor-coupled MseI fragments 10µg X 
Add H2O to final volume 100 
Incubation: 15min at 37°C  
Inactivation: 20min at 65°C 
 
After restriction, fragments are purified and dsDNA concentration measured as described in 
paragraph 2.4.1.  
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
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2.5.2 Selection of the MseI-fragment fractions depending on the reformed six-cutter 
restriction sites 
The basic protocol to select MseI-fragment fractions carrying identical (simple fractions) or 
different (mixed fractions) six-cutter restriction sites at their opposite ends is highly similar 
except that for the mixed fractions an additional ligation/restriction cycle has to be included. 
By these means the different ends of a mixed fraction are coupled with different site-specific 
adaptors. 
2.5.2.1 Ligation of the non-biotinylated fractioning-adaptor to the digested DNA  
Digested DNA, as generated in paragraph 2.5.1, is ligated with the non-biotinylated form of 
each of the four specific adaptors, according to the ends generated from the digesting enzyme. 
26R (A,C,G,T) Adaptor Ligation mix [µl] 
OPA+ Buffer (10X) 10  
ATP (10mM) 10 
T4 DNA ligase (5U/µl) 10 
26RNn 30 
5 µg digested DNA  X  
H2O to a final volume 
 
100 
 
The ligation reaction is purified as described in paragraph 2.4.1 and eluted in 41µl of PCR 
grade water. The ligated adaptor is fully converted to a double-stranded form by a fill-in 
reaction incubated for 20 minutes at 72°C. 
Fill-in reaction mix [µl] 
PCR-Buffer 1 (10X) 5  
dNTPs (10mM) 2  
BSA (20mg/ml) 1,25 
Taq DNA Polymerase (5U/µl) 1  
Ligated DNA sample 41 
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The fill-in reaction is purified as described in paragraph 2.4.1, eluted in 80µl of PCR grade 
water, and the dsDNA concentration measured as described in paragraph 2.4.1. 
2.5.2.2 Second specific restriction digestion for the mixed fractions 
The DNA generated in paragraph 2.5.2.1 was digested with a second specific restriction 
enzyme:  
 
 
 
 
 
 
The digestion product was purified as described in paragraph 2.4.1, eluted in 50µl of water 
and the dsDNA concentration measured as described in paragraph 2.4.1. 
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
2.5.3 Ligation of the MseI-fragments to the streptavidin-conjugated fractioning-adaptor 
complex  
After removal of the resuspension buffer from the streptavidin-conjugated fractioning-adaptor 
complex, either 600ng of DNA MseI-fragments for simple fractions or 1250ng for mixed 
fractions (generated, respectively, in section 2.5.1 and 2.5.2.2) were added and roll-incubated 
together in the presence of a ligase for 30 minutes at room temperature. 
 
 
 
 
2nd Specific restriction digestion mix [µl] 
Specific Fast Digest Buffer (10X)  10 
Specific Fast Digest Enzyme 10 
DNA Sample ca. 5µg 50 
H2O to a final volume 100 
Incubation: 15min at 37°C  
Inactivation: 20min at 65°C 
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Bio26R (A,C,G,T) adaptor ligation mix [µl] 
Quick ligation buffer 2X 20 
Quick Ligase (50U/µl) 1 
Digested DNA: simple fractions 600ng, 
mixed fraction:1250ng 
X 
Streptavidin-conjugated fractioning-adaptor 
complex add H2O to final volume 
40 
After the ligation reaction, the streptavidin-conjugated fractioning-adaptor complex ligated to 
the DNA were washed three times with 200µl of BW buffer and finally resuspended in 200µl 
of BW buffer.  
2.5.4 First fractioning PCRs  
2.5.4.1 Simple fractions  
For simple fractions one biotinylated adapter and, on consequence, one amplification primer 
is needed.  Before PCR initiation, the bead resuspension buffer is replaced by the PCR 
reagents and a fill-in reaction for the adaptors is performed for 5 minutes at 68°C. After 
incubation, the enrichment primer is added and the 1st genome fractioning PCR directly 
performed on the beads: 
1st Fractioning PCR Simple 
Fractions (AA, TT, CC, GG) mix 
[µl] 
PCR-Buffer 1 (10X) 5 
23R´1 (10 µM) 5 (after 5 min at 68°C) 
23R´2 (10 µM) — 
dNTPs (10 mM) 2 
BSA (20mg/ml) 1 
DNA Polymerase Mix 1 
Template on beads — 
H2O 35,75 
 
 
Materials and Methods  
 49 
 
 
 
 
2.5.4.2 Mixed Fractions 
As the mixed fractions have been ligated to different specific fractioning-adaptors (one 
biotinylated adaptor and one non-biotinylated adaptor), two specific amplification primers are 
needed for the fractioning PCR. Before PCR initiation, the bead resuspension buffer is 
replaced by the PCR reagents and the 1st Fractioning PCR directly performed on the beads. 
1st Fractioning PCR Mixed Fractions 
(AG, AT, AC, TG, TC, CG) mix 
[µl] 
PCR-Buffer 1 (10X) 5 
23R´1 (10 µM) 5 
23R´2 (10 µM) 5 
dNTPs (10 mM) 2 
BSA (20mg/ml) 1,25 
DNA Polymerase Mix (5U/µl) 1 
Template on beads — 
H2O 35,75 
 
 
 
 
 
 
 
1st Fractioning PCR Simple Fractions protocol 
Temperature 14 Cycles 1 Cycle 
94°C 40 sec — 
60°C 30 sec — 
68°C 1 min 40 sec+ 1 sec/Cycle 3 min 40 sec 
1st Fractioning PCR Mixed Fractions Protocol 
Temperature 14 Cycles 1 Cycle 
94°C 40 sec — 
60°C 30 sec — 
68°C 1 min 40 sec+ 1 sec/Cycle 3 min 40 sec 
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2.5.5 ssDNA nuclease digestion and 2nd Fractioning PCR   
PCR reactions were transferred to a magnetic stand. After the liquid becomes clear, the 
supernatant is removed from the magnetic streptavidin-conjugate beads, transferred to a new 
microvessel and digested at 37°C for one hour with ExonucleaseI. By these means excess of 
primers and single stranded DNA is degraded.  
ExonucleaseI digestion mix [µl] 
1st Fractioning PCR 50 
ExoI Buffer 10X 6 
ExonucleaseI  4 
The enzyme is heat-inactivated at 80°C for 20 minutes. A 2nd fractioning PCR is performed 
for simple and mixed fractions in an identical manner. 
2ndFractioning PCR mix [µl] 
PCR-Buffer 1 (10X) 5 
23R´1 (10 µM) 5 
23R´2 (10 µM) 0-5 
dNTPs (10 mM) 2,0 [µl] 
BSA (20mg/ml) 1,25 [µl] 
DNA Polymerase Mix 1 [µl] 
Template 1st Fractioning 5,0 [µl] 
H2O 35,75 [µl] 
 
2nd Fractioning PCR protocol     
Temperature 14 Cycles 8 Cycles 1 Cycle 1 Cycle 
94°C 40 sec 40 sec 40 sec — 
60°C 30 sec 30 sec 30 sec — 
68°C 
1 min 30 sec 
+ 1 sec/Cycle 
1 min 45 sec 
+ 1 sec/Cycle 
 
1 min 53 sec 
 
3 min 40 sec 
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All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
2.6 Normalization of the genome MseI-fractions (from paragraph 2.5.5) 
Driver and Tester DNAs are normalized with Trimmer-2 cDNA normalization Kit (Evrogen, 
Moscow, RUS). For normalization, 1200ng of DNA are used according to the instruction of 
the manufacturer, with minor modifications: the number of PCR cycles for amplification of 
the normalized DNA sample was shifted to 9-11-13-15 cycles for optimization of PCR 
parameters and primers and annealing temperature adapted to the WGA protocol.  
All necessary quality controls have been applied as described in paragraph 2.3.1.2 – 2.3.1.5. 
2.7 Subtractive Hybridization of the genome MseI-fractions 
2.7.1 Re-amplification of the genome MseI-fractions  
The normalized genome MseI-fractions were re-amplified to generate sufficient high-quality 
dsDNA amounts needed for subtractive hybridization, e.g. 48 reactions were prepared for the 
Driver (lymphocyte pool) and one reaction for the Tester (K562 single cell) using a starting 
amount of 5 ng of the normalized 2nd Fractioning PCR. The reagents and PCR program have 
been the same used in paragraph 2.5.5 with the exception that maximum 11 cycles have been 
performed.  
Adaptors used for the fractioning, are removed by digestion directly after DNA amplification: 
TruI digestion mix [µl] 
Buffer R 10X 50 
TruI (50U/µl) 6 
ExonucleaseI  4 
 
The digestion reaction was incubated for 3 hours at 65°C. 
The dsDNA product was purified and concentration of dsDNA measured as described in 
paragraph 2.4.1.  
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2.7.2 Ligation of a specific biotinylated subtractive-adaptor (BioR21)  
Tester DNA is ligated to a specific biotinylated-adaptor, BioR21, for selective amplification 
after the first round of subtraction. The Driver will not be ligated to any adaptor. 
BioR21 ligation mix [µl] 
OPA+ Buffer (10X) 10  
          BioR21 (100 µM) 20 
ATP (10 mM) 10 
T4 DNA Ligase (5 U/µl) 10 
Tester Sample 3µg X  
H2O To 100  
 
The ligation reaction is incubated for 2 hours at 16C°. After purification the dsDNA 
concentration is measured as described in paragraph 2.4.1. 
2.7.3 Driver and Tester precipitation before the subtractive hybridization 
For the 1st round of subtractive hybridization (S.H.) 500ng of Tester, ligated with BioR21 
subtractive adaptors, is used. The adapter-ligated Tester and the Driver are mixed together, 
extracted with Phase Lock Gel (5 PRIME GmbH, Hilden, DE) in phenol-chloroform-
isoamylalchol according to the manufacturer and precipitated with 10 µl of linear 
polyacrylamide carrier (LPA) 5mg/ml, salt (ammonium acetate, 3M, pH 5.2) for 1/10 of the 
volume, and 2,25% (v/v) of ethanol, overnight -20°C. For the sample recovery after 
precipitation, a centrifugation step of 45 minutes at 4°C and 14.000 rpm was performed; the 
pellet has been washed one time with ethanol 70% for 10 minutes at 22°C and 14.000 rpm. 
2.7.4 First round of subtraction: generation of the depletion product 1 (DP1) 
The pellet was resuspended in 6 µl of 1X hybridization buffer (50mM HEPES, 0.2mM 
EDTA), incubated 5 minutes at 50°C to fully resuspend the DNA, transferred into a low-
binding PCR tube (Axygen) and covered with 35µl of Mineral oil (Sigma-Aldrich, St. Louis, 
MO). After a10 minute denaturation step at 95°C, 1 µl of sodium chloride (NaCl) 5M was 
added and subtractive hybridization was performed for 18-24 hours at 68°C.  
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2.7.5 Positive selection of the re-hybridized Tester/Tester sequences with magnetic 
streptavidin- conjugated beads 
The reaction is diluted with 44 µl of 1X TE. Five µl of Nanolink Streptavidin Magnetic beads 
(Solulink Inc., San Diego, California) are washed two times with 200µl of BW buffer, 
resuspended in 200µl of BW buffer in low binding PCR tubes (Axygen), mixed with the 
sample and agitated for 30 minutes at 40C°. The particles were washed three times in 200µl 
BW buffer at room temperature.  
2.7.6 First enrichment PCR and ssDNA nuclease digestion  
The first enrichment PCR was started after removal of the washing buffer by direct addition 
of the PCR reagents to the bead-ligated DNA sample. 
1st Enrichment PCR Mix                                        [µl] 
PCR-Buffer 1 (10X)                                     5 
R21 (10 µM)                                      5 (after 5 min at 68°C) 
dNTPs (10 mM)                                     2 
BSA (20mg/ml)                                     1,25 
DNA Polymerase Mix (5U/µl)                                     1 
Template on beads                                      — 
H2O                                      35,75 
1st Enrichment PCR Protocol 
Temperature 1 Cycle 10 Cycles 1 Cycle 
94°C — 30 s — 
60°C — 30 s — 
68°C 5 min 2 min 10 min 
 
The supernatant of the reaction was isolated on a magnet, purified with Agencourt AmpureXP 
and digested with MBN (New England Biolabs) to remove single stranded DNA.  
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Mung Bean Nuclease Digestion [µl] 
MBN Buffer (10X) 4 
Mung Bean Nuclease (10U/µl) 3 
DNA Template  33 
 
The digestion was performed for 30 minutes at 30°C, then inactivated by adding 160µl of 
Tris-HCl pH 8.9 and incubating at 98°C for further 5 minutes. 
2.7.7 Second enrichment PCR 
Enrichment PCR2 was performed to amplify the depletion product 1 (DP1). Eight reactions 
per sample were prepared: 
2nd Enrichment PCR mix [µl] 
PCR-Buffer 1 (10X) 5 
R21 (10 µM) 5  
dNTPs (10 mM) 2 
BSA (20mg/ml) 1,25 
DNA Polymerase Mix (5U/µl) 1 
Template  25 
H2O 10,75 
 
2nd Enrichment PCR protocol 
Temperature 1 Cycle Temperature 26 Cycle 1 Cycle 
94°C 1 min 94°C 30 s — 
  60°C 30 s — 
  68°C 2 min 10 min 
 
The product was purified with QIAquick PCR Purification Kit (Qiagen) and quantified with 
Qubit dsDNA Reagents and Kits (Invitrogen). Absolute qPCR quantification was performed 
to determine the copy number of BCR/ABL per nanogram of DNA as previously described in 
paragraph 2.3.1.5. 
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At least three rounds of subtractive hybridization were performed and DP1, DP2 and DP3 
products separated on a 1.5% agarose gel for 45 minutes at 160V in 1X TBE. 
Absolute qPCR quantification was performed to determine the copy number of BCR/ABL 
breakpoint-MseI-fragment per nanogram of DNA as previously described in paragraph 
2.3.1.5. 
2.8 Normalization of the first depletion product (DP1) 
The first depletion product is normalized with Trimmer-2 cDNA normalization Kit as 
described in paragraph 2.6.  
Absolute qPCR quantification was performed to determine the copy number of BCR/ABL 
breakpoint-MseI-fragment per nanogram of DNA as previously described in paragraph 
2.3.1.5. 
2.8.1 Second round of subtraction: generation of the depletion product (DP2) 
The normalized DP1 is directly used for a second round of depletion and enrichment. The 
R21 adaptor is not removed but it does not carry a biotinylated residue, as previous 
amplifications were carried out with non-biotinylated R21 primer (enrichment PCR and 
normalization PCR). The second round of hybridization is performed with 500ng of 
normalized DP1 (Tester) and 40µg of Driver leaving the Driver/Tester ratio unaltered 
compared to the first subtraction round. The subtraction is carried as previously described in 
paragraphs 2.7.2-2.7.3-2.7.4. After the subtraction, the re-hybridized DNA is digested directly 
with Mung Bean Nuclease (NEB):  
 
Mung Bean Nuclease Digestion [µl] 
MBN Buffer (10X) 4 
Mung Bean Nuclease (10U/µl) 3 
Re-hybridized DNA  6 
H2O 27 
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The enzyme is inactivated as described in the paragraph 2.7.6 and the digested DNA re-
amplified with a single amplification step as described in paragraph 2.7.7. 
The PCR product was purified and dsDNA quantified as described in paragraph 2.7.7. 
Absolute qPCR quantification was performed to determine the copy number of BCR/ABL 
breakpoint-MseI-fragment per nanogram of DNA as previously described in paragraph 
2.3.1.5. 
2.8.2 Third round of subtraction: generation of the depletion product (DP3) 
The third round of subtraction is performed as in paragraph 2.8.1 with the exception that the 
DP2 product is not normalized.  
Absolute qPCR quantification was performed to determine the copy number of BCR/ABL 
breakpoint-MseI-fragment per nanogram of DNA as previously described in paragraph 
2.3.1.5. 
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3. Theoretical considerations of method design 
3.1 Design of a method for breakpoint identification in single tumour cells and definition 
of relevant quality controls  
Systematic enrichment and isolation of molecular breakpoints in single tumour cells would 
allow breakpoint identification down to the nucleotide level without the need to sequence 
whole genomes of tumour cells. Such a methodological approach can only be built upon a 
deterministic whole genome amplification (WGA) method ensuring little or no patient-to-
patient and cell-to-cell variation whilst it is not applicable to stochastic WGA approaches. 
Ampli1 WGA meets these requirements as it is based on the MseI-restriction of a single cell 
genome, ligation of adaptors and exponential amplification of the ligated MseI-fragments. To 
implement a breakpoint identification method on the MseI-fragment population of a single 
cell, a strategy to reduce the sequence complexity of the human genome whilst preventing the 
simultaneous loss of genetic information has to be developed. With that goal in mind a step 
termed “Genome Fractioning” aimed at reducing the complexity of the genome has been 
developed. As Ampli1 WGA relies on the MseI-restriction (recognition/restriction site 
TTAA) of the genome each created MseI-fragment will have defined nucleotides next to its 
genomic MseI restriction sites: such a nucleotide is defined as the “differentiating base”. As a 
consequence, there are ten different types of nucleotide combinations forming the ends of 
MseI-fragments: (a) either simple combinations if the same nucleotides occur next to the 
genomic MseI restriction site (A/A, C/C, G/G, T/T) or (b) mixed combinations if the genomic 
nucleotides next to the MseI restriction sites are different (A/C, A/G, A/T, C/G, C/T, G/T) 
(Figure 4).  
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Figure 4: The WGA contains a myriad of MseI-fragments of different lengths with various combinations of differentiating bases. The final 
aim of the genome fractioning is the selective isolation of genomic MseI-fragments characterized by the identical differentiating bases. The 
final genomic fractioning contains just MseI-fragments of different base pair length with the same base after the MseI restriction site (in this 
case the nucleotide T, representing the T/T fraction). For simplicity not all the nucleotide combinations have been designed in the picture. 
Theoretically, this leads to a 10-fold reduction of complexity of the original MseI-fragment 
population and consequently to the selective isolation of a distinct MseI-fragment population 
(MseI-fraction) characterized by their nucleotide combination of differentiating bases. The ten 
resulting discrete MseI-fractions of lower complexity can be subsequently modified and 
subjected to subtractive hybridization vs. germline single cell genomes, allowing for PCR-
based amplification of breakpoint-carrying MseI-fragments (Figure 5). 
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Figure 5: Overview of the method. The whole genome of a normal single cell and a tumor cell is amplified. Discrete genomic MseI-fragment 
populations are isolated, including genomic Mse-fragments containing a breakpoint sequence; the selection of discrete populations of the 
genome implies a reduction in complexity compared to the initial whole genome. The subtractive hybridization between the selected 
genomic population of the normal and cancer cell will enrich differential sequences, such as genomic breakpoints.  
To monitor the successful implementation of the method, the leukemia cell line K562 
harboring a well-characterized BCR/ABL fusion breakpoint contained in a specific MseI-
fragment containing the G/G nucleotides was selected. High quality single cell K562 WGAs 
will help to evaluate the efficiency of each experimental step during the setting up of the 
breakpoint identification method by assessing the proper quality controls and by controlling 
the enrichment of the desired fusion sequence (Figure 6). 
 
 
Normal Cell Cancer Cell with Fusion gene 
Whole Genome Amplification Whole Genome Amplification 
Selection of determined genomic populations Selection of determined genomic populations 
(including breakpoint fragments) 
Subtractive Enrichment of differential genomic sequences between normal and cancer cell 
Fragment with breakpoint 
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Figure 6: Quality control implemented for the original WGA library necessary for the proper assessment of the method.  
3.1.1 Ampli1 quality control PCR to assess the quality of the WGA 
The use of a high quality WGA is fundamental for the establishment of the method. Therefore 
the PCR-based Ampli1 quality control assay (Polzer et al., 2014), which enables the 
identification of high-quality amplified WGA samples, has been applied. Assay primers have 
been designed to amplify the four marker amplicons CK19, TP53 exon2/3, D5S2117, KRAS 
residing on MseI-fragments of different length classes. The WGA samples of highest quality 
samples can be identified by the presence of all four tested markers. Samples showing a lower 
number of positive markers were not used during method implementation.  
3.1.2 Assessment of the MseI-fragments length distribution of high and low-quality 
WGA  
As additional quality control the MseI-fragment length distribution of WGAs of diverse 
quality has been determined. By this means the MseI-fragment profile of high quality WGAs 
would be considered as standard benchmark for all the succeeding steps. In this way the 
changes of the MseI-fragment profile can be monitored during the development of the 
protocol. This control also enables to detect the unspecific enrichment of repetitive sequences 
as prominent PCR products at an early stage of method development. As the method consists 
of different steps of adaptor ligations and amplifications, it is not unlikely that MseI-
WGA 
Ampli1 control PCR  Assess the genome integrity (GII)  
Bioanalyzer trace Assess the MseI-fragment length distribution 
MseI-fragment PCR Assess the complete MseI-fragment population 
dsDNA concentration Assess the optimal double stranded amount of DNA 
qPCR BCR/ABL gene Assess the absolute copy number of the fusion gene BCR/ABL 
DNA recovery Assess the proper method for the best DNA recovery/purity 
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fragments representing highly repetitive sequences of the genome are selected and over-
represented. This quality control also enables to ensure homogeneous MseI-fragment size 
distributions of the library samples.  
3.1.3 Specific MseI-fragment control PCR to identify the ten discrete populations in the 
original WGA 
High-quality WGA samples contain theoretically the complete population of the MseI-
fragments composed of the ten different genomic fractions as defined by their differentiating 
base combinations. The concept of the differentiating base in the MseI-fragments allows the 
design of primer pairs amplifying markers specifically residing in discrete MseI-fragment. By 
systematically exploiting this concept, a total of 77 primer pairs have been designed in order 
to identify 77 different MseI-fragments (fragment length from 128bp to 1936bp), located in 
different genomic loci and representing the ten different fractions (Figure 7).  
 
 
Figure 7: Specific MseI-fragment control PCR. Primer pairs (dark blue arrows) have been designed on the MseI-fragments in between the 
differentiating bases for each possible nucleotide combination. The specific MseI-fragment control PCR performed on WGA will give the 
amplification of all the combinations, while after the genomic fractioning we will have the amplification of one specific MseI-fragments 
population.  
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The established specific MseI-fragment control PCR allows controlling the reliable genome 
fractioning and isolation of the selected MseI-fragments during the development of the 
procedure for the genome complexity reduction. It is expected that all the control MseI-
fragments representative for each of the ten nucleotide combinations to be preserved from the 
WGA up to the final selective isolation step; by these means accidental losses of the control 
MseI-fragments can be assessed at each step of the protocol. A genome fractioning is defined 
successful if the control amplicon contained within the MseI-fragments harboring the 
expected differentiating bases is amplified with the specific primers (Table 12-successful 
genome fractioning-pure). A genome fractioning is not successful if the control amplicon 
contained within the MseI-fragments harboring the expected differentiating bases is not 
amplified (Table 12-unsuccessful genome fractioning-negative), or if the isolated genome 
MseI-fraction will include amplified controls, indicating the presence of MseI-fragments 
harboring unexpected differentiating bases (Table 12-unsuccessful genome fractioning-
unpure). 
Table 12: Schematic representation of the specific MseI-fragments control PCR performed on the WGA and specifically isolated MseI-
fragments population.  
 
3.1.4 Precise assessment of the double strand DNA concentration of the WGA 
As fully double strand DNA (dsDNA) enables proper functioning of the critical steps such as 
enzymatic digestions and adaptor ligations during method development, in the first place, an 
ultrasensitive method based on the use of a fluorescent intercalating dye specific for dsDNA 
was used. Using this assay the initial dsDNA amount of the WGA could be assessed and the 
optimal dsDNA amount for consecutive steps of the protocol determined.  
 
Specific primers for: WGA 
Successful Genome 
Fractioning (Pure) 
Unsuccessful Genome 
Fractioning (Negative) 
Unsuccessful Genome 
Fractioning (Unpure) 
MseI-fragments  A/A + - - - 
MseI-fragments  C/C + - - + 
MseI-fragments  G/G + - - - 
MseI-fragments  T/T + + - + 
MseI-fragments  A/C + - - - 
MseI-fragments  A/G + - - - 
MseI-fragments  A/T + - - + 
MseI-fragments  C/G + - - + 
MseI-fragments  C/T + - - - 
MseI-fragments  G/T + - - - 
Sample DNA concentration DNA total amount 
K562 single cell 1 20 ng/µl 1000 ng 
K562 single cell 2 21,3 ng/µl 1065 ng 
K562 single cell 3 21,6 ng/µl 1080 ng 
K562 single cell 4 22,1 ng/µl 1105 ng  
K562 single cell 5 19,8 ng/µl 990 ng  
K562 single cell 6 0,003 ng/µl 0,15 ng  
K562 single cell 7 18,6 ng/µl 930 ng  
K562 single cell 8 20,8 ng/µl 1040 ng  
K562 single cell 9 21 ng/µl 1050 ng  
K562 single cell 10 19,1 ng/µl 955 ng  
K562 single cell 11 18,4 ng/µl 920 ng  
Lymphocytes pool 54,6 ng/µl 2730 ng  
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3.1.5 Absolute qPCR quantification of the MseI-fragment carrying the BCR/ABL 
breakpoint in WGA amplified K562 single cells  
To establish an assay for absolute quantification of the MseI-fragment carrying the BCR/ABL 
fusion gene breakpoint (BCR/ABL breakpoint-MseI-fragment), the initial copy numbers of 
the BCR/ABL translocation in amplified single K562 cells was assessed. This qPCR assay 
allows monitoring the degree of enrichment of the BCR/ABL breakpoint-MseI-fragment 
during each step of method development thereby optimizing and defining critical checkpoints 
for the complete process.  
3.1.6 Choice of the purification system to define optimal parameters for the DNA 
recovery  
The fidelity of the method used for the isolation/purification of DNA is of critical importance 
when considering the success of subsequent protocol establishment. It is required that the 
DNA purification procedure results in high yields of high quality DNA. High DNA recovery 
is a fundamental pre-requisite to avoid losses of informative MseI-fragments in order to 
ensure a broader representative population to be analyzed.   
 
3.2 Concept of the WGA library modification  
The genome fractioning to reduce the complexity of the WGA, in order to select specific 
MseI-fragment populations, requires some preceding steps involving the modification of the 
original Ampli1 WGA library. First, the WGA representation is re-amplified and the original 
adaptors are removed. Secondary adaptors will then be ligated to create a restriction site for a 
six-cutter enzyme that will generate specific ends for a tertiary type of adaptor, needed for the 
specific MseI-fragments selection before the final enrichment step.  
3.2.1 Re-amplification of the MseI-fragments population and removal of the primary 
Lib1-adaptor  
In order to generate sufficient amounts of high-quality double-stranded MseI-fragments for 
the successive steps of the protocol, the whole genome amplified MseI-fragment population 
needs to be re-amplified for a limited number of cycles. After the re-amplification, the 
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primary Lib1-adaptors need to be removed by digesting the re-amplified WGA representation 
with the restriction enzyme MseI (Figure 8). It is important at this step to ensure complete 
double strandedness of the re-amplified MseI-fragments to achieve optimal digestion of the 
primary Lib1-adaptors thereby providing sufficient dsDNA amounts for the consecutive steps 
of the protocol.  
 
Figure 8: The WGA needs to be re-amplified to obtain sufficient amounts of DNA. After the re-amplification, the Lib1-adaptor is removed 
by digestion with MseI enzyme. In the red box are indicated, as example, the differentiating nucleotides after the MseI restriction site. 
3.2.2 Introduction of the secondary adaptors  
After removal of the original Lib1-adaptors used for the generation of the WGA, it is 
necessary to implement a step to mark each MseI-fragment of the original MseI-fragments 
population for subsequent fractioning. This is achieved by introducing secondary adaptors 
(J24) only differing at their terminal nucleotide position. Using these adaptors in equimolar 
ratios, each MseI-fragment terminus will randomly ligate to one of the four adaptors with the 
same probability. The function of the J24 (A,C,G,T) adaptors is to create a restriction site for 
a six-cutter enzyme that will digest the recognition sequence according to the reformed site at 
the end of the original MseI-fragment (Figure 9). This means that a restriction site is 
generated every fourth ligation, i.e. four different possibilities of ligation will form four 
different recognition sequences for specific six-cutter enzymes. This process is independent 
from the distribution of the differentiating bases in the genome. Whenever the secondary 
adaptor ligation does not lead to the formation of a palindromic six-cutter enzyme restriction 
5´AGTGGGATTCCTGCTGTCAGTTAATNNNNNNNNN 
3´TCACCCTAAGGACGACAGTCAATTANNNNNNNNN NNNNNNNNNATTAACTGACAGCAGGAATCCCACT 3´   NNNNNNNNNTAATTGACTGTCGTCCTTAGGGTGA 5´   
Lib1-Adaptor Lib1-Adaptor Specific Sequence MseI MseI 
Lib1-Adaptors digestion  
Reamplification 
                     5´TAATNNNNNNNNN 
3´TANNNNNNNNN NNNNNNNNNAT 3´   NNNNNNNNNTAAT 5´   
Specific Sequence 
MseI MseI 
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site at the end of the original MseI-fragment, the MseI-fragment will be excluded for further 
use. The probability that a reformed restriction site is created results from the percentage of 
successfully digested and removed Lib1-adaptors for the percentage of successfully ligated 
J24 (A,C,G,T) adaptors, that means the adaptors in which the terminal nucleotide forms a 
palindromic sequence with the differentiating base. At 100% efficiency of MseI digestion and 
J24 (A,C,G,T) ligation, one fragment has 6.25% of possibilities to be digested by the specific 
six-cutter. This implies that the amount of DNA used for the digestion is considerable high 
and necessarily in a double strand form.  
 
Figure 9: The J24 (A,C,G,T) adaptors are designed to create a restriction site for four different six-cutter enzymes, according to the N-
terminal base of the adaptor (base at position 23) that will ligate, and to the differentiating base after the MseI restriction site (base at position 
28). After the J24 (A,C,G,T) adaptor ligation, the J24 adaptor ligated MseI-fragments are shortly re-amplified with J20n primer in order to 
obtain sufficient amount of DNA for the specific restriction digestion. The MseI digestion site is underlined, differentiating nucleotide are 
indicated in the red boxes, J20 primers as long blu arrows. 
After J24 (A,C,G,T) adaptor ligation, adaptor-ligated MseI-fragments are further amplified to 
enrich all the successfully reformed MseI-fragments. For this purpose, a primer (J20) 
complementary to the unique part of the J24 adaptors is used for the amplification (Figure 9). 
The end of this process enriches all the original MseI-fragments according to the new 
5´TGTAGGTTCCAGCGTCTCAGACNTTAATNNNNNNNNN 
3´              AGAGTCTGNAATTANNNNNNNNN   NNNNNNNNNATTAANGTCTGAGA 3´     NNNNNNNNNTAATTNCAGACTCTGCGACCTTGGATGT 5´   
J24 (A,C,G,T) J24 (A,C,G,T) Specific Sequence MseI MseI 
Position 1 
Position  
23  28  
28  23  1  
5´TGTAGGTTCCAGCGTCTCAGACNTTAATNNNNNNNNN 
3´ACATCCAAGGTCGCAGAGTCTGNAATTANNNNNNNNN   NNNNNNNNNATTAANGTCTGAGACGCTGGAACCTACA 3´     NNNNNNNNNTAATTNCAGACTCTGCGACCTTGGATGT 5´   
J24 (A,C,G,T) J24 (A,C,G,T) Specific Sequence MseI MseI 
Position 1 
Position  
23  28  
28  23  1  
Fill-in adaptors 
5´TGTAGGTTCCAGCGTCTCAGACNTTAATNNNNNNNNN 
3´ACATCCAAGGTCGCAGAGTCTGNAATTANNNNNNNNN   NNNNNNNNNATTAANGTCTGAGACGCTGGAACCTACA 3´     NNNNNNNNNTAATTNCAGACTCTGCGACCTTGGATGT 5´   
J24 (A,C,G,T) J24 (A,C,G,T) Specific Sequence MseI MseI 
Position 1 
Position  
23  28  
28  23  1  
J20 PCR amplification 
J24 (A,C,G,T) adaptors ligation 
                     5´TAATNNNNNNNNN 
3´TANNNNNNNNN NNNNNNNNNAT 3´   NNNNNNNNNTAAT 5´   
Specific Sequence 
MseI MseI 
J20 primer 
J20 primer 
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reformed six cutter restriction sites. For optimal performance, the ligation efficiency of the 
four different J24 (A,C,G,T) adaptors should be ideally the same and, moreover, the 
secondary amplification needs to be optimized to obtain sufficient amounts of high quality 
dsDNA for the specific digestion.  
 
3.3 Molecular properties of the Genome Fractioning procedure 
(Complexity Reduction Step) 
The WGA library modification comprises series of steps transforming the MseI-fragment 
population in a condition that enables the reduction of the human genome complexity 
(“Genome Fractioning”). This genome fractioning procedure consists mainly of three basic 
steps: the specific restriction digestion, the selection of the digested MseI-fragments with 
specific fractioning-adaptors, and the selective enrichment PCR (fractioning PCR).   
3.3.1 Specific restriction digestion to select specific MseI-fragments 
The amplified J20 adaptor-ligated MseI-fragments have to be specifically selected by 
enzymatic digestion with individual six-cutters enzymes according to the reformed restriction 
site at the end of the original genomic MseI-fragments. As previously mentioned, according 
to the ligation of the nucleotide at position 23, a new restriction site will be created for one of 
the four different six-cutter enzymes: DraI (23TTTAAA28), VspI (23ATTAAT28), KspAI 
(23GTTAAC28) and BspTI (23CTTAAG28) (Figure 10). Only the digestion with specific 
enzymes will allow to select a pre-determined population of MseI-fragments: the digestion 
with one enzyme will select MseI-fragments harboring simple nucleotide combinations, 
whereas the digestion with two enzymes will select MseI-fragments harboring mixed 
nucleotide combinations. For instance, if the isolation of original MseI-fragments harboring 
on both sides the differentiating base T (simple fraction; 23ATTAAT28) is intended, the VspI 
enzyme is used to cut the J20 re-amplified MseI-fragment population (Figure 10, top line), or 
if the isolation of the original MseI-fragments harboring on both sides the differentiating base 
A (simple fraction; 23TTTAAA28) is intended, the DraI enzyme is used to cut the J20 re-
amplified MseI-fragment population (Figure 10, second line). However, if the isolation of 
original MseI-fragments harboring on both sides the two different differentiating bases T/A 
(mixed fraction; 23ATTAAT28 and 23TTTAAA28) is intended, two restriction enzymes (VspI 
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and DraI) have to be used to used to cut the J20 re-amplified MseI-fragment population 
(Figure 10, fifth line). 
 
 
Figure 10: Specific digestion. The amplified J20 adaptor-ligated MseI-fragments are digested with the specific six-cutter enzymes in order to 
pre-select the sequences that are going to be enriched in the genome fractioning step. The restriction site for each enzyme is represented. 
Either one or two restriction enzymes can be used to select the original MseI-fragments according to the base ligated before the MseI site 
(green box) and the differentiating nucleotide present after the MseI site (red box). 
 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNATTAATGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNTAATTACAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence VspI VspI 
5´TAGGTTCCAGCGTCTCAGACTTTAAANNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGAAATTTNNNNNNNNN NNNNNNNNNTTTAAAGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNAAATTTCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence DraI DraI 
5´TAGGTTCCAGCGTCTCAGACCTTAAGNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGGAATTCNNNNNNNNN NNNNNNNNNCTTAAGGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNGAATTCCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence BspTI BspTI 
5´TAGGTTCCAGCGTCTCAGACGTTAACNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGCAATTGNNNNNNNNN NNNNNNNNNGTTAACGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNCAATTGCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence KspAI KspAI 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTTAAAGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNAAATTTCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence VspI DraI 
5´TAGGTTCCAGCGTCTCAGACTTTAAANNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGAAATTTNNNNNNNNN NNNNNNNNNCTTAAGGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNGAATTCCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence DraI 
5´TAGGTTCCAGCGTCTCAGACCTTAAGNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGGAATTCNNNNNNNNN NNNNNNNNNGTTAACGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNCAATTGCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence BspTI KspTI 
5´TAGGTTCCAGCGTCTCAGACTTTAAANNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGAAATTTNNNNNNNNN NNNNNNNNNGTTAACGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNCAATTGCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence DraI KspTI 
5´TAGGTTCCAGCGTCTCAGACCTTAAGNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGGAATTCNNNNNNNNN NNNNNNNNNATTAATGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNTAATTACAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence BspTI VspI 
 BspTI 
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3.3.2 Use of the specific fractioning-adaptors coupled to magnetic streptavidin-
conjugated beads 
The fractioning-adaptors 26R (A,C,G,T) and Bio26R (A,C,G,T) are specifically designed to 
ligate to the original MseI-fragments according to the ends generated by the digestion of the 
six-cutter restriction enzymes at the reformed site after the J24 (A,C,G,T) adaptor ligation. 
Depending on the original MseI-fragment harboring the same or different reformed six-cutter 
restriction site at the opposite ends, either a biotinylated or a non-biotinylated version of the 
26R adaptor has to be used. To be precise, one biotinylated fractioning-adaptor will be used 
for the MseI-fragments that harbor the same restriction site on the opposite ends (simple 
fraction), and one biotinylated and one non-biotinylated fractioning-adaptor will be used for 
the MseI-fragments that harbor different restriction sites on the opposite ends (mixed fraction) 
(Table 11). The use of biotinylated fractioning-adaptors coupled to magnetic streptavidin-
conjugated beads is essential to positively select those MseI-fragments, which have been 
correctly ligated after the specific digestion. They are used either for the simple or the mixed 
fractions as part of a streptavidin-conjugated fractioning-adaptor complex generated by pre-
incubation with magnetic streptavidin-conjugated beads. By this means unbound fractioning-
adaptors can be easily removed through consecutive washes of the magnetic streptavidin-
conjugated beads. 
3.3.3 Molecular mechanisms involved in the generation of the simple fractions  
Streptavidin-conjugated fractioning-adaptor complexes containing the Bio26R (A,C,G,T) 
fractioning-adaptor are ligated to specifically digested MseI-fragments, e.g. with VspI (Figure 
11). The streptavidin-conjugated fractioning-adaptor complex is incubated with the digested 
MseI-fragments to allow binding of the fractioning-adaptors to the respective DNA ends. 
MseI-fragments that bound to the streptavidin-conjugated fractioning-adaptor complex are 
then isolated with the help of a magnet, the fractioning-adaptors are completed with a fill-in 
reaction and the DNA is amplified by the 1st fractioning PCR, consisting of a limited number 
of cycles, with one amplification primer complementary to the biotinylated fractioning-
adaptors (Figure 11).  
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Figure 11: Selection and enrichment of the simple MseI-fragments. In the case of simple MseI-fragments the same ends will be generated on 
both sides of the DNA sequence: a single biotinylated fraction-adaptor (Bio26RT) will be used to ligate the ends; the biotinylated 
fractioning-adaptors are incubated with magnetic streptavidin-conjugated beads (brown circles) to allow the binding of the Bio26RT 
fractioning-adaptor to the beads; the DNA molecules are incubated with the streptavidin-conjugated fractioning-adaptor complex to allow the 
ligation of the DNA to the fractioning-adaptors. The DNA molecules that have incorporated the fractioning-adaptors will be positively 
selected. After the ligation the fractioning-adaptors are completed by filled-in reaction to allow the PCR with specific primers (long blue 
arrow). The differentiating nucleotides are indicated in the red box. 
The 1st fractioning PCR is followed by a single strand nuclease digestion step to remove 
single strand DNA (ssDNA) molecules originating from the linear amplification of MseI-
fragments that just bound a single adaptor, e.g. in the process of isolating the MseI-fragments 
carrying a T as a differentiating base at both fragment ends (harboring a VspI restriction site 
on both sides), MseI-fragments presenting the mixed differentiating base combinations A/T, 
T/G or C/T at their fragment ends (harboring a VspI restriction site only on one side) will also 
be ligated with the biotinylated fractioning-adaptor specific for the VspI restriction site, 
positively selected and linearly amplified (Figure 12). Following the removal of such linear 
VspI digestion 
Fill-in of the biotinylated adaptor Bio-26RTn 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
!
!5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
!
!
!
!
Binding of the biotinylated 
adaptors Bio26RT on the 
beads 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RTn !
!
Exponential amplification 
Fractioning PCR 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNATTAATGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNTAATTACAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence VspI VspI 
                      5´TAATNNNNNNNNN 
                        3´TANNNNNNNNN NNNNNNNNNAT 3´   NNNNNNNNNTAAT 5´   
Specific Sequence 
VspI VspI 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN 
3´      ddC-GTTGCAGTCCTAATTANNNNNNNNN NNNNNNNNNATTAATCCTGACGTTG-ddC 3´   NNNNNNNNNTAATTAGGACTGCAACTCGGCTCTGATATG-Bio 5´   
Bio26RT Bio26RT Specific Sequence VspI VspI !
! !!
5´Bio-GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN 
3´CATATCAGAGCCGAGTTGCAGTCCTAATTANNNNNNNNN NNNNNNNNNATTAATCCTGACGTTGAGCCGAGACTATAC 3´   NNNNNNNNNTAATTAGGACTGCAACTCGGCTCTGATATG-Bio 5´   
Bio26RT 
Bio26RT 
Specific Sequence 
!
! !!
Ligation of the DNA to the 
streptavidin conjugated-adaptor 
complex 
Amplification Primer 23R‘Tm  
Amplification Primer 23R‘Tm  
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amplification products by Exonuclease I digestion, the 2nd fractioning PCR is performed to 
exponentially amplify the dsDNA molecules carrying the same adaptor on both fragment 
ends. 
 
Figure 12: Mechanism of linear amplification. MseI-fragments harboring T/A, T/G, or T/C as differentiating bases are cut by the enzyme, 
e.g. VspI, only on one DNA terminus, so they will bind the fractioning-adaptors streptavidin-conjugated bead complex. The other DNA 
terminus will remain undigested and will preserve the sequence of the J20n primer. During the PCR, the amplification primer will prime only 
on one binding site generating always a 5’-3’ ssDNA molecule.  The ssDNA generated is digested with Exonuclease I (yellow circle) to 
reduce the background of adaptor-ligated MseI-fragments that have not been exponentially amplified. Other mechanisms that could generate 
linear amplified DNA are also incomplete digestion of one side of the MseI-fragment or, again, failed ligation of the specific fractioning-
adaptor that bounds only on one side instead of two. The differentiating nucleotides are indicated in the red box. 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTTAANGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNAAATTNCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence VspI 
? 
VspI digestion 
                      5´TAATNNNNNNNNN 
                        3´TANNNNNNNNN NNNNNNNNNTTTAANGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNAAATTNCAGACTCTGCGACCTTGGAT 5´   
J20n Specific Sequence VspI 
? 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN 
3´      ddC-GTTGCAGTCCTAATTANNNNNNNNN 
Bio26RT Specific Sequence VspI !
!
Ligation of the DNA to the 
streptavidin conjugated-
adaptor complex 
NNNNNNNNNTTTAANGTCTGAGACGCTGGAACCTA 3´   
NNNNNNNNNAAATTNCAGACTCTGCGACCTTGGAT 5´   
J20n 
? 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN 
3´CATATCAGAGCCGAGTTGGAGTCCTAATTANNNNNNNNN 
Bio26RT Specific Sequence !
!
Linear amplification 
Fractioning PCR 
Amplification Primer 23R‘Tm  
NNNNNNNNNTTTAANGTCTGAGACGCTGGAACCTA 3´   
NNNNNNNNNAAATTNCAGACTCTGCGACCTTGGAT 5´   
J20n 
? 
NNNNNNNNNATTAANGTCTGAGACGCTGGAACCTA 3´ 5´TCTCGGCTCAACGTCAGGATTAATNNNNNNNNN J20n 
Specific Sequence 
Digest ssDNA with nuclease (ExoI) 
Fill-in of the biotinylated adaptor Bio-26RTn 
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3.3.4 Molecular mechanisms involved in the generation of the mixed fractions  
Concerning the generation of the mixed fractions, the concept is very similar to the one 
applied to the simple fractions except that two six-cutters are used to generate two different 
ends on the MseI-fragment. Accordingly, two different site-specific fractioning-adaptors are 
ligated, one biotinylated and one not-biotinylated (Figure 13). J20 adaptor-ligated MseI-
fragments are digested with the first specific enzyme, for example DraI, and the non-
biotinylated fractioning-adaptor (26RA) is ligated to the cleaved end followed by a fill-in 
reaction to create a fully double-strand fragment end. After digestion of the J20 adaptor-
ligated MseI-fragments with the second specific enzyme, e.g. VspI, cleaved fragments are 
incubated with the pre-formed streptavidin-conjugated fractioning-adaptor complex (with 
Bio26RT) to allow for ligation and magnetic capture of correctly ligated MseI-fragments. The 
biotinylated fractioning-adaptor ligated to the second restriction site of the MseI-fragment is 
not filled-in to avoid the exponential amplification of MseI-fragments that are digested from 
the same enzyme and ligated by the same biotinylated fractioning-adaptors (e.g. MseI-
fragments harboring the T/T nucleotides; Figure 11). Also, MseI-fragments harboring T/C 
and T/G nucleotides that are digested on one side from the enzyme VspI and ligated to the 
biotinylated fractioning-adaptors will be prevented from linear amplification due to the lack 
of the amplification primer binding site. A 1st fractioning PCR is necessary to enrich the 
MseI-fragments that have been successfully ligated with two different site-specific 
fractioning-adaptors. Similar to the simple fractions a ssDNA digestion step is implemented 
before the 2nd fractioning PCR.  
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Figure 13: Generation of the mixed fractions. Bio26RT adaptors are pre-bound on the magnetic streptavidin-conjugated beads represented as 
brown circles. Amplification primers 23R’Tm and 23R’Am are represented as long blue arrow. The differentiating nucleotides are indicated 
in the red box. 
 
 
 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTTAAAGTCTGAGACGCTGGAACCTA 3´   NNNNNNNNNAAATTTCAGACTCTGCGACCTTGGAT 5´   
J20n J20n Specific Sequence VspI DraI 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTT 3´   NNNNNNNNNAAA 5´   
J20n Specific Sequence VspI DraI 
DraI digestion 
Ligation of the non-biotinylated adaptor 26RA 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTTAAACAAGCGCAGC-ddC          3´   NNNNNNNNNAAATTTGTTCGCGTCGACTAACTGCTTAA 5´   
J20n Specific Sequence VspI DraI 26RA 
5´TAGGTTCCAGCGTCTCAGACATTAATNNNNNNNNN 
3´ATCCAAGGTCGCAGAGTCTGTAATTANNNNNNNNN NNNNNNNNNTTTAAACAAGCGCAGCTGATTGACGAATT 3´   NNNNNNNNNAAATTTGTTCGCGTCGACTAACTGCTTAA 5´   
J20n Specific Sequence VspI DraI 26RA 
Fill-in of the non-biotinylated adaptor 26RA 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
!
!5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
!
!
!
!
!
!
!
!
Binding of the biotinylated 
adaptors Bio26RT on beads 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT !
!
VspI digestion 
                      5´TAATNNNNNNNNN 
                        3´TANNNNNNNNN NNNNNNNNNTTTAAACAAGCGCAGCTGATTGACGAATT 3´   NNNNNNNNNAAATTTGTTCGCGTCGACTAACTGCTTAA 5´   
Specific Sequence 
VspI DraI 
26RA 
Ligation of the DNA to 
the beads-adaptor 
complex 
5´Bio-GTATAGTCTCGGCTCAACGTCAGGAT 
3´      ddC-GTTGCAGTCCTAAT 
Bio26RT 
!
!
5´Bio-GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN 
                              TANNNNNNNNN NNNNNNNNNTTTAAACAAGCGCAGCTGATTGACGAATT 3´   NNNNNNNNNAAATTTGTTCGCGTCGACTAACTGCTTAA 5´   
Bio26RT 
26RA 
Specific Sequence 
!
!
Exponential amplification 
Fractioning PCR 
Amplification Primer 23R‘Tm  
  3´ddC-
GTTGCAGT
CCTAAT
Amplification Primer 23R‘Am  
  3´CATATCAGAGCCGAGTTGCAGTCCTAATTANNNNNNNNN NNNNNNNNNAAATTTGTTCGCGTCGACTAACTGCTTAA 5´   
 5´GTATAGTCTCGGCTCAACGTCAGGATTAATNNNNNNNNN NNNNNNNNNTTTAAACAAGCGCAGCTGATTGACGAATT 3´   Amplification Primer 23R‘Am  
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3.4 Subtractive DNA Hybridization as a tool to enrich genomic breakpoints 
in cancer genomes of single cells 
Subtractive DNA hybridization is a technique allowing for the enrichment of sequences 
differing between two closely related cDNA or genomic DNA samples. In subtractive 
hybridization techniques, one DNA population (the “Driver”) is hybridized in excess with a 
second DNA population (the “Tester”), which is similar but not identical to the first DNA 
population. The differences between these two DNA populations (present in the Tester, but 
not in the Driver) are the “target” sequences for isolation. Typically, the Tester DNA is 
digested with a restriction endonuclease, ligated to adaptors and mixed with an n-fold excess 
of digested Driver DNA. The DNA mixture is then denatured and allowed to re-associate to 
form three types of hybrids: Tester-Tester and Driver-Driver homohybrids and Tester-Driver 
heterohybrids. The chance that a non-target Tester sequence hybridizes with its Tester 
complement is substantially smaller than the chance that it hybridizes with its complement 
from the Driver DNA population. The target sequence is present only in the Tester and will 
therefore always hybridize with its complement from the Tester DNA population. The excess 
of Driver DNA is thus used to drive the non-target Tester sequences from the pool of Tester 
DNA. In order to reach a proper DNA re-hybridization, the conditions for the re-association 
have to be almost optimal. The choice and optimization of the subtractive DNA hybridization 
procedure are important to ensure the maximum enrichment of differential MseI-fragments, in 
this case the best enrichment of the BCR/ABL breakpoint-MseI-fragment sequence. In order 
to yield optimal results, the re-amplification step to generate sufficient amounts of genome 
MseI-fraction must be optimized. Moreover, the maximum binding capacity of the magnetic 
streptavidin-conjugated beads for biotinylated MseI-fragment sequences has been investigated 
to evaluate if a reverse approach consisting in the use of large amount of biotinylated Driver 
DNA for the subtraction would be possible. Also different methods for the re-hybridization of 
nucleic acids can be tested (Figure 14).  
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Figure 14: Overview of the optimization steps necessary to establish the process of subtractive hybridization. 
3.4.1 Re-amplification of Driver and Tester samples to obtain sufficient DNA for 
subtraction 
In order to yield enough DNA amounts for the different rounds of subtraction the Driver and 
Tester DNA must be re-amplified. Moreover, it is important that the re-amplification is 
optimized to maximize the amount of dsDNA. This will allow the proper assessment of the 
Driver to Tester ratio necessary for the optimal enrichment of the BCR/ABL breakpoint-
MseI-fragment.  
3.4.2 DNA precipitation of Driver and Tester 
To ensure fast and proper renaturation, high amount of Driver DNA has to be mixed with 
limited amounts of Tester DNA before the re-hybridization in small volumes. The 
precipitation of the mixed DNA is necessary for this step, as well as an almost complete 
recovery of the mixed DNA sample to ensure that the Driver to Tester ratio is unchanged in 
the following re-hybridization. Classical phenol-chloroform-isoamylalcohol extraction and 
ethanol precipitation can be used but also commercial systems excluding contamination of the 
organic phase and yielding maximum recovery of DNA are available. 
Subtractive 
Hybridization 
Re-amplification 
genome fraction 
Optimize PCR parameters to 
ensure the most dsDNA amount 
Driver-Tester DNA 
precipitation 
Optimize DNA precipitation for 
best recovery  
Test removal of 
Biotinylated sample 
Useful to test if a reverse 
approach can be used 
(biotinylated Driver) 
Test different re-
hybridization method 
Assess the optimal method for re-
naturation of MseI-fragments 
Test method 
limitation 
Assess specificity and sensitivity 
of the assay 
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3.4.3 Subtractive approaches with biotinylated Driver or Tester DNA 
Subtractive DNA hybridization approaches can either use a biotinylated Driver DNA sample 
to completely remove background sequences derived from selection of Tester-Driver 
heterohybrids, or a biotinylated Tester DNA sample to positively select Tester-Tester specific 
homohybrids.  One problem that occurs by using the latter approach is the simultaneous 
selection of the Tester-Driver heterohybrids that are linearly amplified in the enrichment 
PCR. These sequences are mostly, but not always completely, removed by the help of an 
ssDNA nuclease. If an approach with biotinylated Drive DNA would prove to be successful, 
any selection and linear amplification of the Tester-Driver heterohybrids could be excluded, 
and also the intermediate nuclease step to remove ssDNA could be excluded. 
3.4.4 Subtractive hybridization using different re-hybridization methods 
Different methods available from literature can be used to re-hybridize DNA. The choice of a 
method to ensure the best enrichment of differential MseI-fragments between a Driver and 
Tester sample can be assessed considering different factors. First the method has to prove that 
after the re-hybridization most of the DNA is again double stranded and second that the level 
of enrichment of differential MseI-fragments, in this case BCR/ABL breakpoint-MseI-
fragment, is considerable.  
3.4.5 Specificity and sensitivity of the subtractive hybridization method 
The selected method has to provide an appropriate specificity and sensitivity. This can be 
investigated by spiking known amounts of differential MseI-fragments in a Driver sample that 
underwent genome fractioning in order to simulate the process of subtraction hybridization. A 
specific method will provide the complete banding pattern of re-hybridized and enriched 
MseI-fragments without any other fragment deriving from improper hybridization. 
Additionally if the method is sensitive all the MseI-fragments spiked-in at very low amounts 
will be detectable after re-hybridization followed by endpoint PCR. 
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3.5 First subtraction: generation of the Depletion product (DP1) 
Figure 15 depicts the exact subtractive DNA hybridization approach used in this experimental 
setting. Briefly, the enriched genome MseI-fraction is re-amplified using a limited-cycle PCR 
to generate sufficient amounts of DNA for subtractive DNA hybridization. Many reactions 
are generally performed in order to generate the necessary quantities of the Driver DNA 
sample (lymphocyte pool), while only one reaction is sufficient to generate the necessary 
amount of Tester DNA sample (K562 single cell). The Driver and Tester DNA are digested 
with MseI enzyme to remove the fractioning-adaptor remnants. Prior to the first round of 
subtraction the Tester DNA is ligated with biotinylated subtractive-adaptor (BioR21-adaptor) 
in order to select, after the re-hybridization, Tester-Tester homohybrids and the Tester-Driver 
heterohybrids by the use of magnetic streptavidin-conjugated beads. A large excess of Driver 
and limited amount of Tester are mixed together and heat-denatured. The re-hybridization of 
the samples is happening in aqueous solution in a time frame of 20-24 hours. The re-
hybridized DNA sequences are mixed together with magnetic streptavidin-conjugated beads 
to allow the binding of the Tester-Tester homohybrids and Tester-Driver heterohybrids while 
Driver-Driver will not bind on the beads. The BioR21-adaptor is completed by a fill-in 
reaction, and the DNA sequences immobilized on the beads are amplified by a first 
enrichment PCR with a non-biotinylated primer (R21 primer) complementary to the BioR21-
adaptor, followed by mung bean nuclease digestion to remove ssDNA molecules originating 
from linear amplification of Tester-Driver heterohybrids. This step is followed by a second 
enrichment PCR resulting in the exclusive exponential amplification of the Tester-Tester 
homohybrids carrying the BioR21-adaptor on both fragment ends. Subsequently the first 
depletion product (DP1) is normalized in order to minimize the presence of cross-annealed 
repetitive sequences in the re-hybridized sample thereby counteracting the excessive 
accumulation of such chimeric sequences in successive steps of the protocol. 
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Figure 15: Generation of Depletion Product 1 (DP1). Fractioning-adaptors, removed after genome fractioning, are indicated in red. 
Biotinylated subtractive-adaptors (BioR21-adaptor), ligated only to the Tester, are indicated in green. Magnetic streptavidin-conjugated 
beads necessary to positively select Tester-Tester and Tester-Driver sequences are represented as brown circles. ssDNA nuclease necessary 
for the removal of linearly amplified sequences is represented as yellow circle. NB: Tester/Tester common sequences represent DNA 
sequences that are also present in the Driver sample but that are not completely subtracted. Tester/Tester unique sequences are exclusively 
present in the Tester sample. 
3.6 Generation of the successive depletion products 
The normalized first depletion product (DP1) is then used for a second round of subtractive 
DNA hybridization. The lack of a BioR21-adaptor (as far as, enrichment amplification and 
amplification of the normalized DP1 product is carried out with the non-biotinylated primer 
R21) does not allow for the second round of subtractive DNA hybridization the use of 
magnetic streptavidin-conjugated beads for selective enrichment of the re-hybridized Tester-
Tester homohybrids. Therefore a mung bean nuclease digestion is performed immediately 
after the re-hybridization of Tester and Driver DNA sample. By this means unpaired ssDNA 
Genome MseI-Fraction Driver Genome MseI-FractionTester 
Reamplification and 
removal of fractioning 
primers 
Reamplification, removal of 
fractioning primers and 
ligation of BioR21-adaptors 
Mix Driver (in excess) and Tester and Hybridize 
Driver/Driver Driver/Tester Tester/Tester common Tester/Tester unique 
No Amplification 
Linear 
amplification  
Exponential 
amplification  
Exponential 
amplification  
Capture on beads Capture on beads 
Nuclease Digestion 1st Subtraction Product 
(DP1) 
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sequences and overhanging subtractive-adaptor ends of Tester-Driver heterohybrids are 
removed thereby excluding those sequences from linear amplification (Figure 16).  
 
Figure 16: Generation of depletion product 2 (DP2). After the first subtraction round, the DP1 is normalized to decrease selected repetitive 
sequences and it is re-hybridized again to an excess of Driver. The DP1 preserve the same primer binding site (R21, in green) but without 
biotinylation motif. After the hybridization Driver-Driver sequences will not be amplified as well as Tester-Driver sequences in which the 
primer binding sites will be digested from the mung bean nuclease (yellow circle). Tester-Tester sequences will be again exponentially 
amplified. NB: Tester/Tester common sequences represent DNA sequences that are also present in the Driver sample but that are not 
completely subtracted. Tester/Tester unique sequences are exclusively present in the Tester sample. 
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4. Results 
4.1. Establishment of the quality controls on WGA amplified K562 single cells 
4.1.1 PCR-based Ampli1 WGA quality control assay 
It is important to ensure that only WGA samples of high-quality are used during the process 
of method development (Method Design Paragraph 3.1.1). Therefore it is necessary to control 
the comprehensive amplification of a single cell genome by testing the presence of the four 
amplicons CK19, TP53, D5S2117, and KRAS (Table 13) (Figure 17).  
Table 13: Ampli1 QC amplicons used to check the DNA integrity of single cell WGA samples. Amplicon name, length of the WGA 
amplified MseI-fragment and length of the PCR fragment are indicated. 
 
 
Figure 17: Multiplex quality control PCR assay of isolated and amplified single cell genomes of the K562 cell line. A positivity rate of 4/4 
and 3/4 markers is representative of very good quality DNA. PCR positive control is composed of a pool of unrelated peripheral blood 
lymphocytes. Please note that almost all cells show a very good WGA quality except for cell number 6. The lack of any detectable MseI-
fragments indicates the loss of the cell during the isolation.  
A cell with good quality DNA is identified by the presence of three or four of the four tested 
amplicons. Not successfully picked/amplified cells will not produce any amplification 
products. This allows to determine the Genome Integrity Index (GII0-4) for each amplified 
single cell genome based on the number of detected PCR bands.  
 
Sample   BCR/ABL copies/ng of DNA  
K562 single cell 1 12215 
K562 single cell 2 11230 
K562 single cell 3 13001 
K562 single cell 4 12214 
K562 single cell 5 11475 
K562 single cell 6 - 
K562 single cell 7 10129 
K562 single cell 8 11214 
K562 single cell 9 11765 
K562 single cell 10 10781 
K562 single cell 11 12601 
K562 genomic DNA unamplified 10229 
Primer ID Lenght of the MseI-Fragment Lenght of the PCR fragment  
      
D5S2117 1376 bp 140 bp 
      
TP53 1374 bp 301 bp 
      
CK19 1146 bp 614 bp 
      
KRAS 192 bp 91 bp 
M       1         2        3         4       5        6         7       8        9        10      11       P       P.C.     N      M      
1-11: K562 single cells 
P: picking control 
P.C.: positive control 
N: negative control 
M: Marker 2-log 
600 bp 
300 bp 
200 bp 
100 bp 
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4.1.2 Whole genome amplified-DNA size distribution 
The determination of the size distribution of initial high-quality WGA libraries allows to 
assess the fragment length profile of the amplified MseI-fragments in such libraries and 
therefore provides an independent indicator for genome integrity (Method Design Paragraph 
3.1.2). From observation, the experimental size distribution of the MseI-fragment population 
ranges from ~250 to ~3000bp (Figure 18).  
 
Figure 18: Examples of bioanalyzer profile of the WGA library for the lymphocytes pool and single K562 cells. The MseI-fragments 
distribution is between ~250 to ~3000bp. The X-axis represents the product size in base pairs (bp) and the Y-axis is the arbitrary 
fluorescence intensity (FU). 
Low quality WGA showed a different profile compared to high quality WGA. As can be 
observed low quality WGAs show low amplification level (from FU data) and ambiguous 
MseI-fragments length distribution reflecting maybe the not optimal outcome of WGA 
amplification (Figure 19). 
 
 
Figure 19: Examples of bioanalyzer profiles of low quality WGA libraries with GII 1-GII 2. The X-axis represents the product size in base 
pairs (bp) and the Y-axis is the arbitrary fluorescence intensity (FU). 
WGA pool of Lymphocytes WGA K562 single cells 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
D5S399 AG/GA 485 bp 178 bp 
RTP3 AG/GA 394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
ZNF23 GC/CG 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
BCR AT/TA  600 bp 358 bp 
WGA library GII 1 WGA library GII 1 
WGA library GII 2 WGA library GII 2 
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4.1.3 Specific MseI-fragment PCR-based quality control assays 
To ensure the proper and orderly separation of the ten sub-genomic MseI-fragments 
populations, it was necessary the establishment of a specific MseI-fragment PCR-based 
quality control assay enabling the detection of genomic MseI-fragments per each 
differentiating base combination (Method Design Paragraph 3.1.3). This assay allows gaining 
a more comprehensive view on the completeness of the genomic MseI-representation in the 
primary WGA sample (Figure 20).  
 
 
Controls for the WGA of single K562 cells: fragment specific PCR 
1E8:*MseIEfragments*containing*A*as*diﬀeren%a%ng*base*
9E19:*MseIE*fragments*containing*T*as*diﬀeren%a%ng*base*
20E22:*MseIEfragments*containing*C*as*diﬀeren%a%ng*base*
23E29:*MseIEfragments*containing*G*as*diﬀeren%a%ng*base*
30E34:*MseIEfragments*containing*A*and*T*as*diﬀeren%a%ng*bases*
Controls for the WGA of single K562 cells: fragment specific PCR 
36E38:*MseIEfragments*containing*A*and*T*as*diﬀeren%a%ng*bases*
39E43:*MseIE*fragments*containing*A*and*C*as*diﬀeren%a%ng*bases*
44E51:*MseIEfragments*containing*A*and*G*as*diﬀeren%a%ng*bases*
52E58:*MseIEfragments*containing*T*and*C*as*diﬀeren%a%ng*bases*
59E68:*MseIEfragments*containing*T*and*G*as*diﬀeren%a%ng*bases*
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Figure 20: Specific MseI-fragment control PCR of the WGA with specific primers amplifying different MseI-fragments according to the 
nucleotide combination after the MseI restriction sequence. All the ten combinations of MseI-fragments are amplified in the WGA. The table 
summarizes the MseI-fragments and the differentiating bases where primers are located, the length of the MseI-fragments, and the PCR 
amplicons length. The markers are numbered and represent the amplification tested on single cell and negative control. Markers 13, 19, 25, 
29, 31, 69 did not perform successfully on single cells. M: low molecular weight DNA marker (NEB). 
4.1.4 Quantification of dsDNA  
In order to ensure that sufficient quantities of dsDNA are available before the start of method 
development, the dsDNA amount of eleven K562 single cells and one pool of ten 
lymphocytes, which underwent Ampli1 WGA, are comparatively measured (Method Design 
Paragraph 3.1.4). With the exception of K562 single cell 6, all tested single cell samples 
showed similar results (Table 14). The higher amount of generated dsDNA in the cell pool is 
a result of the higher initial DNA quantity. 
 
 
Controls for the WGA of single K562 cells: fragment specific PCR 
70E75:*MseIEfragments*containing*G*and*C*as*diﬀeren%a%ng*bases*
Nr. Primer ID Differentiating base 
 MseI-fragment 
lenght (bp)  
PCR-
Product 
(bp) 
Nr. Primer ID Differentiating base 
 MseI-fragment 
lenght (bp)  
PCR-
Product 
(bp) 
Nr. Primer ID Differentiating base 
 MseI-fragment 
lenght (bp)  
PCR-
Product 
(bp) 
1 D5S2117 A/A 1376 147 26 D16S3019 G/G 605 220 51 D17S800 AG/GA 333 153 
2 BCR  A/A 751 243 27 BCR G/G 367 329 52 TP53 TC/CT 1032 461 
3 BRCA1 A/A 594 151 28 D5S592 G/G 348 191 53 ENTPD3 TC/CT 651 290 
4 PDPR A/A 568 144 29 BCR G/G 142 138 54 ZFHX3 TC/CT 576 170 
5 TP53  A/A 558 374 30 BCR AT/TA 790 583 55 CDH3 TC/CT 552 119 
6 LPO A/A 316 193 31 BCR AT/TA 701 346 56 D5S1360 TC/CT 513 139 
7 TRAK1 A/A 247 214 32 BCR AT/TA 600 358 57 D6S308 TC/CT 262 214 
8 TRAK1 A/A 128 113 33 D5S299 AT/TA 550 159 58 OPN1SW TC/CT 283 76 
9 BCR T/T 1936 413 34 UBP1 AT/TA 394 180 59 BCR TG/GT 1351 679 
10 D16S3066 T/T 536 190 35 SRP19 AT/TA 350 110 60 BCR TG/GT 1068 300 
11 BCR T/T 508 235 36 D5S816 AT/TA 307 178 61 BCR TG/GT 881 379 
12 CLASP2 T/T 294 195 37 D16S3040 AT/TA 302 140 62 BCR TG/GT 756 368 
13 D6S314 T/T 277 210 38 APIG1 AT/TA 220 219 63 BCR TG/GT 670 192 
14 COG4 T/T 261 217 39 ZKSCAN7 CA/AC 648 257 64 D5S615 TG/GT 641 227 
15 TFRC T/T 242 131 40 CDH3 CA/AC 637 221 65 APC  TG/GT 618 330 
16 TOP2B T/T 209 177 41 RH27788 CA/AC 576 389 66 MYRIP TG/GT 600 174 
17 ABL1  T/T 173 125 42 D6S453 CA/AC 479 140 67 FAM117A TG/GT 260 176 
18 D5S500 T/T 159 132 43 AGTR1 CA/AC 279 105 68 CCK TG/GT 231 109 
19 ABL1 T/T 157 142 44 D6S1633 AG/GA 1317 270 69 ZNF19 TG/GT 216 131 
20 BCR C/C 1233 324 45 ULK4 AG/GA 682 126 70 BCR GC/CG 1071 258 
21 ABL1 C/C 291 273 46 CDH1 AG/GA 486 179 71 ZNF23 GC/CG 417 290 
22 ABL1 C/C 203 148 47 ZFHX3 AG/GA 480 144 72 TRAK1 GC/CG 355 228 
23 BCR  G/G 1026 297 48 D5S399 AG/GA 485 178 73 ULK4 GC/CG 298 145 
24 BCR G/G 944 360 49 RTP3 AG/GA 394 302 74 HERBB2  GC/CG 226 133 
25 BCR G/G 715 470 50 ANO10 AG/GA 370 190 75 D5S471 GC/CG 188 106 
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Table 14: dsDNA measurement of the WGA amplified K562 single cells and of the lymphocytes pool. 
 
4.1.5 WGA and BCR/ABL qPCR  
The well-characterized genomic breakpoint of BCR/ABL fusion gene in the K562 cell line 
has been used as a monitoring system to trace the degree of enrichment of BCR/ABL 
breakpoint-MseI-fragment in a single cell genome (Figure 21) (Method Design Paragraph 
3.1.5).  
 
Figure 21: Chromosomal breakpoint (BP) of the K562 leukemia cell line. In dark gray is the sequence of the BCR gene, in light gray the 
sequence of the ABL gene. Control primers for the fragment are K562-5’III and K562-3’. Small black arrows point the differentiating bases 
of the MseI fragment in which the fusion gene is located, in this case an MseI-fragment of 200bp with G nucleotide as differentiating bases. 
Absolute plasmid DNA standards, containing the BCR/ABL breakpoint-MseI-fragment in the 
range from 1000 to 1.000.000.000 copies, have been used to develop a calibration curve 
(Figure 22). 
Speciﬁc!primers!for:! WGA! Speciﬁc!Genome!Frac2on!
MseIHfragments!!A/A! +! H!
MseIHfragments!!C/C! +! H!
MseIHfragments!!G/G! +! H!
MseIHfragments!!T/T! +! +!
MseIHfragments!!A/C! +! H!
MseIHfragments!!A/G! +! H!
MseIHfragments!!A/T! +! H!
MseIHfragments!!C/G! +! H!
MseIHfragments!!C/T! +! H!
MseIHfragments!!G/T! +! H!
Sample DNA concentration DNA total amount 
K562 single cell 1 20 ng/µl 1000 ng 
K562 single cell 2 21,3 ng/µl 1065 ng 
K562 single cell 3 21,6 ng/µl 1080 ng 
K562 single cell 4 22,1 ng/µl 1105 ng  
K562 single cell 5 19,8 ng/µl 990 ng  
K562 single cell 6 0,003 ng/µl 0,15 ng  
K562 single cell 7 18,6 ng/µl 930 ng  
K562 single cell 8 20,8 ng/µl 1040 ng  
K562 single cell 9 21 ng/µl 1050 ng  
K562 single cell 10 19,1 ng/µl 955 ng  
K562 single cell 11 18,4 ng/µl 920 ng  
Lymphocytes pool 54,6 ng/µl 2730 ng  
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Figure 22: A) amplification curves, B) amplicon specific melting peak and C) standard curve for the BCR/ABL breakpoint-MseI-fragment. 
The standard curve ranges from a copy number of 1000 till 1.000.000.000 in 10-fold dilutions. Efficiency, error, intercept and slope are all in 
the acceptable range. 
Plasmid calibration ranges were used to quantify the number of copies of the BCR/ABL 
breakpoint-MseI-fragment in K562 cells before and after Ampli1 WGA. Lymphocyte WGA 
pools were included in the assay to exclude any unspecific BCR/ABL amplification. The 
Figure 23 summarizes the amplification and melting curves of the whole genome amplified 
single cells proving the specificity of the amplified product.  
Error: 0,0015 
Efficiency: 1,89 
Slope: -3,692 
Intercept: -26,94 
A
B
C
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Figure 23: A) amplification curves of the WGA from single K562 cells for the BCR/ABL breakpoint-MseI-fragment, B) melting peak. The 
lymphocyte pool WGA is negative for the fusion gene.  
All single cells showed similar copy numbers for the BCR/ABL breakpoint-MseI-fragment 
(Table 15). The copy numbers in the genomic DNA isolated from the K562 cells is also quite 
similar, indicating that the WGA did not significantly alter the gene ratio, at least for the 
sequence of interest.  
Table 15: BCR/ABL breakpoint-MseI-fragments copies per nanogram of DNA for each amplified K562 single cell and unamplified genomic 
DNA calculated after absolute qPCR. 
  
WGA pool of Lymphocytes  
WGA K562 single cells  
Negative control 
A
B
Sample   BCR/ABL copies/ng of DNA  
K562 single cell 1 12215 
K562 single cell 2 11230 
K562 single cell 3 13001 
K562 single cell 4 12214 
K562 single cell 5 11475 
K562 single cell 6 - 
K562 single cell 7 10129 
K562 single cell 8 11214 
K562 single cell 9 11765 
K562 single cell 10 10781 
K562 single cell 11 12601 
K562 genomic DNA unamplified 10229 
Primer ID Lenght of the MseI-Fragment Lenght of the PCR fragment  
      
D5S2117 1376 bp 140 bp 
      
TP53 1374 bp 301 bp 
      
CK19 1146 bp 614 bp 
      
KRAS 192 bp 91 bp 
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4.1.6 Optimization of the DNA recovery with different purification systems 
To select the best-working purification system under the given conditions (Method Design 
Paragraph 3.1.6), it was necessary to compare the following products with respect to purity 
and amount of the recovered dsDNA: Microcon YM30 (Millipore), Wizard SV PCR Clean-
Up System (Promega Corporation), Qiagen PCR Purification Kit (Qiagen), AmpureXP 
purification beads (Beckman Coulter), DNA Clean & Concentrator 25 (Zymo Research 
Corporation, Irvine, CA). Starting amounts of 5µg dsDNA derived either from PCR 
amplification or restriction/ligation reactions were purified, and quantity and quality of the 
recovered dsDNA assessed by Qubit and Nanodrop measurement. Results of the use of the 
different purification systems are summarized in Table 16. The purification of PCR reactions 
gave similar results in terms of DNA recovery between the different systems: the Microcon 
column, mainly used to concentrate PCR reactions, gave high recovery but un-pure products 
with a 260/280 ratio very low, indicating the presence of many contaminants, even after 
repetitive washing steps of the column. The other purification method gave high recovery and 
pure samples with best results achieved with the use of AmpureXP beads. The purification of 
restriction and ligation reactions showed to perform differently probably due to the buffer 
composition: Wizard and Zymokit purification system showed a loss of around 40-50% of the 
purified product. The others did not look affected from the change of buffer composition. In 
these two purification systems the optimization of the pH of the binding buffer necessary for 
the correct binding of the DNA to the silica column was not possible, so they were excluded 
from the use in the protocol. Based on these findings, the choice has fallen on Qiagen PCR 
Purification Kit and AmpureXP: the former was used when multiple reactions of the samples 
were set up, and was not possible to use the AmpureXP due to the big amount of beads 
required for the purification.  
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Table 16: Five clean-up systems have been tested in terms of recovery rate and purity. 
Product Microcon YM30 Wizard Qiaquick Zymo AmpureXP 
Technology  Spin Procedure-Size 
exclusion 
Spin Procedure Spin Procedure Spin Procedure  Solide-Phase-Reverse 
Immobilization 
Type of matrix Cellulose Silica 
Membrane 
Silica Membrane Silica 
Membrane 
Magnetic Beads 
Time needed 25-30 min 5 min 5 min 5 min 10 min 
Range Fragment sizes 137 bp - / 100 bp – 10 Kb 100 bp – 10 Kb 50 bp – 23Kb 100 bp – 10 Kb 
Capacity per prep N.A 40µg 10µg 25µg N.A 
DNA Quality A260/260: 0,6-0,9 A260/260: 1,78 A260/260: 1,8 A260/260: 1,79 A260/260: 1,86 
 Recovery 
Performance: 
     
PCR (5µg) 4,8µg 4,4µg 4,7µg 4,7µg 4,9µg 
Restriction/Ligation 
(5µg) 
4,7µg 3,7µg 4,4µg 2,6µg 4,85µg 
The human reference genome (hg19) has been digested in-silico with MseI to determine 
which percentage of each fraction would be lost during purification as a result of different 
molecular weight cut-off levels. The base pair distribution of each of the ten nucleotide 
combinations of MseI-fragments is summarized in Table 17.  
Table 17: In-silico digestion of the human genome (hg19) with MseI enzyme. In the table are shown the base pair distribution of the ten 
MseI-fragments in percentage. 
 
Around 50% of the genomic MseI-fragments are in the range of 5-50bp and can therefore not 
be purified by available purification systems. Although the Zymokit would allow the recovery 
of fragments down to 50bp, the molecular weight cut off was set to a level of 100bp. The 
isolation of MseI-fragments in between 50-100bp would have raised the inherent problem of 
potential carry-over of primer-dimer and adaptor concatamer. MseI-fragments below 100bp 
[%] per fraction   fractions                   
  
MseI-fragment 
length A/A T/T C/C G/G AC/CA AT/TA AG/GA CT/TC CG/GC GT/TG 
Fragments Excluded 0-5 5,87 5,87 6,80 6,79 1,75 5,38 2,11 2,12 1,31 1,73 
  6-10 6,11 6,10 4,33 4,38 5,47 5,98 5,65 5,67 4,80 5,52 
  11-50 28,99 29,02 24,89 24,87 27,51 30,02 27,42 27,40 26,16 27,46 
  51-70 9,04 9,00 8,53 8,60 9,28 9,17 9,39 9,40 8,97 9,34 
    50,01 49,99 44,55 44,64 44,01 50,55 44,57 44,59 41,24 44,05 
Fragments Included 71-100 10,33 10,33 10,19 10,19 10,95 10,83 11,50 11,48 10,74 10,91 
  101-150 12,38 12,38 11,82 11,85 12,64 11,43 12,57 12,64 13,34 12,64 
  151-300 16,21 16,22 19,07 19,03 18,22 16,16 17,68 17,63 18,52 18,23 
  301-600 9,31 9,32 11,03 10,98 11,15 9,15 10,78 10,78 12,41 11,17 
  601-1200 1,77 1,77 3,35 3,32 3,03 1,88 2,89 2,89 3,75 3,00 
    49,99 50,01 55,45 55,36 55,99 49,45 55,43 55,41 58,76 55,95 
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representative of 40-50% of the DNA material would be in theory excluded from the analysis, 
so the theoretical percentage of MseI-fragments that can be further analysed is between 50-
60%. 
 
4.2 WGA library modification: protocol establishment 
WGA modifications required for method implementation involves re-amplification of the 
original WGA, the Lib1-adaptor removal and the introduction of secondary adaptors enabling 
secondary PCR. The establishment of the respective quality control assay has been an 
essential pre-requisite to ensure the proper development of the protocol and, in turn, to define 
quality checkpoints for each step of the procedure (Figure 24). 
 
Figure 24: The diagram shows optimizations (orange boxes) and quality controls (violet boxes) applied at each step of the protocol 
development of the WGA library modification. 
4.2.1 Re-amplification of the genomic MseI-population and Lib1-adaptor removal: 
optimization and quality controls 
In order to obtain sufficient amounts of high-quality dsDNA the optimal number of PCR 
cycles for MseI-fragments re-amplification has been determined (Method Design Paragraph 
WGA 
QC: 
-  Ampli1 PCR 
-  Bioanalyzer trace 
-  MseI-fragment PCR 
-  dsDNA 
concentration 
-    BCR/ABL qPCR 
Reamplification 
and MseI-
adaptor removal  
PCR cycles 
optimization 
QC: 
-  Bioanalyzer trace 
-  MseI-fragment PCR 
-  dsDNA 
concentration 
-  BCR/ABL qPCR 
-  Control of the 
adaptor digestion  
-  PCR for adaptor 
contamination 
J24-adaptor 
ligation and J20 
PCR 
J24 adaptor 
efficiency 
QC: 
-  Bioanalyzer trace 
-  MseI-fragment PCR 
-  dsDNA 
concentration 
-  BCR/ABL qPCR 
Specific 
digestion 
Definition of the quality controls WGA library modification establishment 
PCR cycles 
optimization 
Specific 
Fractioning 
Genomic fractioning establishment 
QC: 
-  Bioanalyzer trace 
-  MseI-fragment PCR 
-  dsDNA 
concentration 
-  BCR/ABL qPCR 
Digestion 
optimization 
-  Adaptor ligation time 
-  Beads selection 
-  Washing buffer 
selection 
QC: 
-  Bioanalyzer trace 
-  MseI-fragment PCR 
-  dsDNA 
concentration 
-  BCR/ABL qPCR 
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3.2.1). The process of PCR cycle optimization is of fundamental importance as reaching a 
plateau effect would result in the generation of unwanted ssDNA by-product unusable in 
dsDNA-dependent enzymatic reactions. After conducting limited cycle PCRs with 10-12-15-
17 cycles for re-amplification of the primary WGA product, the amount of dsDNA has been 
determined. After the 12th PCR cycle the dsDNA amount started to decrease (Table 18).  
Table 18: Summary of the PCR cycles optimization. In bold are the optimal numbers of cycles and the corresponding amount of dsDNA 
obtained.  
 
Based on these results, the number of PCR cycles for re-amplification of the WGA product of 
the K562 single cells and the pool of lymphocytes (Table 19) has been limited to a total 
number of 12. 
Table 19: DsDNA amounts obtained from the re-amplification of the samples after twelve PCR cycles. 
 
Following re-amplification and purification of the primary WGA, the size distribution of the 
MseI-fragment representation is controlled with the DNA High Sensitivity Chip on the 
Agilent Bioanalyzer. The fragment size distribution of the re-amplified and original WGA is 
still similar, although a small shift toward smaller fragment is observed, ranging from ~150 to 
~3000bp (Fig. 25; Fig. 18) showing that limited re-amplification does not change drastically 
the main amplicons length composition. 
 
Figure 25: Examples traces of WGA re-amplification from lymphocyte pool and K562 single cell to control the size distribution and to avoid 
the selection of PCR amplicons. The X-axis represents the product size in base pairs (bp) and the Y-axis is the arbitrary fluorescence 
intensity (FU). 
Re-amplification of the WGA 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification WGA 
Lymphocytes pool --- 114 ng/µl --- --- --- 
Re-amplification WGA K562 
single cell --- 102 ng/µl --- --- --- 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification of the WGA 82ng/µl 108ng/µl 91ng/µl 83ng/µl 64ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Re-amplification K562 single cell  1597 
Samples for Lib1-adaptor removal dsDNA concentration 
Lib1-adaptor removal Lymphocytes pool 124 ng/µl 
Lib1-adaptor removal K562 single cell 112 ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Lib1-adaptor removal K562 single cell 1325 
Re-amplificati n of the WGA 10 ycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification WGA 
Lymphocytes pool --- 114 ng/µl --- --- --- 
Re-amplification WGA K562 
single cell --- 102 ng/µl --- --- --- 
PCR Program 10 ycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification of the WGA 82ng/µl 108ng/µl 91ng/µl 83ng/µl 64ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Re-amplification K562 single cell  1597 
Samples for Lib1-adaptor removal dsDNA concentration 
Lib1-adaptor removal Lymphocytes pool 124 ng/µl 
Lib1-adaptor removal K562 single cell 112 ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Lib1-adaptor removal K562 single cell 1325 
Reamplification WGA lymphocytes pool 
Driver Tester 
Reamplification WGA K562 single cell 
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The absolute quantification using the BCR/ABL standard curve assay was applied to quantify 
the copy number of the BCR/ABL breakpoint-MseI-fragment in the K562 single cell after re-
amplification. The re-amplification of the WGA did not increase the copies of BCR/ABL 
breakpoint-MseI-fragments as would be expected from a further PCR amplification. In table 
are summarized the qPCR results (Table 20). 
Table 20: BCR/ABL breakpoint-MseI-fragments copies/ng of DNA calculated after the WGA re-amplification of the K562 single cell. 
 
Subsequently, the re-amplified WGA was digested to release the original Lib1-adaptor and 
the digestion has been controlled on agarose gel to prove the effective removal of the Lib1-
adaptor (Figure 26). 
 
Figure 26: Lib1-adaptor removal from re-amplified lymphocyte pool and K562 single cell. Digested and un-purified DNA has been 
controlled on agarose gel. The yellow arrow indicates the digested adaptor.  
Moreover, to exclude adaptor contamination or minimal adaptor carry-over, 0,5 µl of the 
digested sample has been re-amplified with the Lib1 primer (Figure 27). 
 
Re-amplification of the WGA 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification WGA 
Lymphocytes pool --- 114 ng/µl --- --- --- 
Re-amplification WGA K562 
single cell --- 102 ng/µl --- --- --- 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification of the WGA 82ng/µl 108ng/µl 91ng/µl 83ng/µl 64ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Re-amplification K562 single cell  1597 
Samples for Lib1-adaptor removal dsDNA concentration 
Lib1-adaptor removal Lymphocytes pool 124 ng/µl 
Lib1-adaptor removal K562 single cell 112 ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Lib1-adaptor removal K562 single cell 1325 
M              1                2               3               M 
1:!Lib1Eadaptor!removal!Lymphocytes!pool!
2:!Lib1Eadaptor!removal!K562!single!cell!
M:!Marker!2Elog!
M               1               2 
1:!ReCampliﬁca+on!of!Lib1Cadaptor!removed!sample!with!Lib1Cprimer!
M:!2Clog!molecular!marker!!
1
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Figure 27: Re-amplification of Lib1-adaptor removed sample with Lib1-primer to exclude adaptor carry-over. As can be observed a very 
light smear barely visible. 
After controlling the proper digestion, the samples are purified for complete adaptor removal 
and dsDNA amount measured by Qubit/PicoGreen – Broad Range assay (Table 21). 
Table 21: DsDNA concentration obtained after the Lib1-adaptor removal. 
 
Additionally, the purified digestion product was analysed with the DNA High Sensitivity 
Chip on the Agilent Bioanalyzer to control the size distribution, which remains invariant 
compared to the re-amplification step (Figure 28).  
  
Figure 28: Examples trace of Lib1-adaptor removal after re-amplification. The X-axis represents the product size in base pairs (bp) and the 
Y-axis is the arbitrary fluorescence intensity (FU). 
The established absolute quantification using the BCR/ABL standard curve assay qPCR was 
also used here to quantify the copy number of the BCR/ABL breakpoint-MseI-fragment in the 
K562 single cell after the removal of the Lib1-adaptor (Table 22). The digestion with MseI 
and the purification did not affect significantly the copy numbers of the BCR/ABL 
breakpoint-MseI-fragment compared to the re-amplification. 
Table 22: BCR/ABL breakpoint-MseI-fragments copies/ng of DNA calculated after the digestion of the Lib1-adaptor. 
 
The specific MseI-fragments PCR-based quality control was assayed on re-amplified and 
purified Lib1-adaptor digested lymphocyte pool and K562 single cell samples. Loss of MseI-
fragments was not observed in any of the tested samples indicating that during these two steps 
all ten MseI-fragments combinations are preserved (Figure 29).  
Re-amplification of the WGA 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification WGA 
Lymphocytes pool --- 114 ng/µl --- --- --- 
Re-amplification WGA K562 
single cell --- 102 ng/µl --- --- --- 
PCR Pr gram 10 cycles 12 cycles 15 cycles 17 cy les 19 cycles 
Re-amplification of the WGA 82ng/µl 108ng/µl 91ng/µl 83ng/µl 64ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Re-amplification K562 single cell  1597 
Samples for Lib1-adaptor removal dsDNA concentration 
Lib1-adaptor removal Lymphocytes pool 124 ng/µl 
Lib1-adaptor removal K562 single cell 112 ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Lib1-adaptor removal K562 single cell 1325 
Lib1-adaptor removal Re-amplification of the WGA 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification WGA 
Lymphocytes pool --- 114 ng/µl --- --- --- 
Re-amplification WGA K562 
single cell --- 102 ng/µl --- --- --- 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-amplification of the WGA 82ng/µl 108ng/µl 91ng/µl 83ng/µl 64ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Re-amplification K562 single cell  1597 
Samples for Lib1-adaptor removal dsDNA concentration 
Lib1-adaptor removal Lymphocytes pool 124 ng/µl 
Lib1-adaptor removal K562 single cell 112 ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
Lib1-adaptor removal K562 single cell 1325 
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Figure 29: Specific MseI-fragment control PCR. After re-amplification and Lib1-adaptor removal step, control PCR was performed and was 
positive in all of the samples. The specific MseI-fragment amplified is indicated in curly brackets at the edge of the gel. In the small table the 
control primers used for this step are listed. 
4.2.2 Ligation of the secondary adaptors and secondary PCR: optimization and quality 
controls  
After successfully implementing primary WGA re-amplification and Lib1-adaptor removal, 
the secondary adaptor ligation and amplification has been established (Method Design 
Paragraph 3.2.2). To determine the ligation efficiency of each of the four J24 adaptors, each 
adaptor was ligated individually to the sample, and then the dsDNA amount assessed for each 
reaction after J20-mediated re-amplification of the ligated samples (Table 23). In each of the 
four reactions, a similar amount of dsDNA was measured after re-amplification.  
 
 
J20 PC
R
 
J20 PC
R
  A/A  C/C  A/G 
 T/T  T/G  A/C 
  1     2      3     4     P     N   1     2      3     4     P     N   1     2      3     4     P     N     M 
1: Lymphocyte pool – Re-amplification  
2: K562 single cell – Re-amplification  
3: Lymphocyte pool – Lib1 removal  
4: K562 single cell – Lib1 removal 
P: Positive control  
N: Negative control 
M: 2-log molecular marker 
 
   1    2    3    4    P   N    1   2    3    4    P    N    1   2    3    4    P   N    M 
   1    2    3    4    P   N    1   2    3    4    P    N    1   2    3   4   P   N    M 
J20 PC
R
  G/C  G/G 
 T/C 
1      2      3      4      P    N 
1      2      3     4       P     N                                                    M 
1: Lymphocyte pool – Re-amplification  
2: K562 single cell – Re-amplification  
3: Lymphocyte pool – Lib1 removal  
4: K562 single cell – Lib1 removal 
P: Positive control  
N: Negative control 
M: 2-log molecular marker 
 
 A/T 
   1    2    3    4     P   N     1     2    3     4     P     N                                  M 
   1    2    3    4     P   N     1     2    3     4     P     N   M 
J20 PC
R
  G/C  G/G 
 T/C 
1      2      3      4      P    N 
1      2      3     4       P     N                                                    M 
1: Lymphocyte pool – Re-amplification  
2: K562 single cell – Re-amplification  
3: Lymphocyte pool – Lib1 removal  
4: K562 single cell – Lib1 removal 
P: Positive control  
N: Negative control 
M: 2-log molecular marker 
 
 A/T 
   1    2    3    4     P   N     1     2    3     4     P     N                                  M 
   1    2    3    4     P   N     1     2    3     4     P     N   M 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
RTP3 AG/GA 394 bp 302 bp 
BCR T/T 1936 bp 413 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
BCR G/G 944 bp 390 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
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Table 23: dsDNA amount obtained after the ligation of each single adaptor with different terminal nucleotides to the DNA deprived of the 
Lib1-adaptors. 
 
The MseI-fragment length distribution of each reaction product showed to be of similar 
length, except that the ligation and amplification of J24 adaptors with terminal nucleotide C 
and G gave a slight shift towards the amplification of bigger fragments. J24 adaptors with 
terminal nucleotide A and T gave an amplification peak at 481bp while J24 adaptors with 
terminal nucleotide C and G gave a peak at 485bp, so a total shift of 50bp (Figure 30). 
 
Figure 30: Bioanalyzer profile derived from the singular ligation and PCR amplification of the J24 adaptors with different terminal 
nucleotides. The amplification profile is very similar between them; a slight base pair shift towards bigger fragments can be noted in the 
amplification with the J24 adaptors with terminal nucleotide C and G. The X-axis represents the product size in base pairs (bp) and the Y-
axis is the arbitrary fluorescence intensity (FU). 
After the ligation of the secondary adaptors, the PCR cycles for the J20 PCR have been 
optimized (Table 24).   
Table 24: Summary of the PCR cycles optimization for the J20 secondary PCR. In bold are the optimal numbers of cycles and the 
corresponding amount of dsDNA obtained. 
 
J24 adaptor used in combination to 100ng of 
MseI-digested DNA dsDNA concentration 
J24 adaptor-terminal nucleotide A (2µM) 62,0ng/µl 
J24 adaptor-terminal nucleotide C (2µM) 63,4ng/µl 
J24 adaptor-terminal nucleotide G  (2µM) 61,7ng/µl 
J24 adaptor-terminal nucleotide T (2µM) 62,6ng/µl 
PCR Progr m 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
J20 PCR  45ng/µl 51ng/µl 67ng/µl 59ng/µl 48ng/µl 
J20 secondary PCR 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
  J20 secondary PCR Lymphocytes pool --- --- 74ng/µl --- --- 
J20 secondary PCR K562 single cells --- --- 61ng/µl --- --- 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
J20 secondary PCR K562 single cell 3463 
J24 adaptor-terminal nucleotide A  J24 adaptor-terminal nucleotide T  
J24 adaptor-terminal nucleotide G  J24 adaptor-terminal nucleotide C  
J24 adaptor used in combination to 100ng of 
MseI-digested DNA dsDNA concentration 
J24 adaptor-terminal nucleotide A (2µM) 62,0ng/µl 
J24 adaptor-terminal nucleotide C (2µM) 63,4ng/µl 
J24 adaptor-terminal nucleotide G  (2µM) 61,7ng/µl 
J24 adaptor-terminal nucleotide T (2µM) 62,6ng/µl 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
J20 PCR  45ng/µl 51ng/µl 67ng/µl 59ng/µl 48ng/µl 
J20 secondary PCR 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
  J20 secondary PCR Lymphocytes pool --- --- 74ng/µl --- --- 
J20 secondary PCR K562 single cells --- --- 61ng/µl --- --- 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
J20 secondary PCR K562 single cell 3463 
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Lymphocyte pool and K562 single cell have been amplified for 15 cycles followed by 
purification and dsDNA quantification (Table 25). 
Table 25: dsDNA concentration obtained after the J20 secondary PCR for the secondary adaptor-ligated lymphocyte pool and K562 single 
cell. 
 
Subsequently, the size distribution of all secondary PCRs were analysed with the DNA High 
Sensitivity Chip on the Agilent Bioanalyzer. The J20 primary PCR products show a slight 
different profile ranging from smaller fragments (100bp) to bigger ones (3000bp) (Figure 31). 
 
Figure 31: Examples traces of J20 secondary PCR derived from the samples to control the size distribution. The J20 PCR ranges from 100-
3000bp. The X-axis represents the product size in base pairs (bp) and the Y-axis is the arbitrary fluorescence intensity (FU). 
The absolute quantification qPCR assay was applied to quantify the copy numbers of the 
BCR/ABL breakpoint-MseI-fragment in the K562 single cells after the J20 secondary re-
amplification PCR (Table 26). The copies/ng increased compared to the previous steps due to 
the effect of a secondary amplification.  
Table 26: BCR/ABL breakpoint-MseI-fragments copies/ng of DNA calculated after the J20 secondary PCR. 
 
Identical to Results Paragraph 4.2.1, the fraction-specific PCR-based quality controls were 
assayed on amplified and purified secondary re-amplification products of lymphocyte pool 
and K562 single cell samples. As experienced in the previous chapter, in none of the tested 
samples loss of MseI-fragments was noted indicating that during these two steps all ten MseI-
fragments combinations are preserved (Figure 32). 
 
J24 adaptor used in combination to 100ng of 
MseI-digested DNA dsDNA concentration 
J24 adaptor-terminal nucleotide A (2µM) 62,0ng/µl 
J24 adaptor-terminal nucleotide C (2µM) 63,4ng/µl 
J24 adaptor-terminal nucleotide G  (2µM) 61,7ng/µl 
J24 adaptor-terminal nucleotide T (2µM) 62,6ng/µl 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
J20 PCR  45ng/µl 51ng/µl 67ng/µl 59ng/µl 48ng/µl 
J20 secondary PCR 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
  J20 secondary PCR Lymphocytes pool --- --- 74ng/µl --- --- 
J20 secondary PCR K562 single cells --- --- 61ng/µl --- --- 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
J20 secondary PCR K562 single cell 3463 
Reamplification WGA lymphocytes pool Reamplification WGA K562 single cell 
J20 secondary PCR lymphocytes pool J20 secondary PCR K562 single cell 
J24 adaptor used in combination to 100ng of 
MseI-digested DNA dsDNA concentration 
J24 adaptor-terminal nucleotide A (2µM) 62,0ng/µl 
J24 adaptor-terminal nucleotide C (2µM) 63,4ng/µl 
J24 adaptor-terminal nucleotide G  (2µM) 61,7ng/µl 
J24 adaptor-terminal nucleotide T (2µM) 62,6ng/µl 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
J20 PCR  45ng/µl 51ng/µl 67ng/µl 59ng/µl 48ng/µl 
J20 secondary PCR 10 cycles 12 cycl s 15 cycles 17 cycles 19 cycles 
  J20 secondary PCR Lymphocytes pool --- --- 74ng/µl --- --- 
J20 secondary PCR K562 single cells --- --- 61ng/µl --- --- 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragments copies/ng of DNA 
J20 secondary PCR K562 single cell 3463 
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Figure 32: Specific MseI-fragment control PCR for the secondary amplification J20 PCR. The samples show the amplification for all the 
control primer pairs. The specific MseI-fragment amplified is indicated in curly brackets at the edge of the gel. In the small table the control 
primer used for this step are listed. 
 
 
 
 
 
1: J20 PCR Lymphocyte pool 
2: J20 PCR K562 single cell 
P: Positive control  
N: Negative control 
M: 2-log molecular marker 
 
T/T A/A T/G C/C A/G 
A/C G/C G/G A/T T/C 
600 bp 
300 bp 
200 bp 
100 bp 
600 bp 
300 bp 
200 bp 
500 bp 
500 bp 
  1    2    P    N    1    2    P    N    1    2    P    N    1    2    P    N    1    2    P    M  
  1    2    P    N    1    2    P    N    1    2    P    N    1    2    P    N    1    2    M         P          M      
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
D5S399 AG/GA  489 bp 178-201 bp 
BCR T/T 1936 bp 413 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
BCR G/G 944 bp 390 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
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4.3 Genome fractioning: specific selection and enrichment of MseI-
fragments 
The major challenge of the genome fractioning is to efficiently separate each of the ten MseI-
fragments populations thereby minimizing cross-contamination of undesired other fragments 
(Method Design Paragraph 3.3). The BCR/ABL breakpoint-MseI-fragment is contained 
within the MseI-fragment population characterized by G/G differentiating bases. This MseI-
fragment population is used as the experimental test. Various attempts have been made to 
optimize the procedure and to shorten the length of the protocol. Figure 33 summarizes the 
different approaches and the quality controls applied to assess the successful implementation 
of the genome fractioning procedure.  
 
 
Figure 33: Diagram showing which optimizations (orange boxes) and quality controls (violet boxes) have been applied at each step of the 
protocol development of the genome fractioning. 
4.3.1 Optimization of the genome fractioning procedure: specific digestion of MseI-
fragments  
Three main protocols have been investigated to optimize the genome fractioning (Figure 34) 
(Method Design Paragraph 3.3.1). At first, the specific digestion has been optimized to 
perform at high efficiency in the shortest time. Protocols A and B use a digestion time of 1 
hour while protocol C uses only 15 minutes for the digestion. 
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Figure 34: Different protocols tested for the establishment and optimization of the genome fractioning procedure. 
The specific isolation of MseI-fragments constituting the G/G-fraction requires a BspTI 
digestion. Digested products were separated on an agarose gel to visualize the released J20-
adaptors in all tested samples. The digestion was shown to be successful under both 
conditions (Figure 35).  
 
Figure 35: Control of the specific digestion on agarose gel 3%. The digested J20-adaptors are indicated from the blue arrow. 
Protocol A Protocol B Protocol C 
Specific digestion 
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Specific digestion 
1 hour 
Specific digestion 
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Specific adaptor 
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Beads washing: 
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BW 
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A control PCR to exclude carry-over of the MseI-fragments harbouring the J20-adaptor in the 
next step of the protocol has not been performed. In fact, at this step not all the J20-amplified 
MseI-fragments are digested by the specific enzyme, but only those harbouring the correct 
reformed restriction site. This means that most of the J20-amplified MseI-fragments will 
remain undigested. 
4.3.2 Optimization of the genome fractioning procedure: beads selection, fractioning-
adaptor ligation and washing buffer conditions 
The ligation of the specific fractioning-adaptor to the digested MseI-fragments has been 
evaluated in order to shorten the incubation time (Method Design Paragraph 3.3.2). Two types 
of magnetic streptavidin-conjugated beads have been tested, the Dynabeads M-280 
(Invitrogen, Inc.) and the Nanolink beads (Solulink Inc.). Biotinylated fractioning-adaptors 
pre-bound either to streptavidin-conjugated Dynabeads M-280 or Nanolink beads have been 
incubated with the specifically digested MseI-fragments generated in the previous Paragraph 
4.3.1 (Figure 34).  
The washing steps for the magnetic streptavidin-conjugated beads have been optimized in 
order to remove the majority of unbound and unspecific bound MseI-fragments whilst not 
applying too stringent washing procedure leading to a loss of specifically bound MseI-
fragments. In protocol A very stringent washing steps are used: Dynabeads M-280 were 
rinsed with washing buffers containing 50% formamide, WP150-WP250, at high temperatures 
(50°C) four times for 4 minutes. In protocol B, one wash with BP2X and two washes with 
BP1X were used at room temperature for washing of Dynabeads M-280. In protocol C three 
washing steps at room temperature with BW buffer have been used to rinse the Nanolink 
beads (Figure 34). The final outcome of these different practical approaches is directly related 
to the results of the specific MseI-fragment PCR and qPCR for BCR/ABL (Result Paragraph 
4.3.3). 
4.3.3 Optimization of the genome fractioning procedure: generation of simple genomic 
fractions and quality controls 
After implementation of the various washing procedures, the best-suited protocol was 
identified on the basis of purity of the generated fractions i.e. absence of cross-contaminating 
MseI-fragments after specific MseI-fragment control PCR, and the obtained enrichment of the 
Results  
 99 
BCR/ABL breakpoint-MseI-fragment observed after absolute quantification by qPCR 
(Method Design Paragraph 3.3.3).  
The specific MseI-fragment control PCR performed to ensure the proper MseI-
fragment isolation for each experimental setting showed different outcome. The enrichment of 
the MseI-fragment population containing the differentiating bases G/G shows the lowest 
background of unwanted MseI-fragments amplified with the use of Nanolink beads and BW 
buffers (Figure 36 C) compared to if Dynabeads M-280 would be used (Figure 36 A-B). 
Under stringent washing conditions (Figure 36 A) the Dynabeads M-280 showed similar, but 
not considerably better results to the Nanolink beads. If Dynabeads M-280 are washed with 
BP2X-BP1X (Figure 36 B), they show a high background of unwanted amplified MseI-
fragments as can be seen from their amplification after the specific genome fractioning.  
The absolute quantification BCR/ABL after the genome fractioning with the use of 
Protocol A showed a decrease in BCR/ABL breakpoint-MseI-fragment copy numbers in the 
final genome MseI-fraction product compared to Protocol B and Protocol C. Protocol B and 
Protocol C performed equally good in terms of BCR/ABL breakpoint-MseI-fragment 
enrichment. Based on these results Protocol C is the most suitable to perform the genome 
fractioning of the K562 single cells (Table 27). 
Table 27: Selection of the suitable protocol for genome fractioning based on the BCR/ABL breakpoint-MseI-fragment enrichment and purity 
of the specific MseI-control PCR. 
 
 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
RTP3 A/G  394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR T/G 670 bp 192 bp 
RH27788 A/C 576 bp 389 bp 
ZNF23 G/C 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 T/C 1032 bp 461 bp 
BCR A/T  600 bp 358 bp 
Protocol  BCR/ABL breakpoint-MseI-fragment copies/ng Purity of the MseI-fraction Specific MseI-fragment PCR Optimal protocol   
Protocol A 32.165 ++ ✖
Protocol B 54.125 - ✖
Protocol C 52.935 +++ ✔
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Figure 36: Specific MseI-fragment control PCR after genome fractioning using three different protocols. The isolated MseI-fragments carry a 
G/G nucleotide as differentiating bases. (A) Genome fractioning using protocol A; (B) genome fractioning using protocol B; (C) genome 
fractioning using protocol C. 1: genome fractioning of the lymphocyte pool, 2: genome fractioning of the K562 single cell; P: positive 
control; N: negative control. Yellow asterisks are indicating the MseI-fragments that are amplified after the specific genome fractioning, 
representing “contaminating” fragments. These are coming from the amplification of randomly bound fragments on the magnetic 
streptavidin-conjugated beads that are not properly washed away.  The specific MseI-fragment amplified is indicated in curly brackets at the 
edge of the gel. In the table the control primers used are indicated. 
After selecting Protocol C as the standard protocol for genome fractioning, quality controls 
have been applied to identify and define thresholds for specific steps of genome fractioning. 
The specific digestion with BspTI of the J20 secondary PCR from lymphocytes pool and 
K562 single cells (from Paragraph 4.3.1) was quantified to identify the exact amount of 
dsDNA at this step of method development (Table 28). 
Table 28: dsDNA concentration obtained after the specific enzyme digestion. 
 
Furthermore, the size distribution of the specific digestion with BspTI enzyme, for G/G-MseI-
fraction selection, was determined on the Agilent Bioanalyzer (Figure 37). The MseI-
fragments length distribution at this step range from ~100bp till ~3000bp and it is very similar 
to the J20 secondary. Generally, the size distribution of the specific digestions did not indicate 
a visible or significant size shift after J20-adaptors removal, although the digestion was 
successful (Figure 35). 
 
WGA pool of Lymphocytes WGA K562 single cells 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
D5S399 AG/GA 485 bp 178 bp 
RTP3 AG/GA 394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
ZNF23 GC/CG 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
BCR AT/TA  600 bp 358 bp 
Samples for specific digestion dsDNA concentration 
Specific digestion Lymphocyte pool 141ng/µl 
Specific digestion K562 single cell 135ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragment copies/ng of DNA 
Specific digestion K562 single cell 3299 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
not-normalized 144ng/µl 
Genome MseI-fraction K562 single cell 
not-normalized 151ng/µl 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
Normalized 195ng/µl 
Genome MseI-fraction K562 single cell 
Normalized 167ng/µl 
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Figure 37: Example of bioanalyzer traces of specific digestion with BspTI enzyme derived from the analysed samples to control the size 
distribution. The MseI-fragments length distributions at this step range from ~100bp till ~3000bp. The X-axis represents the product size in 
base pairs (bp) and the Y-axis is the arbitrary fluorescence intensity (FU) 
Finally, the absolute BCR/ABL qPCR assay was performed to determine the number of 
BCR/ABL breakpoint-MseI-fragment copies (Table 29). The copy numbers do not differ 
significantly from the previous step meaning that the specific digestion and purification do 
not induce a further loss of the BCR/ABL breakpoint-MseI-fragment. 
Table 29: BCR/ABL breakpoint MseI-fragment copies/ng of DNA calculated after the BspTI specific digestion of the K562 single cell. 
 
The specific digestion represents the last step of the protocol in which all ten MseI-fragments 
populations are still represented in one sample: after this step each of the ten MseI-fragment 
populations will be specifically selected and individually enriched. The quality of the 
separation process is assayed with the specific MseI-fragments control PCRs to ensure the 
purity and unbiased representation of all ten MseI-fragment populations (Figure 38). 
 
Specific Digestion K562 single cells Specific digestion lymphocytes pool 
Genome fractioning lymphocyte pool - Not Normalized Genome fractioning K562 single cell - Not Normalized 
Samples for specific digestion dsDNA concentration 
Specific digestion Lymphocyte pool 141ng/µl 
Specific digestion K562 single cell 135ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragment copies/ng of DNA 
Specific digestion K562 single cell 3299 
Samples for G nome Fractioning dsDNA c ncentration 
Genome MseI-fraction Lymphocyte pool 
not-normalized 144ng/µl 
Genome MseI-fraction K562 single cell 
not-normalized 151ng/µl 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocy e pool 
Normalized 195ng/µl 
Genome MseI-fraction K562 single cell 
Normalized 167ng/µl 
 A/A  C/C A/G T/T T/G 
 A/C  G/C  G/G  A/T  T/C 
  1    2    P   N    1    2    P   N    1   2   P   N    1   2   P   N    1   2   P     M  
  1   2   P   N    1   2   P   N    1   2   P   N    1   2   P   N     1   2   P   M  
1: Specific Digestion-Lymphocyte pool 
2: Specific Digestion-K562 single cell 
P: Positive control 
N: Negative control 
M: 2-log molecular marker 
700 bp 
300 bp 
200 bp 
100 bp 
500 bp 
700 bp 
300 bp 
200 bp 
100 bp 
500 bp 
Results  
 103 
 
Figure 38: Specific MseI-fragment control PCR assayed for the digestion with BspTI. The samples show the amplification for all the control 
primer pairs. The specific MseI-fragment amplified is indicated in curly brackets at the edge of the gel. In the table the control primers used 
are listed. 
The final genome MseI-fraction, representing all the MseI-fragments containing the G/G 
nucleotide (Figure 36 C), has been quantified to assess the dsDNA concentration (Table 30). 
Table 30: dsDNA concentration obtained at the end of the genome fractioning procedure. 
 
Moreover, the size distribution of the final genome MseI-fraction has been analysed on the 
Agilent Bioanalyzer. The digital profile generated from the lymphocyte pool and the K562 
single cell showed that the genome fractioning could lead to a selective enrichment of certain 
amplicon sequences. This effect was more pronounced in the genome fractioning of the single 
K562 cell compared to the pool of lymphocytes (Figure 39).                
                                                                                             
 
Figure 39: Examples of bioanalyzer profiles of the genome fractioning for the lymphocyte pool and the K562 single cell. The profiles show a 
MseI-fragment length distribution in between ~130 and ~1000bp with peaks selection mainly at 350-450bp. 
To solve the problem related to the sequence selection at the end of the genome fractioning, 
the specifically enriched genome MseI-fraction population was normalized to obtain a 
homogenous distribution of the MseI-fragments length. The normalization showed to be very 
efficient in removing the over-represented DNA sequences (Figure 40). 
 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
RTP3 AG/GA  394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
ZNF23 GC/CG 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA  600 bp 358 bp 
Protocol  BCR/ABL breakpoint-MseI-fragment copies/ng Purity of the MseI-fraction Specific MseI-fragment PCR Optimal protocol   
Protocol A 32.165 ++ ✖
Protocol B 54.125 - ✖
Protocol C 52.935 +++ ✔
Samples for specific digestion dsDNA concentration 
Specific digestion Lymphocyte pool 141ng/µl 
Specific digestion K562 single cell 135ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragment copies/ng of DNA 
Specific digestion K562 single cell 3299 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
not-normalized 144ng/µl 
Genome MseI-fraction K562 single cell 
not-normalized 151ng/µl 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
Normalized 195ng/µl 
Genome MseI-fraction K562 single cell 
Normalized 167ng/µl 
Specific Digestion K562 single cells Specific digestion lymphocytes pool 
Genome MseI-fraction lymphocyte pool - Not Normalized Genome MseI-fraction K562 single cell - Not Normalized 
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Figure 40: Examples of bioanalyzer traces of the normalized genome fractioning for the lymphocyte pool and the K562 single cell. The 
profile shows a homogenous distribution of the MseI-fragments. The normalization suppresses amplicons that are selected during the 
isolation/enrichment of the MseI-GG fraction, re-establishing a homogenous distribution in between ~130 and ~1000bp.  
The dsDNA amount has been also quantified for the normalized genome MseI-fraction (Table 
31). 
Table 31: dsDNA concentration obtained after the normalization of the genome MseI-fraction. 
 
The absolute fold enrichment of the BCR/ABL breakpoint-MseI-fragment at each step of the 
developed method was determined, starting from the original WGA product until the 
specifically enriched MseI-fraction population. Direct comparison of the absolute copy 
numbers should enable to disclose critical steps affecting gain or loss of the desired sequence 
(Figure 41). The WGA of a single cell does not dramatically change the representation of the 
BCR/ABL breakpoint-MseI-fragment compared to the genome of a pool of cells, as the 
unamplified genomic DNA of the K562 cells and the WGA of single K562 single cells do not 
present significant differences in terms of absolute copy numbers. The WGA re-amplification 
of the K562 single cell did not show the expected PCR-based enrichment, instead a loss of the 
breakpoint MseI-fragment was noted. The removal of the Lib1-adaptor from the re-amplified 
sample showed a BCR/ABL breakpoint-MseI-fragment copy numbers similar to the re-
amplified samples, proving the reliability of the purification method in recovering most of the 
MseI-fragments after the digestion. The secondary J20 PCR enriches again slightly the copy 
numbers of the BCR/ABL breakpoint-MseI-fragment, which subsequently remains roughly 
unchanged in the specific digestion for the MseI-fragments selection. The genome fractioning 
shows a significant enrichment of the breakpoint BCR/ABL breakpoint-MseI-fragment 
indicating that complexity reduction is the essential step in selecting a determined population 
of MseI-fragments. Compared to the initial WGA the enrichment after the genome fractioning 
Genome MseI-fraction lymphocyte pool - Normalized Genome MseI-fraction K562 single cell - Normalized 
Samples for specific digestion dsDNA concentration 
Specific digestion Lymphocyte pool 141ng/µl 
Specific digestion K562 single cell 135ng/µl 
Sample for Absolute qPCR BCR/ABL breakpoint-MseI-fragment copies/ng of DNA 
Specific digestion K562 single cell 3299 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
not-normalized 144ng/µl 
Genome MseI-fraction K562 single cell 
not-normalized 151ng/µl 
Samples for Genome Fractioning dsDNA concentration 
Genome MseI-fraction Lymphocyte pool 
Normalized 195ng/µl 
Genome MseI-fraction K562 single cell 
Normalized 167ng/µl 
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is 4.3 fold. If the genome MseI-fraction is normalized, there is a further substantial increase of 
copy numbers of the BCR/ABL breakpoint-MseI-fragment thus bringing the overall 
enrichment up to 13 fold (Figure 41). 
 
Figure 41: Overview of the K562 genome fractioning. On the Y-axis, are shown the copies of BCR/ABL breakpoint-MseI-fragment per 
nanogram of DNA of the K562 single cell sample and, on the X-axis, the step of the protocol controlled.  
 
Based on the obtained results, the genome fractioning protocol was applied to the K562 single 
cell and the pool of lymphocytes to test the selective enrichment of the different MseI-
fragments present in the genome. Figure 42 summarizes some examples of genomic 
fractioning for the selective isolation of MseI-fragments harboring simple nucleotide 
combinations assessed by applying the specific MseI-fragment control PCR. Figure 42 (A) 
shows the selective amplification of the genome MseI-fraction carrying the A/A nucleotide 
combination as differentiating base. Figure 42 (B) shows the isolation of the genome MseI-
fraction harboring G/G nucleotide combination as differentiating bases. Figure 42 (C) shows 
the isolation of the genome MseI-fraction carrying the T/T nucleotide combination. The 
genomic fractioning is quite pure for each MseI-fraction isolated with minimal cross-
contamination of other MseI-fragments. 
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 A/A  A/G  C/C  A/C 
 T/T  T/A  T/C 
T/G G/C G/G 
1   2    P   N M M
M
M M
M M
* 
600 bp 
300 bp 
200 bp 
100 bp 
600 bp 
300 bp 
200 bp 
100 bp 
1: fractioned Lymphocyte pool 
2: fractioned K562 single cell 
P: positive control 
N: negative control 
A) Isolation of the MseI-fraction carrying the A/A nucleotide  
1   2    P   N 
1   2    P   N 1   2    P   N 1   2    P   N 1   2    P   N 1   2    P   N 1   2    P   N 
1   2    P   N 1   2    P   N 
 A/A  A/G  C/C  A/C  G/C G/G 
 T/T  T/A  T/C  T/G 
600 bp 
300 bp 
200 bp 
100 bp 
600 bp 
300 bp 
200 bp 
100 bp 
 1    2   N   P M M
M M
B) Isolation of the MseI-fraction carrying the G/G nucleotide  
 1    2   N   P  1    2   N   P  1    2   N   P  1    2   N   P  1    2   N   P 
 1    2   N   P  1    2   N   P  1    2   N   P  1    2   N   P 
 A/A  A/G  C/C  A/C  G/C GG 
   T/G  T/T  T/A  T/C 
600 bp 
300 bp 
200 bp 
100 bp 
600 bp 
300 bp 
200 bp 
100 bp 
C) Isolation of the MseI-fraction carrying the T/T nucleotide 
* * * * * *
 1   2   N  P 
 1   2   N  P  1   2   N  P 
 1   2   N  P  1   2   N  P  1   2   N  P  1   2   N  P  1   2   N  P 
 1   2   N  P  1   2   N  P 
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Figure 42: Specific MseI-fragment control PCR after the genome fractioning of the lymphocyte pool and K562 single cells. (1) Isolation of 
the genome MseI-fraction carrying the A/A nucleotide after the MseI restriction site: only MseI-fragments with the same differentiating base 
A after the MseI recognition sites are enriched. Sometimes, small levels of “contamination” from other fragments can happen. For example 
in the fractioned genome of lymphocyte pool there is a tiny level of amplification of MseI-fragments with two different differentiating bases, 
in this case A/G (yellow asterisk); (2) genome MseI-fraction containing the G/G nucleotide, where is also located the BCR/ABL breakpoint-
MseI-fragment of the cell line, is also quite clean; (3) genome MseI-fraction with the same differentiating base T/T after the MseI 
recognition sites are enriched; it is pure, except for some unspecific amplification (red asterisks, not corresponding to the size of the positive 
control). The specific MseI-fragment amplified is indicated in curly brackets at the edge of the gel. In the table the control primers used are 
indicated. 
 
4.3.4. Examples of genome fractioning for mixed fractions   
The genome fractioning for the isolation and enrichment of MseI-fragments harboring two 
different nucleotides after the MseI restriction sites (two differentiating bases) has been 
performed applying the same protocol optimized for the simple MseI-fragments (Method 
Design Paragraph 3.3.4). Figure 43 depicts two examples of genome fractioning controlled by 
the use of specific MseI-fragment control PCR.   
 
WGA pool of Lymphocytes WGA K562 single cells 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
D5S399 AG/GA 485 bp 178 bp 
RTP3 AG/GA 394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
ZNF23 GC/CG 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
BCR AT/TA  600 bp 358 bp 
 A/A  A/G  A/G  A/C  G/C  G/G 
 C/C  T/G  T/T  A/T  A/T  T/C 
700 bp 
400 bp 
200 bp 
100 bp 
700 bp 
400 bp 
200 bp 
100 bp 
A) Isolation of the MseI-fraction carrying the T/G nucleotides  
* * *
*
1: fractioned Lymphocyte pool 
2: fractioned K562 single cell 
P: positive control 
N: negative control 
      1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P 
      1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P       1   2   N   P 
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Figure 43: Specific MseI-fragment PCR after the genome fractioning of the lymphocyte pool and K562 single cells for MseI-fragments 
carrying different nucleotides. (1) Selection and enrichment of the MseI-fragments carrying the T/G nucleotides after the MseI restriction 
site. (2) Selection and enrichment of the MseI-fragments carrying the A/G nucleotide after the MseI restriction site. Yellow asterisks are 
denoting the contamination from different MseI-fragments that are amplified after the specific enrichment of a single MseI-fragments 
population; the red asterisks are indicating unspecific amplification of MseI-fragments not corresponding to the specific loci amplified. The 
specific MseI-fragment amplified is indicated in curly brackets at the edge of the gel. In the table the control primers used are indicated. 
 
 
 
 
 
 
 
 
 
 
 
$A/A$ $A/G$ $A/G$
C/C$ G/T$ T/T$
$A/T$ $T/C$
A/C$ G/C$ G/G$
*!*!
2) Isolation of the MseI-fragments carrying the A and G nucleotide after the MseI restriction site (AG)  
1     2     N     P 1     2     N     P 1     2     N     P 
1     2     N     P 1     2     N     P 1     2     N     P 
1     2     N     P 1     2     N     P 
1     2     N     P 1     2     N     P 1     2     N     P 
*! *!
700 bp 
400 bp 
200 bp 
100 bp 
700 bp 
400 bp 
200 bp 
100 bp 
WGA pool of Lymphocytes WGA K562 single cells 
Primer ID Differentiating Base Lenght of the MseI Fragment Lenght of the PCR fragment  
TP53 A/A 558 bp 374 bp 
ABL1 C/C 291 bp 273 bp 
D5S399 AG/GA 485 bp 178 bp 
RTP3 AG/GA 394 bp 302 bp 
BCR T/T 508 bp 235 bp 
BCR TG/GT 670 bp 192 bp 
RH27788 AC/CA 576 bp 389 bp 
BCR GC/CG 1071 bp 258 bp 
ZNF23 GC/CG 417 bp 290 bp 
BCR G/G 715 bp 470 bp 
TP53 TC/CT 1032 bp 461 bp 
BCR AT/TA 790 bp 583 bp 
BCR AT/TA  600 bp 358 bp 
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4.3.5. Summary of the WGA, WGA library modification and genome fractioning 
procedure applied to the K562-Lymphocyte pool 
Here it is shown a summary table of the whole procedure necessary to generate enriched 
genome MseI-fraction and the quality controls necessary for the correct control of the method 
(Table 32). 
Table 32: Summary of the quality controls applied at each step of protocol development. The qPCR for BCR/ABL breakpoint MseI-fragment 
has been applied only to K562 cells. N/A: not assessed.  
 
The GII of the WGA has been assessed with Ampli1 WGA control PCR to identify samples 
of high quality. Each step of the protocol has been controlled for the MseI-fragment length 
distribution to monitor possible changes of the original WGA fragment length profile. As 
observed on the bioanalyzer, the MseI-fragment population remains almost invariant until the 
generation of the genome MseI-fraction that sets the size distribution to 130-1000bp. Specific 
MseI-fragment PCR was performed to assess the completeness of the different MseI-fragment 
population during the protocol development. A total of 75 markers covering all ten different 
nucleotide combinations of MseI-fragments were established on the initial WGA population, 
however, for the successive steps of the protocol 10 markers, one for each representative 
MseI-fragment, have been used. The specific control MseI-fragment PCR has shown that the 
complete population of MseI-fragments is preserved until the digestion with the specific 
enzyme necessary to pre-select the MseI-fragment population. The final genome MseI-
fraction shows the amplification of a single marker for a single MseI-fragment population. 
The assessment of the BCR/ABL breakpoint-MseI-fragment step after step indicates that the 
genome fractioning procedure, in addition to select specific MseI-fragment populations, pre-
enriches the breakpoint. 
 
Sample 
Ampli1 WGA 
control PCR 
Bioanalyzer 
Profile 
Specific MseI-fragment 
PCR (amplified markers) 
qPCR BCR/ABL breakpoint-
MseI-fragment 
WGA 4 markers  250-3000 bp 75 markers out of 75 markers 12.215 copies/ng of DNA 
Re-amplification N/A 150-3000 bp 10 markers out of 75 markers 1.597 copies/ng of DNA 
Lib1-adaptor removal N/A 150-3000 bp 10 markers out of 10 markers 1.325 copies/ng of DNA 
J20 PCR N/A 100-3000 bp 10 markers out of 10 markers 3.463 copies/ng of DNA 
Specific digestion N/A 100-3000 bp 10 markers out of 10 markers 3.299 copies/ng of DNA 
Genome MseI-fraction not 
normalized N/A 130-1000 bp 1 marker out of 10 markers 52.934 copies/ng of DNA 
Genome MseI-fraction 
normalized N/A 130-1000 bp 1 marker out of 10 markers 154.833 copies/ng of DNA 
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4.4 Evaluation of the optimal Subtractive DNA Hybridization procedure 
4.4.1 PCR parameters for the re-amplification of the genome MseI-fraction 
The genome fractioning containing the enriched MseI-fraction need to be re-amplified to 
obtain sufficient amounts of Driver DNA (derived from lymphocyte pool) and Tester DNA 
(derived from K562 single cell) necessary for subtractive DNA hybridization (Method Design 
Paragraph 3.4.1). The re-amplification program has been optimized at 12 cycles (Table 33). 
Table 33: Optimization of the re-amplification protocol for the genome fractioning. dsDNA amount obtained after different PCR cycles are 
indicated. 
 
 
4.4.2 DNA precipitation before the subtractive hybridization 
For the joint precipitation of the Driver and Tester DNA samples prior to the actual 
subtraction the classical phenol-chloroform extraction (Method Design Paragraph 3.4.2) was 
replaced by the use of the Phase Lock Gel Column (5 Prime, Inc.). Table 34 compares the 
DNA recovery results of the two extraction methods after the precipitation of 40µg of DNA 
(the amount usually used for the precipitation of the Driver before the subtraction). 
Table 34: Optimization of the phenol-chloroform extraction protocol. Comparisons between the classical phenol-chloroform extraction and 
the commercial Phase Lock Gel. As can be seen after the phenol-chloroform extraction of 40µg of DNA with Phase Lock Gel almost the all 
DNA could be recovered, while with the classical method of extraction there was a higher risk of DNA loss. 
 
 
4.4.3 Testing the binding of high amounts of biotinylated MseI-fragments 
In order to evaluate a subtractive hybridization approach using high amounts of biotinylated 
Driver DNA, it is necessary to test the complete removal of the biotinylated genome MseI-
fraction by the use of magnetic streptavidin-conjugated beads (Method Design Paragraph 
3.4.3). In order to fulfill the objective, the biotinylation of the Driver DNA sample is 
necessary and is achieved by the use of biotinylated fractioning primers and a dNTPs mixture 
containing biotin-14-dCTP. The experimental steps are summarized in Table 35. 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-Amplification Genome MseI-Fraction 123ng/µl 132ng/µl 127ng/µl 117ng/µl 98ng/µl 
40µg of DNA Phase Lock Gel Classic Phenol-chloroform 
Recovery (µg) 38.5 µg 25µg 
  Experimental details Volume 
PCR Reaction  
Genomic fractioned DNA from the Driver sample 
(100ng/µl) 1µl 
Buffer 1 (10X) 5µl 
10X dNTP Mixture: [1 mM biotin-14-dCTP, 1 mM 
dCTP, 2mM dATP, 2 mM dGTP, 2 mM dTTP in 10 mM 
Tris-HCl (pH 7.5), 1 mM Na2EDTA] 
5µl 
BSA 20mg/ml 1,25µl 
Specific fractioning primers (10µM) 5µl 
Polymeras Mix 1µl 
H2O   31,75µl 
Purification AmpureXP beads used according to the manufacturer  1,8X 
Quantification Qubit dsDNA assay used according to the manufacturer   
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-Amplification Genome MseI-Fraction 123ng/µl 132ng/µl 127ng/µl 117ng/µl 98ng/µl 
40µg of DNA Phase Lock Gel Classic Phenol-chloroform 
Recovery (µg) 38.5 µg 25µg 
  Experimental details Volume 
PCR Reaction  
Genomic fractioned DNA from the Driver sample 
(100ng/µl) 1µl 
Buffer 1 (10X) 5µl 
10X dNTP Mixture: [1 mM biotin-14-dCTP, 1 mM 
dCTP, 2mM dATP, 2 mM dGTP, 2 mM dTTP in 10 mM 
Tris-HCl (pH 7.5), 1 mM Na2EDTA] 
5µl 
BSA 20mg/ml 1,25µl 
Specific fractioning primers (10µM) 5µl 
Polymerase Mix 1µl 
H2O   31,75µl
Purif cation AmpureXP beads used accordi g to the m nufacturer  1,8X 
Quantification Qubit dsDNA assay used according to the manufacturer   
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Table 35: Generation of biotinylated DNA Driver. The genome MseI-fraction has been re-amplified with biotinylated primers and biotin-14-
dCTP nucleotides according to the optimized PCR program. The product has been purified and quantified. 
 
Ten micrograms of the biotinylated Driver DNA sample have been incubated with different 
amounts of magnetic streptavidin-conjugated beads to investigate the removal efficiency of 
biotinylated Driver molecules. Subsequently, the unbound dsDNA amount of the Driver DNA 
sample that remained in solution has been quantified (Table 36). Irrespective of the input 
amount of magnetic streptavidin-conjugated beads, it was always observed an incomplete 
removal of the biotinylated Driver DNA: up to 25% is not binding to the magnetic 
streptavidin-conjugated beads. Due to the substantial difficulties in the removal of high 
amount of biotinylated MseI-fragments it was excluded the use of biotinylated Driver DNA 
for the subtractive hybridization. 
Table 36: Amounts of magnetic streptavidin-conjugated beads used to test the efficient removal of biotinylated Driver. 
 
 
PCR Program 10 cycles 12 cycles 15 cycles 17 cycles 19 cycles 
Re-Amplification Genome MseI-Fraction 123ng/µl 132ng/µl 127ng/µl 117ng/µl 98ng/µl 
40µg of DNA Phase Lock Gel Classic Phenol-chloroform 
Recovery (µg) 38.5 µg 25µg 
  Experimental details Volume 
PCR Reaction  
Genomic fractioned DNA from the Driver sample 
(100ng/µl) 1µl 
Buffer 1 (10X) 5µl 
10X dNTP Mixture: [1 mM biotin-14-dCTP, 1 mM 
dCTP, 2mM dATP, 2 mM dGTP, 2 mM dTTP in 10 mM 
Tris-HCl (pH 7.5), 1 mM Na2EDTA] 
5µl 
BSA 20mg/ml 1,25µl 
Specific fractioning primers (10µM) 5µl 
Polymerase Mix 1µl 
H2O   31,75µl 
Purification AmpureXP beads used according to the manufacturer  1,8X 
Quantification Qubit dsDNA assay used according to the manufacturer   
Streptavidin beads capture Amount of beads used for the capture of 10µg of biotinylated DNA Bound Driver Unbound Driver 
  
5µl 4.2µg 5.8µg 
10µl 5.3µg 4.7µg 
20µl 6.4µg 3.6µg 
30µl 6.8µg 3.2µg 
40µl 7.1µg 2.9µg 
50µl 7.7µg 2.3µg 
60µl 7.5µg 2.5µg 
100µl 7.6µg 2.4µg 
Genome MseI-Fraction 
DNA Copy number of BCR/ABL breakpoint-MseI-fragment 
BCR/ABL breakpoint-MseI-
fragment amount 
40 µg 4.000.000 1040 fg 
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4.4.4 Comparison of different methods for the re-hybridization of nucleic acids  
Subtractive DNA hybridization performed in not optimal conditions can be a limiting factor 
for the proper enrichment of differential sequences, in this case of the BCR/ABL breakpoint-
MseI-fragment (Method Design Paragraph 3.4.4). Therefore, it became necessary to test 
different re-hybridization methods with the aim of achieving the best re-association. In order 
to choose a subtraction method that could be better adapted to the established genome 
fractioning approach, four different experimental systems were set up:  
a) Phenol emulsion re-association technique (PERT) allowing the re-association of DNA in a 
water-salt solution containing phenol 9% by using thermal cycler oscillation between 65° and 
25° C,  
b) Phenol emulsion re-association technique (PERT) allowing the re-association of DNA by 
using strong agitation of the DNA in a water-salt solution containing phenol 9%, 
c) Re-association in small volume solution with 50% formamide,  
d) Re-association n small volume solution with high salt concentration (1M).  
The precise experimental settings of the four methods are summarized in the Table 37. 
Table 37: Summary of the experimental conditions used for testing the different re-hybridization methods. 
 
In order to assess the re-hybridization of the four approaches, known DNA amounts of 
genome MseI-fraction dsDNA have been spiked with known copy numbers of the BCR/ABL 
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breakpoint-MseI-fragment ligated to the specific BioR21-adaptor, used in subtractive DNA 
hybridization (Table 38). 
Table 38: Genome MseI-fraction amount and copies number of BCR/ABL breakpoint-MseI-fragment spiked-in used for the testing the re-
hybridization. 
 
The copy numbers of the BCR/ABL breakpoint-MseI-fragment have been calculated 
according the following formula: number of copies = (amount (ng) * 6.022x1023) / (length 
(bp) * 1x109 * 650 Daltons). The length of the BCR/ABL breakpoint-MseI-fragment 
including the ligated BioR21-adaptor is 242bp. 4.000.000 copies spiked into 40µg of the 
fractioned genomic dsDNA sample represents 0,000000026% of the total dsDNA amount 
(Figure 44). This corresponds to far less (~3.5 fold) than the DNA amount of the BCR/ABL 
breakpoint-MseI-fragments at the onset of the subtractive DNA hybridization, as determined 
by the BCR/ABL absolute qPCR assay on the enriched genome MseI-fraction at the end of 
the genome fractioning (Figure 41).   
 
Figure 44: Experimental overview depicting the four approaches to test the best re-hybridization method. 
After the spiking, the DNA has been extracted by phenol-chloroform and the recovered DNA 
re-hybridized with the four different techniques. The re-hybridized DNA has been extracted 
again to remove contaminants from the hybridization mixture such as the phenol contained in 
Streptavidin beads capture Amount of beads used for the capture of 10µg of biotinylated DNA Bound Driver Unbound Driver 
  
5µl 4.2µg 5.8µg 
10µl 5.3µg 4.7µg 
20µl 6.4µg 3.6µg 
30µl 6.8µg 3.2µg 
40µl 7.1µg 2.9µg 
50µl 7.7µg 2.3µg 
60µl 7.5µg 2.5µg 
100µl 7.6µg 2.4µg 
Genome MseI-Fraction 
DNA Copy number of BCR/ABL breakpoint-MseI-fragment 
BCR/ABL breakpoint-MseI-
fragment amount 
40 µg 4.000.000 1040 fg 
Denature and Renature: 
1. with PERT thermal cycler/agitation 
2. In solution with formamide 50% 
3. In solution with high salt concentration 
Quantification of the dsDNA and qPCR for the Bcr/Abl breakpoint-MseI-fragment 
Phenol-chloroform extraction 
4.000.000 copies of the BCR/ABL 
breakpoint-MseI-fragments ligated to 
Bio-R21 adaptor 
Genome MseI-fraction DNA  
Phenol-chloroform extraction (except for n° 3) 
Adaptor Fill-in + ssDNA removal 
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the PERT and the 50% formamide in the small volume assay. The BioR21-adaptors have then 
been filled-in to render the MseI-fragments sequences amplifiable in the BCR/ABL qPCR 
assay and then the sample was treated with mung bean nuclease to remove non-hybridized 
ssDNA molecules. Enrichment PCR was not carried out to eliminate any subsequent PCR-
introduced shifts in the representation of the BCR/ABL breakpoint-MseI-fragment in the re-
hybridized samples. The quantified amount of dsDNA after the re-hybridization indicated that 
PERT in thermal cycler, PERT in agitation and re-hybridization in high-salt solution gave 
similar results with a maximum DNA re-association rate of 85-90%.  The re-association in 
solution with formamide gave the lowest re-hybridization of dsDNA of around 50% (Figure 
45). 
 
Figure 45: Percentage of dsDNA that re-associate after using four different re-hybridization methods. 
 
The absolute BCR/ABL qPCR quantification assay was performed to determine the amount 
of re-hybridized BCR/ABL breakpoint-MseI-fragments, either with the R21 primer 
complementary to the BioR21-adaptor and with a primer pair specifically designed to amplify 
the breakpoint BCR/ABL sequence, the K562 breakpoint-primer. To ensure that no single-
strand BCR/ABL breakpoint-MseI-fragment will be the target for amplification in the qPCR 
assay, a ssDNA removal step with mung bean nuclease following the re-hybridization was 
performed. The absolute quantification of the re-associated BCR/ABL breakpoint-MseI-
fragment indicated similar re-association rates (Figure 46) irrespective of whether the R21 
primer or the specific K562 breakpoint-primer pair was used (with slightly higher value for 
the K562 breakpoint-primer). The re-hybridization in small volume solution with 50% 
formamide showed 20-25% rate of re-association for the BCR/ABL breakpoint-MseI-
fragment (Figure 46), while PERT in thermal cycler/agitation and in high-salt solution 
showed the highest re-association rate of about 85%.  
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Figure 46: Percentage of BCR/ABL breakpoint-MseI-fragment that re-associate after using four different re-hybridization methods. The Cp 
cycle derived from the amplification of 4.000.000 copies of BCR/ABL breakpoint-MseI-fragment has been set as the default value for 100% 
re-association of the fragment. 
 
The amplification products generated with the specific K562 breakpoint-primer and with the 
R21 primer were investigated by agarose gel electrophoresis. The amplification with the 
specific K562 breakpoint-primer showed specific amplicons for all four hybridization 
methods (Figure 47 A). The amplification with R21 primer showed specific amplicons too 
except for the re-hybridization with 50% formamide where unspecific background 
amplification was observed. Regarding the re-hybridization in high-salt solution the 
amplification with R21 primer showed to generate very intense amplicons maybe reflecting a 
higher degree of dsDNA re-association, although there was no obvious correlation to the 
calculated degree of re-hybridized total DNA (Figure 47 B). Additionally, in order to prove 
that these results are solely based on the proper re-hybridization of the specific BCR/ABL 
breakpoint-MseI-fragment sequences, an identical experiment of re-hybridization was 
performed without carrying out the fill-in reaction for the BioR21-adaptor. As expected, no 
specific amplification product for the BCR/ABL MseI-fragment was visible after PCR with 
R21 primer, but only the smear of re-hybridized MseI-fragments DNA (Figure 47 C).  
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Figure 47: Control PCR performed after the re-hybridization with the different methods; A) PCR for the BCR/ABL breakpoint-MseI-
fragment using the K562 breakpoint-primers showing the specific amplicon size; B) PCR for the BCR/ABL breakpoint-MseI-fragment using 
the R21 primers showing the specific amplicon size. The PCR with the R21 primer gave specific amplification product except for the re-
association in solution with 50% formamide, in which unspecific fragments were amplified; C) PCR of the negative control for the re-
hybridization using the R21 primers. The negative control consists in re-associated DNA in which the fill-in of the BioR21-adaptor has not 
been performed after the re-hybridization. As can be seen there is no amplification of the BCR/ABL breakpoint MseI-fragment by using the 
R21 primers. 
 
The agarose gel electrophoresis results were also confirmed from the melting curve analysis 
for the amplification with the R21 primer (Figure 48 A) and the specific K562 breakpoint-
primer (Figure 48 B). 
 
Figure 48: Melting peak analysis indicating the specificity of the amplification of the BCR/ABL breakpoint-MseI-fragment after the re-
hybridization. (A) Melting peak generated after the amplification with R21 primers: can be observed unspecific amplification of the 
BCR/ABL MseI-fragment after re-hybridization in buffer containing formamide. (B) Melting peak generated after the amplification with 
K562 breakpoint-primers. 
 
Based on the obtained results the following considerations were decisive in selecting the best-
suited method: the re-association in small volume solution with 50% formamide was excluded 
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because of the lowest re-association rate. Of the remaining three methods presenting similar 
results, the classical re-hybridization in solution with high-salt concentration was preferred for 
two reasons: general avoidance of the use of phenol and the exclusion of the additional phenol 
extraction step after the re-hybridization to prevent further loss of DNA material.  
 
4.4.5 Proof of principle of the re-hybridization and detection limit of the technique 
In order to show that the selected re-hybridization method is effective in identifying multiple 
differential MseI-fragment sequences in low copies, a pGEM-T Easy vector containing the 
BCR/ABL breakpoint-MseI-fragment has been spiked in the genome MseI-fraction of a 
Driver sample derived from the normal lymphocytes pool (Method Design Paragraph 3.4.5). 
Before spiking to the genome MseI-fraction, the plasmid was digested with MseI enzyme, 
thereby producing a known pattern of fragments, including the BCR/ABL breakpoint-MseI-
fragment. The MseI-fragments generated from the digestion were ligated to the BioR21-
adaptor. The experimental workflow is illustrated in Figure 49. 
 
 
Figure 49: Experimental setting used to show the enrichment of differential MseI-fragments spiked in a genome MseI-fraction of Driver 
DNA. 
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After the spiking, the DNA sample is extracted with phenol-chloroform-isoamylalcohol and 
precipitated in ethanol over night at -20°C. The recovered pellet is re-suspended in the 
hybridization buffer, denatured and re-hybridized according to the selected protocol. The re-
associated sample is subjected to enrichment PCR with R21 primer and the amplification 
product is analysed by agarose gel electrophoresis (Figure 50). The fragment patterns visible 
after the enrichment PCR is identical to the fragment patterns of the MseI-digested plasmid, 
including the insert BCR/ABL breakpoint-MseI-fragment. Fragments below 200bp were 
barely represented, maybe due to a preferential renaturation or amplifications of amplicons 
between 200bp-1000bp. Moreover, it was not evident any unspecific amplified MseI-
fragments indicating a possible improper re-hybridization. This clearly shows that the selected 
method of re-hybridization is useful in terms of the identification of differential sequences 
present at small quantities. 
 
 
Figure 50: Re-hybridization and enrichment of the MseI-fragments, derived from the MseI digestion of the pGEM-T Easy vector containing 
the BCR/ABL breakpoint-MseI-fragment as insert, spiked in 40µg of genome MseI-fraction DNA. The DNA re-naturation of the plasmid is 
successful and shows the enrichment of almost all the MseI-fragments, including the BCR/ABL breakpoint-MseI-fragment  (yellow arrows). 
Lanes 2, 3, 5, 6, 8 are overloaded due to the higher amount of plasmid spiked-in; lanes 1, 4, 7 represents clear distinction of the fragments. 
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4.5 Subtractive DNA hybridization of the genome fractioned K562 cell: depletion 
product 1 (DP1)   
The first round of subtractive hybridization (Method Design Paragraph 3.5) has been 
performed with different starting amounts of Tester DNA, from 5ng to 1µg, in order to see 
when the maximum level of enrichment is reached, that means a further increase of the initial 
Tester amounts would not result in an increase of the BCR/ABL breakpoint-MseI-fragment 
copy numbers (overview of the experimental design in Figure 51). For simplicity, the DPs 
will always be named after the amount of Tester DNA (for the first round) and amount of DP 
(for the subsequent round) that has been used, the subtraction round where they have been 
generated and if the normalization has been applied or not. 
 
Figure 51: Overview of the subtraction scheme for generating the DP1. Different amount of normalized genome MseI-fraction of the Tester 
have been mixed with an excess of genome MseI-fraction of the Driver (40µg). The DP1s are the results of the subtraction of different 
amount of Tester to evaluate which of the titrations give the best enrichment of the BCR/ABL breakpoint-MseI-fragment. The Driver to 
tester ratio is specified. 
After the first round of subtraction the absolute copy numbers of the BCR/ABL breakpoint-
MseI-fragment was assessed (Figure 52). The Tester DNA amount of 50ng has been 
subtracted in duplicate (two separate experiments) to evaluate the reproducibility of the assay: 
very similar results in the enrichment of the BCR/ABL breakpoint-MseI-fragment copy 
numbers were noted for the 50ng duplicate (with a variability between the two experiment of 
10%). The increasing starting amounts of Tester DNA lead to a substantial progressive 
enrichment of the BCR/ABL breakpoint-MseI-fragment. The enrichment is not anymore 
substantial between 500ng and 1µg of input amount of Tester DNA. For this reason, it 
appears that the maximum enrichment for DP1 can be obtained using Tester DNA amounts in 
the range of 500ng-1µg (22 fold), setting a favourable kinetic enrichment at Driver to tester 
ratio of 80:1-40:1.  
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Figure 52: Quantification of the BCR/ABL breakpoint-MseI-fragment absolute copies/ng of DNA in DP1. There is an increased enrichment 
of the BCR/ABL breakpoint-MseI-fragment by increasing the input amounts of Tester. The enrichment of the first depletion product seems 
to reach the saturation point between 500ng and 1µg of initial Tester amounts. The total fold enrichment of the DP1 reaches around 22 fold 
compared to the initial Tester. 
DP1 products were separated by agarose gel electrophoresis to inspect the effect of unwanted 
selective enrichment of cross-annealed repetitive sequences in the first round of subtractive 
DNA hybridization (Figure 53). The presence of some PCR bands not corresponding to the 
size of the BCR/ABL MseI-fragment warrants a further improvement of the specificity of 
subtractive DNA hybridization. 
 
Figure 53: Agarose gel electrophoresis of the different generated DP1s. Amplicons selection can be observed. 
In order to suppress the unwanted selected sequences, the DP1-500ng and DP1-1µg were 
normalized. The normalization of the DP1 suppresses the over-amplified MseI-fragments 
(Figure 54 A). Additionally, the BCR/ABL qPCR assay was performed on the DP1-500ng-
normalized and DP1-1µg-normalized to assess the effect of the normalization on the 
0 
100000 
200000 
300000 
400000 
500000 
600000 
700000 
800000 
900000 
B
C
R
/A
B
L 
br
ea
kp
oi
nt
-M
se
I-f
ra
gm
en
t 
co
pi
es
 
1: DP1-5ng  
2: DP1-15ng 
3: DP1-30ng  
4: DP1-50ng 
5: DP1-100ng 
6: DP1-250ng 
7: DP1-500ng 
8: DP1-1µg 
M: 2-log molecular marker 
1         2         3        4         5         6        7        8         M    
Results  
 121 
enrichment of the BCR/ABL breakpoint-MseI-fragment. It has been clear that the 
normalization of the DP1-500ng and DP1-1µg contributed to a further enrichment of the 
BCR/ABL breakpoint-MseI-fragment, respectively, of 3,0 fold and 1,8 fold compared to the 
respectively not-normalized DP1s (Figure 54 B). The normalization of the DP1-500ng 
showed to be more effective than the normalization of the DP1-1µg. The total achievable 
enrichment after the first subtraction round of 500ng of Tester, including the normalization, 
was 64 fold, while for the subtraction of 1µg of Tester was 39 fold. 
 
Figure 54: A) Example of normalization of DP1. The subtracted Tester shows an irregular profile due to the selection of MseI-fragments that 
are preferentially amplified (maybe belonging to repetitive elements of the genome). The normalization of the DP1 re-establishes a 
homogeneous distribution of the MseI-fragments. B) qPCR assay for the BCR/ABL breakpoint MseI-fragment. The normalization further 
increases the copies of BCR/ABL breakpoint MseI-fragment. 
 
4.6 Optimization of the second round of subtractive DNA hybridization: depletion 
product 2 (DP2)   
To perform the second round of subtractive hybridization two different Driver to Tester ratios 
have been tested using the DNA of the normalized DP1-500ng and DP1-1µg (Figure 55): 
1. Driver to Tester ratio of 800:1 and 80:1 obtained by subtracting, respectively, 50ng 
and 500ng of the DP1-500ng-normalized sample; 
2. Driver to Tester ratio of 400:1 and 40:1 obtained by subtracting, respectively, 100ng 
and 1µg of the DP1-1µg-normalized sample.  
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The higher ratios (800:1 and 400:1) will assess if an increase of the Driver to Tester ratio 
would favour the kinetic enrichment of the BCR/ABL breakpoint-MseI-fragment, while the 
lower ratios (80:1 and 40:1), previously used, if are still optimal to achieve a continuous 
enrichment.  
 
 
Figure 55: Scheme for the generation of DP2 product. The DP1-500ng and DP1-1µg have been normalized and subtracted in order to 
generate DP2s. For the normalized DP1-500ng, 50ng and 500ng of DNA have been used for the subtraction; for the normalized DP1-1µg, 
100ng and 1µg of DNA amounts have been subtracted. 
The generated DP2s were assayed by qPCR for the BCR/ABL breakpoint-MseI-fragment. 
The DP2-50ng did not show any enrichment compared to the DP1-500ng-normalized, while 
the DP2-500ng showed 1,6 fold enrichment compared to the DP1-500ng-normalized (Figure 
56 A). The DP2-100ng and DP2-1µg did not show any enrichment in comparison to the DP1-
1µg-normalized (Figure 56 A). Therefore, either the experimental normalization of DP1-
500ng either the constant ratio Tester-Driver 1:80 were considered as essential factors in the 
process of selective enrichment of BCR/ABL breakpoint-MseI-fragment sequences. In 
addition, the generated DP2s were separated by agarose gel electrophoresis to inspect the 
MseI-fragment distribution and the eventual presence of selected sequences. The smear 
appeared to be very homogeneous (Figure 56 B).  
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Figure 56: DP2s analysis after second round of subtractive hybridization. Only the DP2-500ng showed to slightly enrich the BCR/ABL 
breakpoint-MseI-fragment. The subtraction of 100ng and 1µg deriving from DP1-1µg-normalized did not succeed in the enrichment as well 
as the subtraction of 50ng DNA deriving from the DP1-500ng-normalized. 
Subsequently, the DP2-500ng, that showed the better enrichment, has been normalized to 
assess if an additional normalization step would lead to an increased copy numbers of the 
BCR/ABL breakpoint-MseI-fragment, as previously observed for the normalization of the 
DP1. However, the normalization of the DP2-500ng did not bring to any increase in the copy 
number of the BCR/ABL breakpoint-MseI-fragment indication that a further normalization is 
not required (Figure 57). 
 
Figure 57: Normalization of the DP2-500ng showing loss of the BCR/ABL breakpoint-MseI-fragment. 
 
4.6.1 Optimization of the 3rd round of Subtractive DNA hybridization: absolute 
quantification of depletion product 3 (DP3) and agarose gel inspection 
For the third round of subtractive hybridization the Driver to Tester ratio is maintained at 80:1 
as this ratio was showed to preserve the enrichment of the BCR/ABL breakpoint-MseI-
fragment. The subtraction of 500ng of DNA, deriving either from DP2-500ng-normalized 
either from DP2-500ng not-normalized, was performed (Figure 58).  
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Figure 58: Scheme for the generation of DP3. Part of the DP2-500ng has been normalized, part it has been left un-normalized. After, 500ng 
of normalized and 500ng of not normalized have been subtracted. 
The generated DP3s were assayed by qPCR. The subtraction of the DP2-500ng-normalized 
did show a loss in the copy numbers of the BCR/ABL breakpoint-MseI-fragment confirming 
the previous results (Figure 57) and indicating that a further normalization does not improve 
the enrichment (violet column, Figure 59 A). On the contrary, the subtraction of the DP2-
500ng-not-normalized showed a minor increase of enrichment (1,23 fold) (orange column, 
Figure 59 A). The DP3 products have been observed by agarose gel electrophoresis and no 
evident differences in the intensity and size distribution of the MseI-fragments were noted 
(Figure 59 B). 
 
 
Figure 59: A) subtraction of 500ng DNA of normalized and not normalized DP2-500ng. The fold enrichment of the BCR/ABL breakpoint-
MseI-fragment is 1,23 fold if the subtraction of a DP2-500ng-not normalized is performed (orange column). The subtraction of 500ng of 
normalized DP2-500ng does not increase the copy numbers of the BCR/ABL breakpoint-MseI-fragment (violet column). B) agarose gel 
inspection of the DP3 deriving from the subtraction of a normalized and non-normalized DP2. 
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4.7 Summary of the subtractive hybridization performed on the K562 single cell 
The best final approach for subtractive hybridization used in order to reach the highest 
enrichment of MseI-fragments carrying a fusion breakpoint, as in this specific case of the 
BCR/ABL breakpoint-MseI-fragment, is summarized in the following scheme (Figure 60). 
The final observed enrichment of an MseI-fragment carrying a breakpoint sequence is ≈ 1664 
fold compared to the initial WGA of a single tumor cell. 
 
Figure 60: optimal approach to achieve substantial enrichment of MseI-fragments carrying breakpoint sequences starting from the WGA of a 
single tumor cell. 
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5. Discussion 
5.1 Establishment of a method for the enrichment of genomic breakpoint in single tumor 
cells 
This study describes a method for the enrichment of unknown breakpoint sequences in single 
tumor cells. The method can be applied to high complex genomes, for example from human 
cells, in order to find rearranged genomic sequences that could play a role in the early 
dissemination of cancer cells or for monitoring of minimal residual cancer. In the approach 
presented here, the critical factors to take in consideration are first, the capability of 
controlling the selective isolation of sub-genomic DNA-fragment populations in order to 
maximize the genome complexity reduction but at the same time, minimizing the loss of 
genomic information. Second, the applicability of a subtractive hybridization method suitable 
for the enrichment of fusion breakpoints within the selected sub-genomic DNA-fragments 
population. Additionally, it will be considered the future possibility to combine the novel 
method with automated PCR systems and NGS technologies, in order to increase the potential 
to detect unknown genomic breakpoints. 
5.2 Importance to reduce genome complexity before subtractive hybridization 
The concept of generating “representations” of the genome has been applied for the first time 
by Lisitsyn et al. in the representational difference analysis (RDA) in order to raise the 
efficiency of subtractive hybridization (Lisitsyn et al., 1993). Applications of RDA and 
subtractive hybridization at genomic level showed their potential use for the isolation of 
polymorphic markers in eukaryotic genomes (Lisitsyn et al., 1994; Nadezhdin et al., 2001), 
for the detection of genetic losses and amplifications in tumors (Kibel et al., 1999; Kibel et 
al., 1998; Lisitsyn et al., 1995; Schutte et al., 1995; Zeschnigk et al., 1999), for the 
identification of mouse Y-specific repeats by whole chromosome RDA (Navin et al., 1996), 
for the isolation of species-specific loci (Buzdin et al., 2003; Buzdin et al., 2002). Moreover, 
RDA has been used for filling in extended gaps in large-scale sequencing projects (Frohme et 
al., 2001). However, it is well documented from experiments (Clapp et al., 1993; Wieland et 
al., 1990) and from computational modeling (Cho and Park, 1998; Ermolaeva et al., 1996; 
Ermolaeva and Sverdlov, 1996; Milner et al., 1995) that the complexity of the starting 
genome has an influence on the performances of the subtractive hybridization. A genome 
complexity over 5x108bp  (far less than the size of the human genome) become already a 
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limiting factor in the kinetic of the hybridization and, consequently, of the enrichment of 
target sequences (Milner et al., 1995). The high complexity results in insufficient re-
association rate, and in the consequential risk of reducing the enrichment of differential 
genomic sequences present in low abundance in cancer cells. Therefore genome complexity 
must be reduced before subtractive hybridization. The classical RDA approaches reduces the 
complexity of the genome by the use of restriction enzymes: for example the digestion with 
BamHI results in an estimated 55-fold complexity reduction, while with BglII and HindIII the 
complexity reduction is, respectively 13 and 8-fold (Bishop et al., 1983). In the specific case 
discussed in this study, the digestion with MseI generates 19,045,730 millions MseI-
fragments. Of these MseI-fragments, 8,151,761 millions have a base pair distribution in 
between 100-1000bp that represents the optimal size for re-hybridization. This results in an 
estimated 2.3-fold complexity reduction. The 8.151.761 MseI-fragments will represent 43% 
of the total genome. On one side this approach will allow to preserve most of the genome 
information enhancing the success for the identification of genomic breakpoints. On the other 
side the complexity reduction achieved will not be sufficient for a proper enrichment in 
subtractive hybridization.     
5.2.1 Reducing the complexity of MseI genome representations by “Genome 
Fractioning” 
The reduced genome complexity obtained with MseI needs to be counteracted by the 
establishment of a process called “Genome Fractioning”. The applicability of this approach is 
clearly linked to the deterministic nature of the Ampli1 WGA (Klein et al., 1999). For Ampli1 
WGA, the MseI enzyme cuts the genome at the restriction-site TTAA; such approach will 
allow the generation of discrete “representations” of MseI-fragments that can be sorted 
according to the nucleotides next to its genomic MseI restriction site (Figure 4). Ten MseI-
fragments populations, representing each different nucleotide combinations (either simple 
either mixed – Theoretical method design paragraph 3.1), can be separately assayed and will, 
by large, represent most of the genome. Therefore, a highly reproducible method of 
generating MseI-fragments representations with reduced complexity for comparison of tumor 
and normal cells has been possible due to the selective isolation and to the equal enrichment 
of MseI-fragment populations. It is clear that the genome fractioning approach is not thought 
for the application to single cell amplification methods that employ random priming such as 
degenerate-oligonucleotide-primed PCR (DOP) (Telenius et al., 1992), primer extension 
preamplification (PEP) (Zhang et al., 1992), multiple annealing and looping based 
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amplification cycles (MALBAC) (Zong et al., 2012) or multiple strand displacement (Hou et 
al., 2012). Also, the fractioning approach overcomes the major drawback of the classical 
RDA, as established from Lisitsyn et al. The use of a rare cutter enzyme (BamHI, BglII or 
HindIII), to reduce the genome complexity, and of the PCR used to amplify the genomic 
representation ensures a random complexity reduction. It is random because PCR introduces 
biases by amplifying fragments of different size with different efficiency, which is further 
confounded by a systematic bias for sequences with different nucleotide GC content. So the 
final selected amplicons represent only a very small portion comprising 2-10% of the initial 
fragment diversity. Using the here presented genome fractioning approach it is possible to 
perform a non-random, deterministic complexity reduction of the genome without excluding 
90-98% of the initial representation. The established fractioning procedure reduces the 
genome complexity by a 10-fold factor, due to the fact that 10 discrete MseI-fragment 
populations can be exclusively isolated. This means that each selected population will 
theoretically represent 4,3% of the initial MseI-fragments diversity (8.151.761 millions), 
rendering each of them appropriate for a proper subtractive hybridization. Taken together, the 
ten generated MseI-fragment populations (43%) will include in the analysis a portion of the 
genome that is 4 to 20 times bigger compared to the classical RDA approach.  
5.2.2 Major quality controls necessary to define a successful genome fractioning 
In order to set up a proper method for the complexity reduction, the process of genome 
fractioning has been controlled by the use of different quality assays that can be established 
on the WGA of single cells and applied to amplified DNA samples.  
First, the MseI-fragment length distribution has been assessed during the development 
of the protocol to ensure consistent homogeneous MseI-fragment distribution (Table 32). The 
MseI-fragment length does not change significantly during the different steps preceding the 
completion of the genome fractioning; at this point the size distribution of the MseI-fragments 
shortens to 100-1000bp. This effect is due to the magnetic streptavidin-conjugated beads, 
which bind with decreased efficiency long DNA fragments because of steric hindrance effect. 
Nevertheless, the binding of MseI-fragments in between 100-1000bp ensures the optimal size 
selection necessary for the DNA re-hybridization during the subtraction process.  
Second, the process of isolation of discrete MseI-fragment population has been 
followed step by step by the use of specific MseI-fragment control PCRs. The intention of this 
quality control PCR-based assay was to show that the ten different genomic fractions can be 
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properly separated and that minimal or no cross-contamination of different MseI-fractions 
happens during the genome fractioning. Moreover, this assay showed that it is possible to 
assess the completeness of the genomic MseI-representation before the selection of a single 
MseI-fraction (Table 32). The successful selection of the specific MseI-fragments population 
is achieved by the use of the specific six-cutters enzyme and of the biotinylated fractioning-
adaptors. This approach with specific biotinylated fractioning-adaptors ensure that MseI-
fragments belonging to the same population are selected avoiding the co-amplification of 
undesired MseI-fragments. In this regard, it has been shown that also the choice of the 
magnetic streptavidin-conjugated beads and the related washing procedure can influence the 
outcome of the genome fractioning. Dynabeads and Nanolink magnetic streptavidin 
conjugated beads were compared for the generation of the specific MseI-fractions and showed 
to perform differently, with the first type of beads giving a higher background of un-wanted 
MseI-fragments (Table 27). This can be an effect of the physical properties of the magnetic 
streptavidin-conjugated beads. In fact, due to the bigger diameter of the Dynabeads (2.8µm) 
the chance of unspecific binding of not-biotinylated MseI-fragments is higher compared to the 
Nanolink beads that have a smaller diameter (heterogeneous population 0.15-0.77µm) but 
high binding capacity. Such property leads to lower non-specific binding of not-biotinylated 
MseI-fragments besides to lower costs, because a considerably fewer amount of beads is 
needed.  
Third, the establishment of the quantitative PCR assay has been fundamental to assess 
the copy numbers of the BCR/ABL breakpoint-MseI-fragment during the setup of the genome 
fractioning protocol in order to define steps of loss/gain of the fusion breakpoint. By absolute 
quantitative PCR means, it has been shown that the genome fractioning, over to reduce the 
complexity of the genome, has also a role on the selective enrichment of the determined 
MseI-fraction (Figure 41). In fact, the generated genome fraction is enriched for the 
BCR/ABL breakpoint-MseI-fragment by a factor of 4,3 fold compared to the initial 
abundance in the WGA. 
A problem observed is that genome fractioning can lead to the over-amplification of 
selected MseI-fragments. This effect it is, as expected, more pronounced on the genome 
fractioning of single cell compared to pools of cells. These over-amplified MseI-fragments 
maybe represent repetitive abundant sequences of the human genome as well as preferentially 
amplified sequences due to the consecutive steps of restriction digestion, adaptors ligation and 
PCR amplification. Nevertheless, the normalization of the genome MseI-fraction has shown 
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that it is possible to suppress these sequences and to re-establish a homogeneous 
representation of the MseI-fragments (Figure 40). Additionally, the suppression of these 
sequences increases the representation of MseI-fragments present in lower amount, as shown 
from the further enrichment of the BCR/ABL breakpoint-MseI-fragment by a factor of 3 fold 
compared to the not-normalized genome MseI-fraction (Figure 41).   
5.3.3 Putting into perspective: automation of the genome fractioning procedure 
The genome fractioning procedure includes many handling steps that lead to a time-
consuming procedure and the introduction of technical error. Even small errors in the 
accuracy of DNA sample preparation can translate into huge differences after amplification. 
Of course, it is not impossible to think that this problem can be solved by the use of the many 
liquid-handling systems present on the market (Gaisford, 2012). These robots enable high 
reproducibility and accuracy of low-volume dispensing, which is difficult to achieve using 
manual methods. Additionally, the establishment of the complete procedure on a microfluidic 
system, where all steps of the genome fractioning protocol are executed in a sequential way, 
may be possible. Here handling could be reduced and throughput of the analyzed samples 
could be increased. The use of such systems would, of course, enhance also the possibility to 
enrich rare differential sequences. Indeed, many microfluidic systems use droplet digital PCR. 
This type of PCR has many advantages over the conventional PCR especially because it 
allows the efficient amplification of genomic libraries and other complex mixtures of genes 
avoiding the generation of chimeric fragments by recombination between homologous regions 
of DNA (Meyerhans et al., 1990). A variety of PCR protocols have been proposed to 
minimize these problems, most of which rely on high template concentrations and low 
numbers of PCR cycles (Polz and Cavanaugh, 1998; Qiu et al., 2001). In the presented study, 
to minimize the bias in PCR, the number of cycles has been lowered, avoiding the over-
amplification of the DNA, the generation of ssDNA and consequent formation of chimeric 
sequences. However, an approach as droplet PCR would allow the amplification of complex 
DNA mixtures by segregating template fragments in the minute aqueous droplets of the 
emulsion and amplified by PCR separately. This would prevent the formation of chimeric 
products while enabling the use of small amounts of template DNA and high numbers of PCR 
cycles (Williams et al., 2006). To summarize, the genome fractioning procedure represents, to 
the current knowledge, the only approach to reduce the complexity of the genome whilst 
preserving most of the genomic information. 
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5.4 Applicability of subtractive hybridization to genome fractioning for the enrichment 
of MseI-fragments carrying fusion breakpoint  
This study provides a proof-of-principle that genome fractioning, starting from WGA of a 
single cell, can be coupled to subtractive hybridization. Subtractive hybridization showed to 
be very effective in the enrichment of MseI-fragments carrying breakpoints, such as the 
BCR/ABL fusion investigated in this work. In fact, the total enrichment achieved after three 
rounds of subtraction was 1664 fold (Figure 60). The presented method performed similar or 
even better than reported examples of subtractive hybridization applied on complex 
mammalian genomes. For example, Wieland et al. after three rounds of subtraction obtained 
between 100- and 700-fold enrichment for bacteriophage λ DNA sequences spiked in human 
placenta DNA (Wieland et al., 1990). Similarly, Hansen-Hagge et al., in a spiking experiment 
with λ DNA sequences, observed during the first three rounds of subtractive hybridization a 
100-fold enrichment of the λ fragment (Hansen-Hagge et al., 2001). Another approach for the 
subtraction of high complex genome is the in-gel competitive re-association method, in which 
the re-hybridization of Driver and Tester samples happens during electrophoresis. Yokota et 
al. isolated tissue specific changes in repetitive DNA sequences in rats with an enrichment of 
3000 fold after two rounds of hybridization (Yokota et al., 1989; Yokota and Oishi, 1990), 
although such level of enrichment is not surprising due to the fact that it is related to repetitive 
element of the genome. Sasaki et al. used the same approach for the enrichment of DNA 
sequences of papillomavirus in cervical cancer with a final 560 fold enrichment after two 
cycles of in-gel re-association (Sasaki et al., 1994). It is relevant that the method presented in 
this thesis has been established and tested on whole genome amplified single K562 cells 
carrying a fusion breakpoint. So, these results show a real observed enrichment of a 
breakpoint harbored in the genome of the cell, avoiding all the errors related to spiking 
experiments with external DNA sequences.  
5.4.1 Comparison of different subtractive hybridization approaches. 
Subtractive hybridization suffers from technical limitations depending on genome complexity, 
despite the many efforts to improve it for genome-wide comparison. Limitations in the re-
hybridization of complex genomes can be partially solved by experimental factors, such as the 
use of special techniques as solvent exclusion (Barr and Emanuel, 1990) or phenol emulsion 
re-association technique (PERT) (Bruzel and Cheung, 2006; Goldar and Sikorav, 2004; 
Kohne et al., 1977; Laman et al., 2001; Miller and Riblet, 1995; Travis and Sutcliffe, 1988; 
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Wieder and Wetmur, 1982) that enhance the re-hybridization rate by several fold. In a 
variation of classical PERT, thermal cycler oscillations between 25°C and 65C°, during which 
the emulsion is formed and broken, resulted in a high rate of reassociation ranging from 100% 
for lambda digested DNA to only 16% of the human genome DNA (Bruzel and Cheung, 
2006). In the presented study, different hybridization methods were compared for the 
application on WGA of single cells: the classical hybridization in high-salt solution at 68°C, 
hybridization with formamide at 42°C, and PERT in agitation or with thermal cycling 
oscillations. In this proof-of-principle experiment, known amount of BCR/ABL breakpoint-
MseI-fragments were spiked in a genome fraction and the re-association rate was controlled 
by quantifying the dsDNA total amount and by detecting the re-hybridized copies of 
BCR/ABL breakpoint-MseI-fragment. The re-hybridization in high-salt solution at 68°C and 
PERT using agitation or thermal cycling gave similar results with a percentage of re-
association of the total dsDNA and of the BCR/ABL breakpoint-MseI-fragment of about 
85%. The number of BCR/ABL breakpoint-MseI-fragments spiked constituted 
0,000000026% of the total DNA suggesting that it is possible to detect very low copies of 
fusion breakpoint. Additionally, multiple different MseI-fragments, presents at even lower 
amount than before mentioned, can re-associate specifically confirming the sensitivity and 
specificity of the established protocol (Figure 50). PERT has been claimed to be more suitable 
for complex genomes, due to the higher re-association rates, when compared to classical 
subtractive hybridization in high salt solution, but based on our evidence both protocols 
performed equally well. Probably, the reduction in sequence complexity achieved by genome 
fractioning enables equal performance, while in high complex genomic mixtures PERT may 
represent the method of choice.  
5.4.2 Importance of Driver to Tester ratio for optimal enrichment  
Driver to Tester ratio is one of the factors that can influence subtractive hybridization. 
According to the literature, high amount of Driver sample were used, but the Driver to Tester 
ratio was kept to 80:1 because this approach enabled a constant level of enrichment for the 
BCR/ABL breakpoint-MseI-fragment after three subtraction rounds. Indeed, I found that the 
rule “the higher the Driver to Tester ratio the higher the enrichment” is not always true for all 
the subtractive approaches and depends on the experimental scheme (Cho and Park, 1998). 
For the double-strand Tester selection used in this work, in which only re-hybridized double 
strand Tester is selected, I noted an optimum Driver to Tester ratio between 1:50-1:100.  
Discussion  
 133 
5.4.3 Use of biotinylated Driver for subtractive hybridization 
The uses of a biotinylated Tester or Driver DNA is an additional factor influencing the 
subtractive hybridization. In the first case Tester/Tester homohybrids are selected by the use 
of magnetic streptavidin-conjugated beads, and in the second case background Driver/Tester 
heterohybrids are removed from the solution. In this study, I noticed that after biotinylation of 
Driver DNA with biotinylated primers and biotin-14-dCTP, the removal with streptavidin-
conjugated magnetic beads was incomplete and even up to 25% of the Driver remained 
unbound. This is probably due to the incomplete biotinylation or the incomplete capture from 
the streptavidin magnetic beads. Some groups have used approaches with biotinylated Driver 
to remove Driver/Tester hybrids (Sive and St John, 1988; Straus and Ausubel, 1990; Sun et 
al., 1992) in which the driver was photobiotinylated, and removed trough the addition of 
streptavidin. Barr and Emanuel reported that even after two rounds of photobiotinylation 
around 1% of the Driver DNA remains unbiotinylated (Barr and Emanuel, 1990). Under these 
conditions, the incomplete removal of biotinylated driver affects drastically the efficiency of 
the subtraction (Cho and Park, 1998). For this reason, I have preferred an approach using 
biotinylated Tester DNA for the first round of subtractive hybridization followed by a 
classical approach without biotinylation in the next two rounds. 
5.4.5 The role of repetitive sequences in subtractive hybridization 
Subtractive hybridization is hampered by the presence of repetitive elements in the 
mammalian genome that constitute up to two-thirds of genome sequences (de Koning et al., 
2011; Lander et al., 2001; Venter et al., 2001). These repetitive sequences re-associate much 
faster than unique sequences (Milner et al., 1995) and subtracted genomic libraries can be 
greatly enriched in the number of these sequences (Rubin et al., 1993). Moreover the presence 
of repetitive sequences in high complex genome can lead to cross-annealing between them in 
regions of partial annealing (Hames and Higgins, 1985) and, consequently, to the formation of 
chimeric sequences that alter the DNA analysis. These chimeric sequences can constitute up 
to 40-60% of the DNA subtracted library (Chalaya et al., 2004). The chimeric sequences are 
directly correlated to the complexity of the genome that is analyzed and are the main problem 
that makes the subtractive hybridization less applicable to mammalian genomes. An attempt 
to solve the problem generated by repetitive elements is the use of Cot DNA, commercially 
available and enriched in genomic repeats that can be used to “capture” these sequences. I did 
not use any competitor DNA because it has been shown that breakpoints are often located in 
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or near repetitive elements of the genome (Deininger and Batzer, 1999; Kolomietz et al., 
2002; Wei et al., 2003) and at enrichment sites of microhomologous sequences (Kato et al., 
2012; Lawson et al., 2011). This could have reduced the possibility to identify such fusion 
sequences. Additionally, Chalaya et al 2004 showed that the use of competitor DNA to 100 
fold excess during subtractive hybridization decreases the number of clones containing 
genomic repeats only from 93% to 76-78%, so chances for success using this approach were 
deemed low. Instead, the same research group showed in their mispaired DNA rejection 
(MDR) method that mung bean nuclease digests loops formed from improper hybridized 
DNA and reduces chimera formation from 60% to 4% (Chalaya et al 2004). Repetitive 
elements share regions of homology that, although not identical, can form imperfect 
heteroduplexes. For this reason, I used mung bean nuclease to reduce the improperly 
mispaired DNA duplexes. Additionally, linearly amplified Driver/Tester hybrids can be 
digested by mung bean nuclease. Hansen-Hagge et al. addressed the problem of repetitive 
sequences and artificial repeat-mediated fusion sequences by the use of a highly specific 
ligation reaction and purification of such ligation products with streptavidin-coupled magnetic 
beads (Hansen-Hagge et al., 2001). In this way they could achieve a 100-fold enrichment of 
the sequences of interest in the first three rounds of subtraction that declined subsequently, 
due to the fact that some other sequences start to dominate. This was also observed in the 
current study, when after the second round of subtraction only a negligible enrichment of the 
BCR/ABL breakpoint-MseI-fragment was achieved. To circumvent the problem, the 
normalization of the DP1 helped to suppress the sequences that were over-represented after 
the first round of subtraction. This increased the amount of detectable BCR/ABL breakpoint-
MseI-fragment in qPCR assay by a factor of 3 folds (Figure 54 B).  
5.4.6 Improvement of subtractive hybridization by sample normalization 
The normalization of the first depletion product (DP1) enabled to further enrich the target 
sequence despite the presence of repetitive sequences. Normalization enabled to slightly 
increase the enrichment of the fusion BCR/ABL breakpoint-MseI-fragment until the third 
round of subtractive hybridization. However the normalization and subtraction of the second 
depletion product (DP2) did not improve the enrichment of the BCR/ABL breakpoint-MseI-
fragment. This evidence indicates that an equalized MseI-fragment library has been reached, 
meaning that the abundance of the BCR/ABL breakpoint MseI-fragment is similar to other 
MseI-fragments. The normalization results presented here are supported by the only data 
available regarding normalization of genomic DNA: normalization proved to be very useful 
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for the evaluation of the sequencing data of the human genome due to the reduction of 
repetitive elements (Shagina et al., 2010). In that study, normalization reduced the number of 
repetitive elements from 40% to 25%, the most affected sequences being Alu, LINE L1P, 
ERV-K, and ERV1 repeats, as well as satellite sequences.  
5.5 Advantages of the method in the era of next generation sequencing  
Until recent years, the detection of new structural rearrangements has been very challenging, 
but the unprecedented increase in the throughput of DNA sequencing driven by next-
generation technologies now allows efficient analysis of complete genomes and 
transcriptomes (Fuller et al., 2009; Metzker, 2010). Nevertheless, it is not yet feasible to 
sequence large numbers of complex genomes in their entirety because the cost and time 
necessary are still too great. To obtain 30-fold coverage of a human genome (90 Gb in total) 
would currently require several sequencing runs and would cost several thousand euros. In 
addition to the price demands, such a project would request laboratory time and funding and 
would place a substantial load on a research center’s informatics infrastructure. The presented 
method aims also to support the discovery of genomic rearrangements by a combined 
approach with next generation sequencing technologies. The developed protocol in which it is 
possible to selectively divide genomic sub-regions and to enrich, through subtractive 
hybridization, differential genomic sequences characteristic of cancer cells, could reduce 
significantly costs and efforts, and the resulting informatics data would be considerably less 
difficult to analyze compared with whole-genome sequencing. Strategies for direct selection 
of genomic regions were already developed in anticipation of the introduction of NGS 
(Bashiardes et al., 2005; Dahl et al., 2005) but only limited regions of interest of the genome 
could be enriched. The presented method allows the selection (through the genome 
fractioning) of a large part of the genome and the enrichment (through the subtraction) of 
sequences present uniquely in cancer cells. Each subtracted MseI-fractions, mostly enriched 
in differential DNA sequences, could be bar-coded and pooled allowing to analyze multiple 
genomic MseI-fractions in a single sequencing run. For example, for the investigated genomic 
MseI-fraction, containing the BCR/ABL breakpoint-MseI-fragment, the enrichment level 
achieved (1664 fold) will allow to use a low sequencing coverage sufficient for the detection 
of the translocation. To summarize, the method could provide a cost-effective approach for 
the discovery of structural variation in single cancer cells that can be evaluated for the 
development of potential targeted therapies or of cancer vaccines (neo-antigens). 
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Additionally, the method can be used to isolate defined sub-genomic populations for 
experiments of targeted re-sequencing or custom mini-genome sequencing projects.  
5.6 A method to identify potential biomarkers for monitoring minimal residual disease 
One application of the method in the near future is the genomic characterization of early 
DCCs/CTCs. Genome characterization of the DCCs/CTCs will allow identifying stable 
genomic rearrangements usable as novel biomarkers to monitor MRD, as it is generally 
performed for chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) or acute 
myeloid leukemia (AML). Substantial evidence suggests that translocations represent 
essential and early steps in the initiation of carcinogenesis and that gene fusion, such as 
TMPRSS2-ERG, are early events necessary for the transition from precursor lesion of prostate 
cancer to an invasive phenotype. This renders fusion genes appealing candidates to monitor 
disease state and burden. Until now, applicable targets for MRD detection have been more 
difficult to determine in carcinomas and the monitoring of MRD is much less advanced 
compared to leukemia and lymphoma. Monitoring the clonal expansion or depletion of cell 
populations harboring specific unique DNA sequences, could constitute an ideal method for 
real-time tracking of the efficacy of systemic adjuvant therapy in individual patients during 
follow-up. Manifest metastatic disease is usually resistant to current therapies. Therefore, 
manifestation of metastasis could be prevented if biomarkers were available during minimal 
residual disease, assessing disease activity and enabling timely intervention. After completion 
of standard adjuvant chemotherapies the identification of patients at increased risk for relapse, 
based on the detection level of biomarkers, could represent an application of high clinical 
relevance, as these patients might benefit from an additional treatment with new drugs (Figure 
61). 
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Figure 61: hypothetical scenario for monitoring MRD. qPCR can detect cancer DNA sequences with higher sensitivity compared to classical 
cytogenetic approaches constituting a valid mean to monitor MRD. The red line indicates an arbitrary threshold for the detection of MRD. 
Of course, for such a routine monitoring approach peripheral blood analyses are more 
convenient for patients than invasive BM sampling. Additionally, ‘liquid biopsies’ are an 
attractive alternative option because DNA fragments released from cancer cells, cell-free 
tumor DNA (cfDNA), into the blood can be used to generate molecular profiles of tumors 
(Diaz and Bardelli, 2014). Circulating tumor DNA fragments contain identical genetic defects 
to those in the tumors themselves and virtually all cancer-related molecular alterations can be 
detected in cfDNA, such as somatic point mutations, loss of heterozygosity (LOH), gene copy 
number changes and DNA methylation changes, including translocations. Therefore, 
detection of tumor-specific sequences such translocation breakpoints may enable PCR-based 
disease-activity monitoring and emergence of drug resistance. 
5.6.1 Development of therapeutic drugs targeting the clonal evolution  
Another possible application of the method, but more challenging, is the characterization of 
the early genomic changes in DCCs/CTCs that can be used as potential targets for therapeutic 
drugs. The time lag between the surgical removal of the primary tumor and the manifestation 
of macroscopic metastasis years to decades later, suggests ongoing adaptation and survival of 
these cells in metastatic niches, before acquiring a metastatic growth. Of note, early changes, 
if selected and preserved, are likely to be shared among all tumor cells and may be exploited 
for the prevention of metachronous metastases. Furthermore, such studies may uncover 
functionally important changes driving clonal evolution. A way to monitor genome evolution 
of DCCs/CTCs could be done by the isolation of these single cells from patients at different 
time-points, such as at the diagnosis/surgery of the primary tumor, during the course of 
adjuvant chemotherapy and by multiple samplings during the metastasis-free disease. This 
might allow identification of changes that are stable and shared over time and therefore 
represent potential drug targets (Figure 62).  
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Figure 62: monitoring of the metastatic disease progression. Monitoring DCCs/CTCs evolution is possible by multiple sampling of these 
cells at diagnosis and at different time point of the treatment and follow-up (blue time line). Early and stable genomic changes important for 
early dissemination, homing and survival can be identified at the time of the diagnosis. Such genomic rearrangements can constitute potential 
targets for therapies necessary for the eradication of the MRD. 
For this, a recent interest in a novel class of cancer immunogens has arisen. Neoantigens arise 
as a direct consequence of somatic mutations within tumor cells, therefore they are very 
specific to the tumor, but also unique to the patient (Fritsch et al., 2014; Hacohen et al., 2013; 
Litterman et al., 2013; Wolchok and Chan, 2014). T-cells can recognize these antigens that 
are presented via the MHC on the surface of human tumor cells and thereby mediate cancer 
regression (Kvistborg et al., 2013). Fusion genes are promising candidates as neoantigen, 
because fusion proteins created by chromosomal translocations in tumors can generate 
neoantigenic determinants at the breakpoint, which are unique to the tumor cells (Worley et 
al., 2001). It has been shown already that BCR-ABL fusion gene that arises in chronic myeloid 
leukaemia (CML) is a neoantigen. Peptides derived from the BCR-ABL fusion junction may 
therefore be immunogenic, if appropriately presented to the immune system (Cai et al., 2012; 
Jain et al., 2009; Rajasagi et al., 2014; Scheich et al., 2007; Wong and Chatterjee, 2005). 
Ideally, a personalized neoantigen approach could be applied early in disease evolution and 
immunologic intervention may effectively eliminate incipient disease cells such as 
DCCs/CTCs.  
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6. Summary 
Metastasis is the major cause of cancer-related deaths. Occult cancer cells when found in the 
bone marrow of patients with carcinomas have been termed disseminated cancer cells (DCCs) 
and when found in the blood circulating tumor cells (CTCs). CTCs and DCCs may comprise 
metastasis-initiating cells and surrogate markers for minimal residual disease (MRD) after 
curative surgery of the primary tumor. Numerous studies have shown that the presence of 
DCCs in bone marrow or CTCs in blood detected at time of curative surgery or during the 
follow-up of the patient put the patients at risk for disease progression and death. Therefore, 
there is a medical need to better characterize these cells and identify early oncogenic changes 
that drive metastatic progression. Fusion genes have been shown to be among the very early 
genomic changes necessary for cancer progression, as demonstrated for the TMPRSS2-ERG 
rearrangement in prostate cancer, but the identification of these structural variations has been 
challenging until now, especially in carcinomas, due to the lack of methods able to provide 
high resolution.  
Therefore, this work aimed to develop a method for the enrichment of breakpoint 
sequences that can be applied to DCCs and CTCs. Since these cells are extremely rare the 
method should enable fusion gene identification in single cells. The technique was established 
as downstream application of a deterministic method to amplify the genome of single cells. 
The method was based on the reduction of genome complexity and subtractive hybridization. 
Reduction of complexity was achieved by portioning the genome into ten fractions based on 
deterministic fragment selection. Several approaches of subtractive hybridization were 
subsequently compared and applied. In order to establish the technique, single cells derived 
from the K562 cell line (Tester), harboring the BCR-ABL gene fusion, and a pool of unrelated 
lymphocytes (Driver) were used. The enrichment of the breakpoint fusion was monitored by 
quantitative PCR which demonstrated an enrichment of 1664-fold, sufficient to detect fusion 
sequences by low coverage sequencing. 
 Thus combination of genome fractioning with subtractive hybridization is a valid 
approach for the enrichment of breakpoint sequences and could be applied for the genetic 
characterization of CTCs and DCCs. Future applications of the method might include 
monitoring cancer specific sequences during the course of therapy of solid cancers, as it is 
routinely performed for the BCR-ABL fusion gene to monitor therapy response and disease 
remission, or the identification of novel therapy targets, such as neo-antigens. 
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